



- (72) RUBEN, STEVEN M., US
(72) YOUNG, PAUL E., US
(72) BREWER, LAURIE A., US
(72) EBNER, REINHARD, US
(72) OLSEN, HENRIK S., US
(72) FLORENCE, KIMBERLY A., US
(72) ROSEN, CRAIG A., US
(72) DUAN, ROXANNE, US
(72) MOORE, PAUL A., US
(72) SHI, YANGGU, US
(72) LAFLEUR, DAVID W., US
(72) FLORENCE, CHARLES, US
(72) SOPPET, DANIEL R., US
(72) ENDRESS, GREGORY A., US
(72) FENG, PING, US
(72) KOMATSOULIS, GEORGE A., US
(71) HUMAN GENOME SCIENCES, INC., US
(51) Int.Cl.⁷ C12N 15/11, C12Q 1/68, G01N 33/68, C12N 15/63, A61K 38/17,
C12N 15/12, C12P 21/02, C12N 15/00, C07K 16/00
(30) 1997/08/19 (60/056,555) US
(30) 1997/08/19 (60/056,726) US
(30) 1997/08/19 (60/056,368) US
(30) 1997/08/19 (60/056,728) US
(30) 1997/08/19 (60/056,628) US
(30) 1997/08/19 (60/056,369) US
(30) 1997/08/19 (60/056,629) US
(30) 1997/08/19 (60/056,535) US
(30) 1997/08/19 (60/056,556) US
(30) 1998/06/16 (60/089,510) US
(30) 1998/07/15 (60/092,956) US
(54) **70 PROTEINES SECRETEES HUMAINES**
(54) **70 HUMAN SECRETED PROTEINS**

(57) Cette invention concerne de nouvelles protéines sécrétées humaines et des acides nucléiques isolés contenant les régions codantes des gènes codant ces protéines. On décrit également des vecteurs, des cellules hôtes, des anticorps et des procédés de recombinaison permettant de produire les protéines sécrétées humaines. Cette invention concerne également des procédés de diagnostic et de thérapie utiles pour diagnostiquer et traiter des dérèglements associés à ces nouvelles protéines sécrétées humaines.

(57) The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.



**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/11, 15/63, 15/00, 15/12, A61K 38/17, C07K 16/00, C12P 21/02, C12Q 1/68, G01N 33/68	A1	(11) International Publication Number: WO 99/09155 (43) International Publication Date: 25 February 1999 (25.02.99)																																			
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> (21) International Application Number: PCT/US98/17044 (22) International Filing Date: 18 August 1998 (18.08.98) (30) Priority Data: <table style="width: 100%; border: none;"> <tr><td style="width: 30%;">60/056,555</td><td style="width: 40%;">19 August 1997 (19.08.97)</td><td style="width: 30%;">US</td></tr> <tr><td>60/056,556</td><td>19 August 1997 (19.08.97)</td><td>US</td></tr> <tr><td>60/056,535</td><td>19 August 1997 (19.08.97)</td><td>US</td></tr> <tr><td>60/056,629</td><td>19 August 1997 (19.08.97)</td><td>US</td></tr> <tr><td>60/056,369</td><td>19 August 1997 (19.08.97)</td><td>US</td></tr> <tr><td>60/056,628</td><td>19 August 1997 (19.08.97)</td><td>US</td></tr> <tr><td>60/056,728</td><td>19 August 1997 (19.08.97)</td><td>US</td></tr> <tr><td>60/056,368</td><td>19 August 1997 (19.08.97)</td><td>US</td></tr> <tr><td>60/056,726</td><td>19 August 1997 (19.08.97)</td><td>US</td></tr> <tr><td>60/089,510</td><td>16 June 1998 (16.06.98)</td><td>US</td></tr> <tr><td>60/092,956</td><td>15 July 1998 (15.07.98)</td><td>US</td></tr> </table> (71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US). YOUNG, Paul, E. [US/US]; 122 Beckwith Street, Gaithersburg, MD 20878 (US). BREWER, Laurie, A. [US/US]; 14920 Mt. Nebo Road, Poolesville, MD 20837 (US). EBNER, Reinhard [DE/US]; 9906 Shelburne Terrace #316, Gaithersburg, MD 20878 (US). OLSEN, Henrik, S. [DK/US]; 182 Kendrick Place #24, Gaithersburg, MD 20878 (US). FLORENCE, Kimberly, A. [US/US]; 12805 Atlantic Avenue, Rockville, MD 20851 (US). ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US). DUAN, Roxanne [US/US]; 5515 Northfield Road, Bethesda, MD 20817 (US). MOORE, Paul, A. [GB/US]; 19005 Leatherbark Drive, Germantown, MD 20874 (US). SHI, Yanggu [CN/US]; 437 West Side Drive, Gaithersburg, MD 20878 (US). LAFLEUR, David, W. [US/US]; 1615 Q. Street, N.W. #807, Washington, DC 20009 (US). FLORENCE, Charles [US/US]; 12805 Atlantic Avenue, Rockville, MD 20851 (US). SOPPET, Daniel, R. [US/US]; 15050 Stillfield Place, Centreville, VA 22020 (US). ENDRESS, Gregory, A. [US/US]; 9729 Clagett Farm Drive, Potomac, MD 20854 (US). FENG, Ping [CN/US]; 4 Relda Court, Gaithersburg, MD 20878 (US). KOMATSOULIS, George, A. [US/US]; 9518 Garwood Street, Silver Spring, MD 90901 (US). (74) Agents: HOOVER, Kenley, K. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> Published <i>With international search report.</i> </td> </tr> </table>			(21) International Application Number: PCT/US98/17044 (22) International Filing Date: 18 August 1998 (18.08.98) (30) Priority Data: <table style="width: 100%; border: none;"> <tr><td style="width: 30%;">60/056,555</td><td style="width: 40%;">19 August 1997 (19.08.97)</td><td style="width: 30%;">US</td></tr> <tr><td>60/056,556</td><td>19 August 1997 (19.08.97)</td><td>US</td></tr> <tr><td>60/056,535</td><td>19 August 1997 (19.08.97)</td><td>US</td></tr> <tr><td>60/056,629</td><td>19 August 1997 (19.08.97)</td><td>US</td></tr> <tr><td>60/056,369</td><td>19 August 1997 (19.08.97)</td><td>US</td></tr> <tr><td>60/056,628</td><td>19 August 1997 (19.08.97)</td><td>US</td></tr> <tr><td>60/056,728</td><td>19 August 1997 (19.08.97)</td><td>US</td></tr> <tr><td>60/056,368</td><td>19 August 1997 (19.08.97)</td><td>US</td></tr> <tr><td>60/056,726</td><td>19 August 1997 (19.08.97)</td><td>US</td></tr> <tr><td>60/089,510</td><td>16 June 1998 (16.06.98)</td><td>US</td></tr> <tr><td>60/092,956</td><td>15 July 1998 (15.07.98)</td><td>US</td></tr> </table> (71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US). YOUNG, Paul, E. [US/US]; 122 Beckwith Street, Gaithersburg, MD 20878 (US). BREWER, Laurie, A. [US/US]; 14920 Mt. Nebo Road, Poolesville, MD 20837 (US). EBNER, Reinhard [DE/US]; 9906 Shelburne Terrace #316, Gaithersburg, MD 20878 (US). OLSEN, Henrik, S. [DK/US]; 182 Kendrick Place #24, Gaithersburg, MD 20878 (US). FLORENCE, Kimberly, A. [US/US]; 12805 Atlantic Avenue, Rockville, MD 20851 (US). ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US). DUAN, Roxanne [US/US]; 5515 Northfield Road, Bethesda, MD 20817 (US). MOORE, Paul, A. [GB/US]; 19005 Leatherbark Drive, Germantown, MD 20874 (US). SHI, Yanggu [CN/US]; 437 West Side Drive, Gaithersburg, MD 20878 (US). LAFLEUR, David, W. [US/US]; 1615 Q. Street, N.W. #807, Washington, DC 20009 (US). FLORENCE, Charles [US/US]; 12805 Atlantic Avenue, Rockville, MD 20851 (US). SOPPET, Daniel, R. [US/US]; 15050 Stillfield Place, Centreville, VA 22020 (US). ENDRESS, Gregory, A. [US/US]; 9729 Clagett Farm Drive, Potomac, MD 20854 (US). FENG, Ping [CN/US]; 4 Relda Court, Gaithersburg, MD 20878 (US). KOMATSOULIS, George, A. [US/US]; 9518 Garwood Street, Silver Spring, MD 90901 (US). (74) Agents: HOOVER, Kenley, K. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	60/056,555	19 August 1997 (19.08.97)	US	60/056,556	19 August 1997 (19.08.97)	US	60/056,535	19 August 1997 (19.08.97)	US	60/056,629	19 August 1997 (19.08.97)	US	60/056,369	19 August 1997 (19.08.97)	US	60/056,628	19 August 1997 (19.08.97)	US	60/056,728	19 August 1997 (19.08.97)	US	60/056,368	19 August 1997 (19.08.97)	US	60/056,726	19 August 1997 (19.08.97)	US	60/089,510	16 June 1998 (16.06.98)	US	60/092,956	15 July 1998 (15.07.98)	US	Published <i>With international search report.</i>
(21) International Application Number: PCT/US98/17044 (22) International Filing Date: 18 August 1998 (18.08.98) (30) Priority Data: <table style="width: 100%; border: none;"> <tr><td style="width: 30%;">60/056,555</td><td style="width: 40%;">19 August 1997 (19.08.97)</td><td style="width: 30%;">US</td></tr> <tr><td>60/056,556</td><td>19 August 1997 (19.08.97)</td><td>US</td></tr> <tr><td>60/056,535</td><td>19 August 1997 (19.08.97)</td><td>US</td></tr> <tr><td>60/056,629</td><td>19 August 1997 (19.08.97)</td><td>US</td></tr> <tr><td>60/056,369</td><td>19 August 1997 (19.08.97)</td><td>US</td></tr> <tr><td>60/056,628</td><td>19 August 1997 (19.08.97)</td><td>US</td></tr> <tr><td>60/056,728</td><td>19 August 1997 (19.08.97)</td><td>US</td></tr> <tr><td>60/056,368</td><td>19 August 1997 (19.08.97)</td><td>US</td></tr> <tr><td>60/056,726</td><td>19 August 1997 (19.08.97)</td><td>US</td></tr> <tr><td>60/089,510</td><td>16 June 1998 (16.06.98)</td><td>US</td></tr> <tr><td>60/092,956</td><td>15 July 1998 (15.07.98)</td><td>US</td></tr> </table> (71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US). YOUNG, Paul, E. [US/US]; 122 Beckwith Street, Gaithersburg, MD 20878 (US). BREWER, Laurie, A. [US/US]; 14920 Mt. Nebo Road, Poolesville, MD 20837 (US). EBNER, Reinhard [DE/US]; 9906 Shelburne Terrace #316, Gaithersburg, MD 20878 (US). OLSEN, Henrik, S. [DK/US]; 182 Kendrick Place #24, Gaithersburg, MD 20878 (US). FLORENCE, Kimberly, A. [US/US]; 12805 Atlantic Avenue, Rockville, MD 20851 (US). ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US). DUAN, Roxanne [US/US]; 5515 Northfield Road, Bethesda, MD 20817 (US). MOORE, Paul, A. [GB/US]; 19005 Leatherbark Drive, Germantown, MD 20874 (US). SHI, Yanggu [CN/US]; 437 West Side Drive, Gaithersburg, MD 20878 (US). LAFLEUR, David, W. [US/US]; 1615 Q. Street, N.W. #807, Washington, DC 20009 (US). FLORENCE, Charles [US/US]; 12805 Atlantic Avenue, Rockville, MD 20851 (US). SOPPET, Daniel, R. [US/US]; 15050 Stillfield Place, Centreville, VA 22020 (US). ENDRESS, Gregory, A. [US/US]; 9729 Clagett Farm Drive, Potomac, MD 20854 (US). FENG, Ping [CN/US]; 4 Relda Court, Gaithersburg, MD 20878 (US). KOMATSOULIS, George, A. [US/US]; 9518 Garwood Street, Silver Spring, MD 90901 (US). (74) Agents: HOOVER, Kenley, K. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	60/056,555	19 August 1997 (19.08.97)	US	60/056,556	19 August 1997 (19.08.97)	US	60/056,535	19 August 1997 (19.08.97)	US	60/056,629	19 August 1997 (19.08.97)	US	60/056,369	19 August 1997 (19.08.97)	US	60/056,628	19 August 1997 (19.08.97)	US	60/056,728	19 August 1997 (19.08.97)	US	60/056,368	19 August 1997 (19.08.97)	US	60/056,726	19 August 1997 (19.08.97)	US	60/089,510	16 June 1998 (16.06.98)	US	60/092,956	15 July 1998 (15.07.98)	US	Published <i>With international search report.</i>			
60/056,555	19 August 1997 (19.08.97)	US																																			
60/056,556	19 August 1997 (19.08.97)	US																																			
60/056,535	19 August 1997 (19.08.97)	US																																			
60/056,629	19 August 1997 (19.08.97)	US																																			
60/056,369	19 August 1997 (19.08.97)	US																																			
60/056,628	19 August 1997 (19.08.97)	US																																			
60/056,728	19 August 1997 (19.08.97)	US																																			
60/056,368	19 August 1997 (19.08.97)	US																																			
60/056,726	19 August 1997 (19.08.97)	US																																			
60/089,510	16 June 1998 (16.06.98)	US																																			
60/092,956	15 July 1998 (15.07.98)	US																																			
(54) Title: 70 HUMAN SECRETED PROTEINS																																					
(57) Abstract The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.																																					

70 Human Secreted Proteins

Field of the Invention

This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and
5 their production.

Background of the Invention

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or
10 organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum
15 (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

20 Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or
25 secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins include
30 the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent medical disorders by using
35 secreted proteins or the genes that encode them.

Summary of the Invention

The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting disorders related to the polypeptides, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying binding partners of the polypeptides.

Detailed Description

Definitions

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig

analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard,
5 Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained
10 in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42°C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the
15 filters in 0.1x SSC at about 65°C.

Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages
20 of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37°C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH₂PO₄; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 µg/ml salmon sperm blocking DNA; followed by washes at 50°C with 1XSSPE, 0.1% SDS. In addition, to achieve even
25 lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include
30 Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA⁺ sequences (such
35 as any 3' terminal polyA⁺ tract of a cDNA shown in the sequence listing), or to a

complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

5 The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and
10 double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability
15 or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

 The polypeptide of the present invention can be composed of amino acids joined
20 to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs,
25 as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be
30 branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a
35 nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine,

formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS -
5 STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990);
10 Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting
15 activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present
20 invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

25 Polynucleotides and Polypeptides of the Invention

FEATURES OF PROTEIN ENCODED BY GENE NO: 1

30 The translation product of this gene shares sequence homology with DNA encoding allergens of Cladosporium herbarum, in addition to, the rat TSEP-1 protein (See Genbank Accession No. W12827) which is thought to be important in the modulation of MHC Class I gene expression. As such, protein product of this gene may be beneficial in the prevention and treatment of auto-immune disease and transplant
35 rejection. When tested against myelogenous leukemia cell lines, supernatants removed from cells containing this gene activated Calcium permeability. Thus, it is likely that this gene activates signal transduction pathways in myelogenous leukemia cells through

intracellular calcium release. Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. Alterations in small molecule concentration can be measured to identify supernatants which bind to receptors of a particular cell. In specific
5 embodiments, polypeptides of the invention comprise the sequence:
FITPEDGSKDVVFVHFSAISSQGFKTLAEGQRFVEFEITNGAKGPSAANVIAI (SEQ
ID NO:157). Polynucleotides encoding these polypeptides are also encompassed by the invention.

 This gene is expressed primarily in CD34-depleted white blood cells.

10 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, allergy caused by *Cladosporium herbarum*, hematopoietic and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are
15 useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. blood cells, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph,
20 serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

 The tissue distribution and homology to DNA encoding allergens of
25 *Cladosporium herbarum* indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of allergy caused by *Cladosporium herbarum*. Similarly, the tissue distribution in white blood cells, combined with the observed calcium release activity in myelogenous leukemia cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the
30 diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in immune cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a
35 usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological

disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anaemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behaviour. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:11 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 378 of SEQ ID NO:11, b is an integer of 15 to 392, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:11, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 2

The translation product of this gene shares sequence homology with human histiocyte-secreted factor HSF, a tumor necrosis factor-related protein, which is thought to be important for its potential anti-tumor activity. When tested against K562 cell lines, supernatants removed from cells containing this gene activated the ISRE (interferon-

sensitive responsive element) pathway. Thus, it is likely that this gene activates leukemia cells through the Jaks-STAT signal transduction pathway. ISRE is a promoter element found upstream in many genes which are involved in the Jaks-STAT pathway. The Jaks-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. The gene encoding the disclosed cDNA is believed to reside on chromosome 2. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 2.

10 This gene is expressed primarily in CD34 positive white blood cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for anti-tumor reagents. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. blood cells, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 The tissue distribution in CD34 positive cells, combined with its homology to the human HSF protein, in addition to the detected biological activity within leukemia cell lines, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities. Typical of these are cytokine, cell proliferation/differentiation

modulating activity or induction of other cytokines;
immunostimulating/immunosuppressant activities (e.g. for treating human
immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation
of hematopoiesis (e.g. for treating anaemia or as adjunct to chemotherapy); stimulation
5 or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating
wounds, stimulation of follicle stimulating hormone (for control of fertility);
chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic
or thrombolytic activity (e.g. for treating haemophilia, cardiac infarction etc.); anti-
inflammatory activity (e.g. for treating septic shock, Crohn's disease); as
10 antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation
of metabolism, and behaviour. Also contemplated is the use of the corresponding
nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against
the protein may show utility as a tumor marker and/or immunotherapy targets for the
above listed tissues. Many polynucleotide sequences, such as EST sequences, are
15 publicly available and accessible through sequence databases. Some of these sequences
are related to SEQ ID NO:12 and may have been publicly available prior to conception
of the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
20 more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 451 of SEQ ID NO:12, b is an
integer of 15 to 465, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:12, and where b is greater than or equal to a + 14.

25 **FEATURES OF PROTEIN ENCODED BY GENE NO: 3**

This gene is expressed primarily in CD34 positive blood cells.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
30 not limited to, diseases of the immune and hematopoietic systems, especially those of
CD-34 positive bloodcells. Similarly, polypeptides and antibodies directed to these
polypeptides are useful in providing immunological probes for differential identification
of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,
particularly of the immune system, expression of this gene at significantly higher or
35 lower levels may be routinely detected in certain tissues or cell types (e.g. blood cells,
immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids
(e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or

cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:86 as residues: Gly-7 to Asp-14, Ile-16 to Tyr-36,
5 Lys-47 to Ser-54.

The tissue distribution in CD34 positive blood cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the
10 production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the
15 expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:13 and may have been publicly available prior to conception of the present invention. Preferably,
20 such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 660 of SEQ ID NO:13, b is an integer of 15 to 674, where both a and b
25 correspond to the positions of nucleotide residues shown in SEQ ID NO:13, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 4

This gene is expressed primarily in CD34 positive blood cells.
30 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions: immune or hematopoietic disorders, particularly diseases of CD 34 positive cells. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing
35 immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune or hematopoietic systems, expression of this gene at significantly higher or lower levels

may be routinely detected in certain tissues or cell types (e.g. blood cells, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:87 as residues: Glu-12 to Thr-21.

The tissue distribution in CD34 positive white blood cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:14 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 283 of SEQ ID NO:14, b is an integer of 15 to 297, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:14, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 5

This gene is expressed primarily in Hodgkin's lymphoma tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, Hodgkin's lymphoma, or related immune or hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in

providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune or hematopoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. blood cells, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:88 as residues: Ser-36 to Cys-42.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in Hodgkin's lymphoma indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:15 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 590 of SEQ ID NO:15, b is an integer of 15 to 604, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 6

This gene is expressed primarily in placenta, embryo, and, to a lesser extent, in tonsil and ovary.

5 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the female reproductive system, or developing tissues. Similarly, polypeptides and antibodies directed to these polypeptides are useful in
10 providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the female reproductive or immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. developing, reproductive, immune, and cancerous and wounded tissues) or bodily
15 fluids (e.g. amniotic fluid, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in placental and embryonic tissue indicates that
20 polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders, particularly of the female reproductive system. Similarly, expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Additionally, the expression in immune tissues
25 indicates that this protein may play a role in the proliferation, differentiation, and/or survival of hematopoietic cell lineages. In such an event, this gene may be useful in the treatment of lymphoproliferative disorders, and in the maintenance and differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells. Similarly, embryonic development also involves decisions involving cell
30 differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Alternatively, expression within ovarian tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's
35 disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism),

hypothalamus, and testes. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:16 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1132 of SEQ ID NO:16, b is an integer of 15 to 1146, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 7

This gene is expressed primarily in embryonic tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental disorders, in addition to cancer and other disorders characterized by proliferating tissues. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of embryonic tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. developmental, proliferating, and cancerous and wounded tissues) or bodily fluids (e.g. amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:90 as residues: Ser-11 to His-16.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in

cancer therapy. The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anaemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behaviour. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:17 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 664 of SEQ ID NO:17, b is an integer of 15 to 678, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 8

This gene is expressed primarily in kidney, and to a lesser extent, in other human tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the kidney or urogenital system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders

of the above tissues or cells, particularly of the urinary system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. urogenital, endocrine, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or
 5 cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in kidney indicates that this gene or gene product could be used in the treatment and/or detection of kidney diseases including renal failure,
 10 nephritis, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilms Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Protein, as well as, antibodies directed against the protein may show utility
 15 as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:18 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the
 20 present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1291 of SEQ ID NO:18, b is an integer of 15 to 1305, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID
 25 NO:18, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 9

This gene is expressed primarily in T-cell lymphoma and embryonic tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as
 30 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, developmental, or hematopoietic disorders, particularly T-cell lymphoma or other disorders characterized by proliferating tissues or cells. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing
 35 immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected

in certain tissues or cell types (e.g. blood cells, immune, hematopoietic, developing, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in T-cell lymphoma indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:19 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1046 of SEQ ID NO:19, b is an integer of 15 to 1060, where both a and b correspond to the

positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 10

5 This gene is expressed primarily in adipose tissue, and to a lesser extent, in other human tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, metabolic disorders, particularly those involving anomalous lipid metabolism. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of adipose tissue, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. adipose, and cancerous and wounded tissues) or bodily fluids (e.g. bile, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:93 as residues: Tyr-25 to Thr-32.

The tissue distribution in adipose tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, prevention, and/or treatment of various metabolic disorders such as Tay-Sachs disease, phenylketonuria, galactosemia, hyperlipidemias, porphyrias, and Hurler's syndrome. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:20 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1156 of SEQ ID NO:20, b is an integer of 15 to 1170, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 11

This gene is expressed primarily in infant brain, and to a lesser extent, in human nine week old early stage.

5 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural degenerative or developmental disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological
10 probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous or reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. developing, neural, and cancerous and wounded tissues) or bodily fluids (e.g. amniotic fluid, serum, plasma,
15 urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:94 as residues: Lys-50 to Asp-66, Pro-68 to Glu-77, Glu-102 to Glu-107, Glu-131
20 to Leu-146, Ala-175 to Glu-183, Phe-205 to Lys-216, Val-263 to Thr-281, Pro-304 to Ala-313.

The tissue distribution in infant brain indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease,
25 Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders
30 associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ
35 ID NO:21 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2070 of SEQ ID NO:21, b is an integer of 15 to 2084, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:21, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 12

This gene is expressed primarily in atrophic endometrium.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, atrophic endometriosis, or other disorders of the female reproductive system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the female reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. reproductive, uterine, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of atrophic endometriosis and related uterine disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:22 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 629 of SEQ ID NO:22, b is an integer of 15 to 643, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:22, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 13

This gene is expressed primarily in fetal tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as
5 reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, developmental abnormalities, or disorders characterized by proliferating
tissues. Similarly, polypeptides and antibodies directed to these polypeptides are useful
in providing immunological probes for differential identification of the tissue(s) or cell
10 type(s). For a number of disorders of the above tissues or cells, particularly of the
reproductive system, expression of this gene at significantly higher or lower levels may
be routinely detected in certain tissues or cell types (e.g. developing, proliferating, and
cancerous and wounded tissues) or bodily fluids (e.g. amniotic fluid, serum, plasma,
urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an
15 individual having such a disorder, relative to the standard gene expression level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not having the
disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID
NO:96 as residues: Gly-26 to Arg-37.

Expression within embryonic tissue and other cellular sources marked by
20 proliferating cells indicates that this protein may play a role in the regulation of cellular
division, and may show utility in the diagnosis and treatment of cancer and other
proliferative disorders. Similarly, embryonic development also involves decisions
involving cell differentiation and/or apoptosis in pattern formation. Thus this protein
may also be involved in apoptosis or tissue differentiation and could again be useful in
25 cancer therapy. Protein, as well as, antibodies directed against the protein may show
utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
Many polynucleotide sequences, such as EST sequences, are publicly available and
accessible through sequence databases. Some of these sequences are related to SEQ ID
NO:23 and may have been publicly available prior to conception of the present
30 invention. Preferably, such related polynucleotides are specifically excluded from the
scope of the present invention. To list every related sequence is cumbersome.
Accordingly, preferably excluded from the present invention are one or more
polynucleotides comprising a nucleotide sequence described by the general formula of
a-b, where a is any integer between 1 to 633 of SEQ ID NO:23, b is an integer of 15 to
35 647, where both a and b correspond to the positions of nucleotide residues shown in
SEQ ID NO:23, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 14

The gene encoding the disclosed cDNA is believed to reside on chromosome 19. Accordingly, polynucleotides related to this invention are useful as a marker in
5 linkage analysis for chromosome 19.

This gene is expressed primarily in epididymus.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are
10 not limited to, male infertility. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types
15 (e.g. epididymus, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g. seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of male infertility, possibly related to low sperm motility. Similarly, expression of this gene product in the epididymus may implicate this gene product in playing a vital role in maintaining normal testicular function. As such, this gene product may find utility as a male contraceptive. Protein, as
25 well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:24 and may have been publicly available prior to conception of the present invention. Preferably,
30 such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 811 of SEQ ID NO:24, b is an integer of 15 to 825, where both a and b
35 correspond to the positions of nucleotide residues shown in SEQ ID NO:24, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 15

This gene is expressed primarily in IL5-induced eosinophils.

Therefore, polynucleotides and polypeptides of the invention are useful as
5 reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, acute inflammation, or other immune disorders such as asthma. Similarly,
polypeptides and antibodies directed to these polypeptides are useful in providing
immunological probes for differential identification of the tissue(s) or cell type(s). For a
10 number of disorders of the above tissues or cells, particularly of the immune system,
expression of this gene at significantly higher or lower levels may be routinely detected
in certain tissues or cell types (e.g. blood cells, immune, hematopoietic, and cancerous
and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid
and spinal fluid) or another tissue or cell sample taken from an individual having such a
15 disorder, relative to the standard gene expression level, i.e., the expression level in
healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for the diagnosis and treatment of a variety of
immune system disorders. Expression of this gene product in eosinophils indicates a
20 role in the regulation of the proliferation; survival; differentiation; and/or activation of
potentially all hematopoietic cell lineages, including blood stem cells. This gene product
may be involved in the regulation of cytokine production, antigen presentation, or other
processes that may also suggest a usefulness in the treatment of cancer (e.g. by
boosting immune responses). Since the gene is expressed in cells of lymphoid origin,
25 the natural gene product may be involved in immune functions. Therefore it may be also
used as an agent for immunological disorders including arthritis, asthma, immune
deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, sepsis, acne, and
psoriasis, asthma, and inflammatory disorders, such as inflammatory bowel disease. In
addition, this gene product may have commercial utility in the expansion of stem cells
30 and committed progenitors of various blood lineages, and in the differentiation and/or
proliferation of various cell types. Protein, as well as, antibodies directed against the
protein may show utility as a tumor marker and/or immunotherapy targets for the above
listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
35 related to SEQ ID NO:25 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically excluded
from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 527 of SEQ ID NO:25, b is an integer of 15 to 541, where both a and b correspond to the positions of nucleotide residues shown in
5 SEQ ID NO:25, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 16

This gene is expressed primarily in induced endothelial cells.

Therefore, polynucleotides and polypeptides of the invention are useful as
10 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, arteriosclerosis, or other vasculature disorders, particularly microvascular disease and stroke. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification
15 of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the circulatory system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. cardiovascular, and cancerous and wounded tissues) or bodily fluids (e.g. serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken
20 from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:99 as residues: Ser-33 to Arg-48, Gln-64 to Val-71, Pro-121 to Thr-132, Gln-167 to Lys-181.

25 The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment of endothelial inflammation or occlusion due to arteriosclerosis. Similarly, the protein product of this gene may also show utility in the detection, treatment, or prevention of stroke, aneurysms, or other vascular disorders. Protein, as well as, antibodies directed against the protein may
30 show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:26 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the
35 scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of

a-b, where a is any integer between 1 to 838 of SEQ ID NO:26, b is an integer of 15 to 852, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:26, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 17

This gene is expressed primarily in ovarian cancer, and to a lesser extent, in infant brain, 12 Week old early stage embryo, and synovial hypoxia.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental or proliferative disorders, particularly ovarian cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive or neural systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. neural, developmental, skeletal, and cancerous and wounded tissues) or bodily fluids (e.g. amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:100 as residues: Ser-7 to Gly-17.

The tissue distribution within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Alternatively, expression within infant brain indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked

disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:27 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 4584 of SEQ ID NO:27, b is an integer of 15 to 4598, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:27, and where b is greater than or equal to a + 14.

15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 18**

When tested against PC12 cell lines, supernatants removed from cells containing this gene activated the EGR1 (early growth response gene 1) pathway. Thus, it is likely that this gene activates sensory neuron cells through the EGR1 signal transduction pathway. EGR1 is a separate signal transduction pathway from Jaks-STAT, genes containing the EGR1 promoter are induced in various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation.

This gene is expressed primarily in fetal brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, degenerative neural disorders or developmental disorders, particularly proliferative abnormalities. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. neural, developing, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:101 as residues: Val-16 to Asn-24.

The tissue distribution in infant brain combined with the detected biological EGR1 activity in sensory neurons indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered bahaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:28 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 571 of SEQ ID NO:28, b is an integer of 15 to 585, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 19

The translation product of this gene was shown to have homology to the human zinc finger 91 which is thought to important in the regulation of gene expression (See Genbank Accession No. Q05481). The gene encoding the disclosed cDNA is believed to reside on chromosome 19. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 19.

This gene is expressed primarily in uterine cancer, and to a lesser extent in melanocytes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive disorders, particularly uterine cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a

number of disorders of the above tissues or cells, particularly of the reproductive or integumentary system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. reproductive, epithelial, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in tumors of uterine origins indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of these tumors, in addition to other tumors where expression has been indicated. Alternatively considering the expression within melanocytes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. Moreover, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athlete's foot, and ringworm). Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:29 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 810 of SEQ ID NO:29, b is an integer of 15 to 824, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 20

The translation product of this gene was shown to have homology to the human RAMP2 protein which is thought to be important in calcitonin regulation (See Genbank
 5 Accession No. gnl|PID|e1295011 (AJ001015)). In specific embodiments, polypeptides of the invention comprise the sequence:

RAGGPRLPRTRVGRPAALRLLLLLGAVLNPHEALAQXLPTTGTPGSEGGTVKN
 XETAVQFCWNHYKDQMDPIEKDWCDWAMISRPYSTLRDCLEHFAELFDLGF
 PNPLAERIIFETHQIH FANCSLVQPTFSDPPEDVLLA (SEQ ID NO:158), CWN
 10 HYKDQMDPIEKDWCDWAMISRPYSTLRDCLEHFAELFDLGFPNPLAERIIFETH
 QIH (SEQ ID NO:159), FANCSLVQPTFSDPPEDVLLAMIIAPICLIPFLITLVV
 WRSKDSEAQA (SEQ ID NO:160), RAGGPRLPRT (SEQ ID NO:161), or NPHEA
 LAQ (SEQ ID NO:162). Polynucleotides encoding these polypeptides are also
 encompassed by the invention.

15 This gene is expressed primarily in fetal kidney, spleen, and to a lesser extent in chronic synovitis and lung.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are
 20 not limited to, kidney, endocrine, urogenital, or hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine or haemopoietic system, expression of this gene at significantly higher or lower levels may
 25 be routinely detected in certain tissues or cell types (e.g. endocrine, urogenital, skeletal, cardiovascular, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an
 30 individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:103 as residues: Arg-19 to Gln-26.

The tissue distribution in kidney indicates that this gene or gene product could be used in the treatment and/or detection of kidney diseases including renal failure, nephritis, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis,
 35 hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilms Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's

syndrome. Similarly, considering the homology to the RAMP2 protein, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:30 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 759 of SEQ ID NO:30, b is an integer of 15 to 773, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:30, and where b is greater than or equal to a + 14.

20 FEATURES OF PROTEIN ENCODED BY GENE NO: 21

This gene is expressed primarily in infant brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurodegenerative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. neural, developing, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:104 as residues: Arg-29 to Ile-39.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative

disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered bahaviors, including disorders in feeding, sleep
5 patterns, balance, and preception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many
10 polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:31 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly,
15 preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 955 of SEQ ID NO:31, b is an integer of 15 to 969, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a + 14.

20

FEATURES OF PROTEIN ENCODED BY GENE NO: 22

The gene encoding the disclosed cDNA is believed to reside on chromosome 12. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 12.

25 This gene is expressed primarily in infant and adult brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurodegenerative or developmental disorders. Similarly, polypeptides
30 and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. neural, developing, proliferative, and cancerous and
35 wounded tissues) or bodily fluids (e.g. amniotic fluid, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the

expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:105 as residues: Arg-13 to Glu-22, Ser-34 to Phe-44, Ser-46 to Thr-52.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered bahaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:32 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1341 of SEQ ID NO:32, b is an integer of 15 to 1355, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 23

This gene is expressed primarily in fetal dura mater.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurodegenerative disorders, particularly spina bifida. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. neural, developmental, proliferative, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum,

plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in
 5 SEQ ID NO:106 as residues: Lys-15 to His-21.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, spina bifida, schizophrenia, mania,
 10 dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the
 15 cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:33 and may have been publicly available prior to conception of the present
 20 invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 522 of SEQ ID NO:33, b is an integer of 15 to
 25 536, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:33, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 24

The gene encoding the disclosed cDNA is believed to reside on chromosome 3.
 30 Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 3.

This gene is expressed primarily in fetal liver, spleen, and to a lesser extent in ovary and glioblastoma.

Therefore, polynucleotides and polypeptides of the invention are useful as
 35 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hepatic, immune, or haematopoietic disorders. Similarly, polypeptides

and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the haematopoietic or hepatic system, expression of this gene at significantly higher or lower levels may be routinely
5 detected in certain tissues or cell types (e.g. hepatic, blood cells, immune, haematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, bile, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an
10 individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). In
15 addition the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various wound-healing models and/or tissue trauma. Alternatively, expression within spleen tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this
20 gene product in tonsils indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is
25 expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. and tissues. In addition, this gene product may have commercial utility in the
30 expansion of stem cells and committed progenitors of various Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:34 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present
35 invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer

between 1 to 1109 of SEQ ID NO:34, b is an integer of 15 to 1123, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:34, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 25

This gene is expressed primarily in brain frontal cortex.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurodegenerative disorders, particularly those afflicting the frontal cortex. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. neural, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:108 as residues: Ser-5 to Thr-11, Tyr-90 to Arg-96.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:35 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly,

preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 573 of SEQ ID NO:35, b is an integer of 15 to 587, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID
5 NO:35, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 26

This gene is expressed primarily in brain frontal cortex.

Therefore, polynucleotides and polypeptides of the invention are useful as
10 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurodegenerative disorders, particularly of the frontal cortex. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a
15 number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. neural, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to
20 the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons
25 Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the
30 developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:36 and
35 may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly,

preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 828 of SEQ ID NO:36, b is an integer of 15 to 842, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID
5 NO:36, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 27

This gene is expressed primarily in brain frontal cortex, and to a lesser extent, in the epididymus.

10 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurodegenerative disorders, particularly of the frontal cortex, or reproductive disorders. Similarly, polypeptides and antibodies directed to these
15 polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. neural, urogenital, reproductive, and cancerous and wounded tissues) or bodily fluids
20 (e.g. lymph, seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides
25 corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep
30 patterns, balance, and preception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Alternatively, the expression within the epididymus may suggest that polynucleotides and polypeptides corresponding to this gene are useful for the
35 detection, treatment, and/or prevention of various reproductive disorders, particularly male infertility. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:37 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 939 of SEQ ID NO:37, b is an integer of 15 to 953, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:37, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 28

The translation product of this gene shares sequence homology with the human placental DIFF33-LIKE protein, in addition to the Diff33 gene product (See Genbank Accession Nos. gnl|PID|e1310269 dJ425C14.2 and gil1293563, respectively). Both of these proteins are thought to be important in the regulation of cell-cycle control and growth within reproductive tissues and cells. In specific embodiments, polypeptides of the invention comprise the sequence:

AQERSCLHLVCIRCSCDVVEMGSVLGLCSMASWIPCLCGSAPCLLCRCCPSGN
 NSTVTRLIYALFLLVGVCVACVMLIPGMEEQLNKIPGFCENEKGVVPCNILVGY
 KAVYRLCFGLA (SEQ ID NO:163), IPCLCGSAPCLLCRCCPSGNNSTVTRLI
 YALFLLVGVCVACVMLIPGMEEQLNKIPGFCENEKGVVPCNILVGY (SEQ ID
 NO:164), ARSDGSLEDGDDVHRAVDNERDGVTSYSFFHFMLFLASLYIMM
 TLTNWYRYEPSREMKSQWTAVWVKISS SWIGIVLYVWTLVAPLVLTNRDFD
 (SEQ ID NO:165), NEKGVVPCNILVGYKAVYRLCFGLAMFY (SEQ ID NO:166),
 MIKVKSSSDPRAAVHNGFW (SEQ ID NO:167), GMAGAFCFILIQLVLLIDFAH
 (SEQ ID NO:168), YAALLSATALNYLLSLVAIVLFFV (SEQ ID NO:169),
 PSLLSIIGYNTTSTVPKEGQS (SEQ ID NO:170), YSSIRTSNNSQVNKLTLTSDDES
 (SEQ ID NO:171), DNERDGVTSYSFFHFMLFL (SEQ ID NO:172), or
 IVLYVWTLVAPLVLTNRD (SEQ ID NO:173). Polynucleotides encoding these
 polypeptides are also encompassed by the invention. The gene encoding the disclosed
 cDNA is believed to reside on chromosome 20. Accordingly, polynucleotides related to
 this invention are useful as a marker in linkage analysis for chromosome 20.

This gene is expressed primarily in thymus stromal cells, and to a lesser extent, in human T-cell lymphoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive disorders, particularly those involving proliferative cells, such as cancer and tumor growth. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential
 5 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and tumor growth in various tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. reproductive, immune, cancerous and wounded tissues) or bodily fluids (e.g. lymph, seminal fluid, amniotic fluid, serum, plasma,
 10 urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:111 as residues: Lys-87 to Cys-95, Ala-126 to Asn-131, Ile-154 to Gly-162, Thr-
 15 182 to Asn-190, Ser-203 to Gln-210, Ser-234 to Asn-244, Gly-259 to Ser-266, Asp-278 to Val-284, Glu-313 to Gln-321.

The tissue distribution and homology to Diff33 gene product indicates that polynucleotides and polypeptides corresponding to this gene are useful for identifying or designing drug(S) targeted against cancers/tumors where unregulated growth is due,
 20 in part, to the overexpression of this gene product. Diff33 gene product is 2-15 fold overexpressed in testicular tumors from polyomavirus large T-antigen transgenic mice and thus may play a regulatory role in cell growth. Due to its strong homology to Diff33, this gene may have a similar regulatory role, not only in testicular or placental cancers, but within reproductive tissues, in general. The secreted protein can also be
 25 used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for
 30 treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anaemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections,
 35 tumors); hemostatic or thrombolytic activity (e.g. for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for

regulation of metabolism, and behaviour. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST
5 sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:38 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention
10 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2197 of SEQ ID NO:38, b is an integer of 15 to 2211, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:38, and where b is greater than or equal to a + 14.

15

FEATURES OF PROTEIN ENCODED BY GENE NO: 29

This gene is expressed primarily in breast tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a
20 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive disorders, particularly breast cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic and female
25 reproductive systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. breast, reproductive, endocrine, and cancerous and wounded tissues) or bodily fluids (e.g. breast milk, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene
30 expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:112 as residues: Gly-13 to Pro-19, Pro-38 to Pro-46, Thr-49 to Gly-57.

The tissue distribution in tumors of breast origins indicates that polynucleotides
35 and polypeptides corresponding to this gene are useful for diagnosis and intervention of these tumors, in addition to other tumors where expression has been indicated. Expression within cellular sources marked by proliferating cells indicates that this

protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:39 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 668 of SEQ ID NO:39, b is an integer of 15 to 682, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:39, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 30

The translation product of this gene shares sequence homology with the human ZN-alpha-2-glycoprotein, which is thought to important in the modulation of the immune response and possibly in the regulation of cell division (See Genbank Accession No. gil467671). In specific embodiments, polypeptides of the invention comprise the sequence: DPRVRADTMVR (SEQ ID NO:174), GPAVPQENQDGR YSLTYIYTGLSKHVEDVPAFQALGSLNDLQFFR (SEQ ID NO:175), YNSKDRK SQPMGLWRQVEGME (SEQ ID NO:176), FMETLKDIVEYYNDSNGSHVLQ (SEQ ID NO:177), or NRSSGAFWKYYYDYGKDYIEF (SEQ ID NO:178). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 7. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 7.

This gene is expressed primarily in liver, breast, and to a lesser extent, in spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive or immune disorders, particularly those involving cancer,

such as of the breast. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, hematopoietic, or reproductive systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, reproductive, hematopoietic, hepatic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, breast milk, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:113 as residues: Val-16 to Tyr-25, Tyr-58 to Gln-66, Met-77 to Arg-90, Tyr-104 to Gly-110, Glu-123 to Ser-128, Tyr-135 to Asp-140, Ile-160 to Trp-165.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in spleen indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, expression within the liver indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). In addition the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various wound-healing models and/or tissue trauma. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of

these sequences are related to SEQ ID NO:40 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention
5 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 671 of SEQ ID NO:40, b is an integer of 15 to 685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:40, and where b is greater than or equal to a + 14.

10 **FEATURES OF PROTEIN ENCODED BY GENE NO: 31**

When tested against human Jurket T-cell lines, supernatants removed from cells containing this gene activated the NF-kB (Nuclear Factor kB) transcription pathway. Thus, it is likely that this gene activates T-cells through the NF-kB pathway. NF-kB is a transcription factor activated by a wide variety of agents, leading to cell activation,
15 differentiation, or apoptosis. Reporter constructs utilizing the NF-kB promoter element are used to screen supernatants for such activity.

This gene is expressed primarily in synovial sarcoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a
20 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or musculoskeletal disorders, particularly synovial sarcoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the
25 immune or skeletal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. skeletal, immune, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,
30 the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:114 as residues: Cys-7 to Ser-13.

In addition, the expression of this gene product in synovium would suggest a role in the detection and treatment of disorders and conditions affecting the skeletal
35 system, in particular osteoporosis as well as disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis,

lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid. The detected NF-Kb biological activity in T-cells is
5 consistent with the described uses for this protein. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:41 and may have been publicly available
10 prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 536 of SEQ ID NO:41, b is
15 an integer of 15 to 550, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:41, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 32

The translation product of this gene shares sequence homology with the elastin
20 like protein from *Drosophila melanogaster* which is believed to be important in the maintenance of the extracellular matrix of tissues (See Genbank Accession No. gil762925). When tested against K562 cell lines, supernatants removed from cells containing this gene activated the ISRE (interferon-sensitive responsive element) pathway. Thus, it is likely that this gene activates leukemia cells through the Jaks-STAT
25 signal transduction pathway. ISRE is a promoter element found upstream in many genes which are involved in the Jaks-STAT pathway. The Jaks-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and
30 differentiation of cells. The gene encoding the disclosed cDNA is believed to reside on chromosome 2. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 2.

This gene is expressed in synovial sarcoma.

Therefore, polynucleotides and polypeptides of the invention are useful as
35 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, skeletal disorders, particularly synovial sarcoma. Similarly, polypeptides

and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune or skeletal system, expression of this gene at significantly higher or lower levels may be routinely detected
5 in certain tissues or cell types (e.g. immune, skeletal, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 In addition, the expression of this gene product in synovium, combined with its homology to elastin and ISRE activity, would suggest a role in the detection and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis as well as disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of
15 various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid. Protein, as well as, antibodies directed against the protein may show utility as
20 a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:42 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the
25 present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 588 of SEQ ID NO:42, b is an integer of 15 to 602, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID
30 NO:42, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 33

The translation product of this gene shares sequence homology with the cell division control protein CDC91 from the yeast, *Saccharomyces cerevisiae*.

35 This gene is expressed in testes, colon, and retina. It is also present in several cancerous tissues such as glioblastoma and Wilm's tumor.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancers, including glioblastoma and Wilm's tumor, in addition to reproductive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune or reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, reproductive, gastrointestinal, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, seminal fluid, vitreous humor, aqueous humor, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:116 as residues: Arg-131 to Leu-136.

The tissue distribution and homology to a yeast cell division control protein CDC91, indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:43 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1613 of SEQ ID NO:43, b is an integer of 15 to 1627, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14.

WO 99/09155

47

PCT/US98/17044

<211> 39
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (16)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (39)
 <223> Xaa equals stop translation

<400> 92
 Met Ser Thr Val Lys Gln Ile Val Met Gly Leu Tyr Phe Val Tyr Xaa
 1 5 10 15
 Tyr Val Cys Phe Phe Tyr Ser Thr Phe Cys Gly Ser Ser Val Leu Leu
 20 25 30
 Val Ala Ser Ser Leu Leu Xaa
 35

<210> 93
 <211> 53
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (53)
 <223> Xaa equals stop translation

<400> 93
 Met Cys Leu Phe Phe Glu Asn Val Thr Leu Leu Phe Val Ile Val Leu
 1 5 10 15
 His Phe Ser Ala Phe Arg Pro Leu Tyr Phe His Lys Thr Pro Lys Thr
 20 25 30
 Ala Phe Asn Tyr Ile Ile Met Ser Val Phe Leu Asp Thr Asn Phe Cys
 35 40 45
 Ser Arg Met Thr Xaa
 50

<210> 94
 <211> 337
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (337)
 <223> Xaa equals stop translation

any integer between 1 to 1443 of SEQ ID NO:44, b is an integer of 15 to 1457, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 35

The translation product of this gene shares sequence homology with the human ADAM 21 protein, a testis-specific metalloprotease-like which is thought to be important in egg recognition during fertilization, and possibly in a more general role in integrin-mediated cell-cell recognition, adhesion or signalling (See Genbank Accession No.gil2739137 (AF029900)). In specific embodiments, polypeptides of the invention comprise the sequence:

FCYLCILLIVLFILLCCLYRLCKKSKPXKKQQXVQTPSAKEEEKIQRRPHELPP
 QSQPWVM PSQSQPPVTPSQSHQVMPSQSQPPVTPSQSQPRVMPSQSQPPVM
 PSQSHQQLTPSQSQPPVTPSQRQPQ LMPSQSQPPVTPS (SEQ ID NO:181),
 15 IRHETECGIDHICHRHCVHITILNSNCSPAFCNKRKICNNKHHCHCNLYLWDPP
 NCLIKGYGGSVDSGPP P (SEQ ID NO:179), or GICNNKHHCHC (SEQ ID
 NO:180). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in human testes.

20 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive disorders, particularly of the testis, or allergy, infectious and inflammatory diseases. Similarly, polypeptides and antibodies directed to these
 25 polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, seminal
 30 fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:118 as residues: Arg-12 to Ser-18.

35 The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system or reproductive disorders. The homology of this gene product to a

human metalloproteinase indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, the tissue distribution within testes, combined with its homology to a testes-specific metalloproteinase indicates that the protein product of this gene may show utility in the detection, treatment, and/or prevention of various reproductive disorders, particularly male infertility. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:45 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 874 of SEQ ID NO:45, b is an integer of 15 to 888, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 36

The translation product of this gene shares sequence homology with the human lysozyme which is thought to be important in the hydrolysis of proteins specific to bacteriolysis (See Genbank Accession No.P90343). As such the protein product of this gene may be useful as in antibiotic applications.

This gene is expressed primarily in testes and neutrophils induced by IL-1 and LPS.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders and afflictions, particularly in bacteria infections, and reproductive disorders, such as male infertility. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for

5 differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, seminal fluid, serum, plasma, urine, synovial fluid

10 and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:119 as residues: Lys-30 to Gly-35, Glu-64 to Gly-69.

15 The tissue distribution combined with the homology of the human lysozyme protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders, particularly bacterial infections. Expression of this gene product in neutrophils indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of

20 potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also

25 used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell

30 types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:46 and may have been publicly available prior to conception of the present invention.

35 Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides

comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 738 of SEQ ID NO:46, b is an integer of 15 to 752, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14.

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 37

The translation product of this gene shares sequence homology with human ApoE4L1 protease which is thought to be important in Alzheimer's disease. When tested against PC12 cell lines, supernatants removed from cells containing this gene activated the EGR1 (early growth response gene 1) pathway. Thus, it is likely that this gene activates sensory neuron cells through the EGR1 signal transduction pathway. EGR1 is a separate signal transduction pathway from Jaks-STAT, genes containing the EGR1 promoter are induced in various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation.

This gene is expressed primarily in small intestine, and to a lesser extent in T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, Alzheimer's disease, Downs syndrome, Parkinson's diseases and cardiovascular disease, or gastrointestinal or immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neural system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, gastrointestinal, neural, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, bile, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The homology to ApoE4L1 combined with the detected EGR1 activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, the

gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Alternatively, the expression within the small intestine and T-cells, indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:47 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1774 of SEQ ID NO:47, b is an integer of 15 to 1788, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 38

This gene is expressed primarily in human adult testis.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive or endocrine disorders, particularly male infertility. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male

reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. endocrine, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g. seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:121 as residues: Met-1 to Ser-10.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Alternatively, expression within testes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of a variety of male reproductive disorders, particularly male infertility. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:48 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 646 of SEQ ID NO:48, b is an integer of 15 to 660, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 39

The translation product of this gene shares sequence homology with ankyrin which is thought to be important in cell-cell interactions.

This gene is expressed in osteoblasts and tonsils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, disorders affecting the skeletal or immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, skeletal, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:122 as residues: Lys-41 to Gln-46.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in tonsils indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, expression within osteoblasts indicates a role in the detection and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis as well as disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly

available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:49 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

- 5 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1307 of SEQ ID NO:49, b is an integer of 15 to 1321, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is greater than or equal to a + 14.

10

FEATURES OF PROTEIN ENCODED BY GENE NO: 40

This gene is expressed in bone marrow, testes, liver, and retina.

- Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders affecting the immune, reproductive, or hepatic systems, such as AIDS, infertility, or cirrhosis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, reproductive, hepatic, ocular, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, bile, seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:123 as residues: Leu-20 to Pro-26.
- 15
- 20
- 25

- The tissue distribution in liver indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). Alternatively, The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human
- 30
- 35

immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anaemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility);

5 chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behaviour. Also contemplated is the use of the corresponding

10 nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:50 and may have been publicly available prior to conception

15 of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 534 of SEQ ID NO:50, b is an

20 integer of 15 to 548, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:50, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 41

This gene is expressed primarily in T cells.

25 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders affecting the immune or hematopoietic system, particularly immunodeficiencies such as AIDS. Similarly, polypeptides and antibodies directed to

30 these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily

35 fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the

standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in T-cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:51 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 644 of SEQ ID NO:51, b is an integer of 15 to 658, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:51, and where b is greater than or equal to a + 14.

30 FEATURES OF PROTEIN ENCODED BY GENE NO: 42

This gene is expressed in the immune system, especially T cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the immune system, particularly immunodeficiencies such as AIDS. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell

type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:125 as residues: Thr-6 to Leu-11, Pro-13 to Cys-27, Pro-65 to Met-72.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in T-cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:52 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 608 of SEQ ID NO:52, b is an integer of 15 to 622, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:52, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 43

This gene is expressed in T cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the immune system, particularly immunodeficiencies such as AIDS. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in T-cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:53 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly,

preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 709 of SEQ ID NO:53, b is an integer of 15 to 723, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID
5 NO:53, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 44

The translation product of this gene shares sequence homology with calmodulin which is known to be important in intracellular signalling.

10 This gene is expressed in T cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the immune system, particularly immunodeficiencies such as
15 AIDS. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and
20 cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25 The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in T-cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product
30 may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune
35 deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of

various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible
5 through sequence databases. Some of these sequences are related to SEQ ID NO:54 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides
10 comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 894 of SEQ ID NO:54, b is an integer of 15 to 908, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:54, and where b is greater than or equal to a + 14.

15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 45**

This gene is expressed primarily in the lung and ovary.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are
20 not limited to, cardiopulmonary or endocrine or reproductive disorders, including cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and reproductive systems, expression of this gene at significantly higher or
25 lower levels may be routinely detected in certain tissues or cell types (e.g. cardiopulmonary, endocrine, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in
30 healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis, treatment, or prevention of various lung and reproductive disorders, including cancer. Alternatively, expression within ovaries indicates that polynucleotides and polypeptides corresponding to this gene are
35 useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g.,

hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:55 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 808 of SEQ ID NO:55, b is an integer of 15 to 822, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:55, and where b is greater than or equal to a + 14.

15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 46**

The translation product of this gene was shown to have homology to the human 150 kDa oxygen-regulated protein ORP150, which may be involved in metabolic processes (See Genbank Accession No. AA004278). In specific embodiments, polypeptides of the invention comprise the sequence:

20 GSFRGTGRGRDGAQHPLLYVKLLIQVGHEPMPPTLGTVNLGRKVLVLPSSFFTY
 AKYIVQVDGKIGLFRGLSPRLMSNALSTVTRGSMKKVFPPDEIEQVSNKDD
 MKTSLKKVVKETSYEMMMQCVSRMLAHPLHVIS MRCMVQFVGREAKY
 SGVLSSIGKIFKEEGLLGFFVGLIPHLLGDVVFLWGCNLLAHFINAYLVDDSVS
 DTPGGLGNDQNPGSQFSQALAIRSYTKFV (SEQ ID NO:182). Polynucleotides
 25 encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in the breast, brain, and bone marrow.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the reproductive, neural, or hematopoietic system, including cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, skeletal, and central nervous systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. reproductive, neural, skeletal, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, breast milk, serum, plasma, urine, synovial fluid and spinal fluid) or

another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered bahaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Alternatively, expression within the bone marrow indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoetic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the abovelisted tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:56 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1937 of SEQ ID NO:56, b is an integer of 15 to 1951, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:56, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 47

This gene is expressed primarily in placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. reproductive, developing, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:130 as residues: Ser-49 to Cys-54.

Expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:57 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 649 of SEQ ID NO:57, b is an integer of 15 to 663, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:57, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 48

The gene encoding the disclosed cDNA is believed to reside on chromosome 18. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 18.

5 This gene is expressed primarily in brain.

 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders affecting the brain and central nervous system, particularly
10 neurodegenerative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell
15 types (e.g. neural, cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS,
25 psychoses , autism, and altered bahaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a
30 tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:58 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the
35 present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is

any integer between 1 to 764 of SEQ ID NO:58, b is an integer of 15 to 778, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:58, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 49

The translation product of this gene shares sequence homology with pigment epithelium derived factor which is thought to be important in enhancing neuronal cell survival and inhibiting glial cell proliferation, useful, e.g. in CNS cell culture or to treat neuro-degenerative diseases.

10 This gene is expressed primarily in epithelial cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural or integumentary disorders, particularly those affecting epithelial
15 cells, such as cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, neural, or integumentary system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell
20 types (e.g. epithelial, neural, integumentary, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25 The tissue distribution in epithelium, combined with the homology to the PEDF protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's
30 disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus),
35 keloids, striae, erythema, petechiae, purpura, and xanthelasma. Moreover, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils,

cellulitis, erysipelas, impetigo, tinea, athletes foot, and ringworm). Alternatively, the homology to the PDEF protein also indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons

5 Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the

10 developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:59 and

15 may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is

20 any integer between 1 to 968 of SEQ ID NO:59, b is an integer of 15 to 982, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:59, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 50

25 This gene is expressed primarily in the ovary and placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the reproductive system, including developing tissue.

30 Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. reproductive, developing, and

35 cancerous and wounded tissues) or bodily fluids (e.g. amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,

the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:133 as residues: Cys-43 to Lys-49.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of a variety of reproductive disorders, particularly infertility. In addition, expression within placental tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:60 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 392 of SEQ ID NO:60, b is an integer of 15 to 406, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:60, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 51

This gene is expressed primarily in immune cells, including B cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, particularly B cell lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune or hematopoietic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and

spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:134 as residues:

5 Thr-15 to Cys-21, Pro-60 to His-65, Pro-68 to Asp-74.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in B-cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of

10 potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also

15 used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell

20 types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:61 and may have been publicly available prior to conception of the present invention.

25 Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 799 of SEQ ID NO:61, b is an integer of 15 to 813, where

30 both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:61, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 52

This gene is expressed primarily in pineal gland, epididymus, and to a lesser

35 extent in bone marrow, melanocyte and cd34 positive cell.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endocrine, reproductive, or immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. reproductive, endocrine, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in pineal gland indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Alternatively, the expression in a variety of immune and hematopoietic disorders indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:62 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides

comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 832 of SEQ ID NO:62, b is an integer of 15 to 846, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:62, and where b is greater than or equal to a + 14.

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 53

When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activation site) promoter. Thus, it is likely that this gene activates promyelocytic cells through the Jaks-STAT signal transduction pathway. GAS is a promoter element found upstream in many genes which are involved in the Jaks-STAT pathway. The Jaks-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

15

This gene is expressed primarily in frontal cortex and cerebellum.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural or hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neural system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. neural, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20

25

30

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the

35

developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:63 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1428 of SEQ ID NO:63, b is an integer of 15 to 1442, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:63, and where b is greater than or equal to a + 14.

15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 54**

This gene is expressed primarily in T-cell activated by PHA.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, particularly those involving T lymphocytes, such as immunodeficiency disorders and AIDS. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:137 as residues: Ser-17 to Met-22, Cys-25 to Thr-37.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in T-cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product

may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also

5 used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell

10 types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:64 and may have been publicly available prior to conception of the present invention.

15 Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 990 of SEQ ID NO:64, b is an integer of 15 to 1004, where

20 both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:64, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 55

The translation product of this gene shares sequence homology with mouse

25 transmembrane protein which is thought to be important in tumorigenesis (See Genbank Accession No. gil535682). In specific embodiments, polypeptides of the invention comprise the sequence:

ARAAPRLLLLFLVPLLWAPAAVRAGPDEDLSHRNKEPPAPAQQLQPQPVAVQG
 PEPARVEDPYGVAVGGTVGHCLCTGLAVIGGRMIAQKISVRTVTIIGGIVFLA
 30 FAFSALFISPDSGF (SEQ ID NO:183). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in skin tumor, colorectal tumor, placenta and synovial fibroblast and to a lesser extent in multiple sclerosis, lymphoma, hypothalamus and spinal cord.

35 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, integumentary disorders, particularly tumors, sclerosis, or reproductive or neural disorders, such as schizophrenia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neural and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. skeletal, reproductive, integumentary, neural, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:138 as residues: Gly-7 to Pro-15.

The tissue distribution combined with its homology to a putative tumorigenic protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression within skin and colon tumors, in addition to placental tissue, and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Additionally, the expression in hematopoietic cells and tissues indicates that this protein may play a role in the proliferation, differentiation, and/or survival of hematopoietic cell lineages. In such an event, this gene may be useful in the treatment of lymphoproliferative disorders, and in the maintenance and differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:65 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1669 of SEQ ID NO:65, b is an integer of 15 to 1683, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:65, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 56

The translation product of this gene was shown to have homology to the human hMed7 protein which is thought to play a pivotal role in regulation of the human RNA
 5 polymerase II C-terminal domain (See Genbank Accession No.gil2736290 (AF031383)). In specific embodiments, polypeptides of the invention comprise the sequence:

FRIAWLLCLMICLIQKQECRVKTEPMDADDSNNCTGQNEHQRENSGHRRDQIIE
 KDAALCVLIDEMNERP (SEQ ID NO:184), RVKTEPMDADDSNNCTGQNEHQ
 10 ENSGHRRDQIIEKDAALCVLIDEMNERP (SEQ ID NO:185), QVSALPPPPMQYI
 KEYTDENIQEGLA (SEQ ID NO:186), SQGIERLHPMQFDHKKELRKLNMS (SEQ
 ID NO:187), or LETAERFQKHLERVIMIQNCLASLPDDLPH (SEQ ID NO:188).
 Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in fetal tissues, placenta, and various tumors.
 15 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental disorders and tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes
 20 for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. developmental, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid)
 25 or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution combined with the homology to the human hMed7 protein indicates that polynucleotides and polypeptides corresponding to this gene are
 30 useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Additionally, the expression in hematopoietic cells and tissues indicates that this protein may play a role in the proliferation, differentiation, and/or survival of hematopoietic cell
 35 lineages. In such an event, this gene may be useful in the treatment of lymphoproliferative disorders, and in the maintenance and differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells.

Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the abovelisted tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:66 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1427 of SEQ ID NO:66, b is an integer of 15 to 1441, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:66, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 57

This gene is expressed primarily in human early stage brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions:developmental or neural disorders, particularly malignant fibrous histiocytoma and related cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neural system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g.neural, developmental, and cancerous and wounded tissues) or bodily fluids (e.g.lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses , autism, and altered bahaviors, including disorders in feeding, sleep

patterns, balance, and preception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Alternatively, the tissue distribution indicates that polynucleotides and

5 polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Additionally, the expression in hematopoietic cells and tissues indicates that this protein may play a role in the proliferation, differentiation,

10 and/or survival of hematopoietic cell lineages. In such an event, this gene may be useful in the treatment of lymphoproliferative disorders, and in the maintenance and differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein

15 may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the abovelisted tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID

20 NO:67 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of

25 a-b, where a is any integer between 1 to 608 of SEQ ID NO:67, b is an integer of 15 to 622, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:67, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 58

30 The translation product of this gene was shown to have homology to an R47650 Interferon induced 1-8 gene encoded polypeptide which is known to be able to inhibit retroviral protein synthesis and/or assembly of retroviral structural proteins. The polypeptide can be used for treating or preventing retroviral infection, e.g. HIV; HTLV; bovine leukaemia virus, or can be used to assay the efficacy of interferon therapy. They

35 can also be used for extracorporeal treatment of a host's cells or for inhibiting retroviral replication in the cell. In specific embodiments, polypeptides of the invention comprise the sequence: MTMITPSSKLTLTGKNKWSSTAVAAALE LVDPPGCRNSPPPPH

TPFSYAFGVLDGNLGGGERKDRSGLPQPLLLLSPRVRIAGAPPPSWFLRTRPFSF
 CLYLLRILSLLMWLTPLPPLPAGGWPGGQVPAGAVNRXCAFVLVCACAVFL
 CFDRS (SEQ ID NO:189), or LTLTKGNKSWSSSTAVAAALELVDPPGCR (SEQ ID
 NO:190). Polynucleotides encoding these polypeptides are also encompassed by the
 5 invention.

This gene is expressed primarily in eosinophils, fetal liver, and small intestine
 Therefore, polynucleotides and polypeptides of the invention are useful as
 reagents for differential identification of the tissue(s) or cell type(s) present in a
 biological sample and for diagnosis of diseases and conditions which include, but are
 10 not limited to, hepatic, developmental, or immune disorders, particularly inflammation.
 Similarly, polypeptides and antibodies directed to these polypeptides are useful in
 providing immunological probes for differential identification of the tissue(s) or cell
 type(s). For a number of disorders of the above tissues or cells, particularly of the
 immune or hepatic system, expression of this gene at significantly higher or lower
 15 levels may be routinely detected in certain tissues or cell types (e.g. hepatic, immune,
 developmental, gastrointestinal, and cancerous and wounded tissues) or bodily fluids
 (e.g. lymph, bile, serum, plasma, urine, synovial fluid and spinal fluid) or another
 tissue or cell sample taken from an individual having such a disorder, relative to the
 standard gene expression level, i.e., the expression level in healthy tissue or bodily
 20 fluid from an individual not having the disorder. Preferred epitopes include those
 comprising a sequence shown in SEQ ID NO:141 as residues: Glu-12 to Gln-18.

The tissue distribution indicates that polynucleotides and polypeptides
 corresponding to this gene are useful for the diagnosis and treatment of a variety of
 immune system disorders. Expression of this gene product in eosinophils indicates a
 25 role in the regulation of the proliferation; survival; differentiation; and/or activation of
 potentially all hematopoietic cell lineages, including blood stem cells. This gene product
 may be involved in the regulation of cytokine production, antigen presentation, or other
 processes that may also suggest a usefulness in the treatment of cancer (e.g. by
 boosting immune responses). Since the gene is expressed in cells of lymphoid origin,
 30 the natural gene product may be involved in immune functions. Therefore it may be also
 used as an agent for immunological disorders including arthritis, asthma, immune
 deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel
 disease, sepsis, acne, and psoriasis. and tissues. In addition, this gene product may
 have commercial utility in the expansion of stem cells and committed progenitors of
 35 various blood lineages, and in the differentiation and/or proliferation of various cell
 types. Alternatively, expression within infant liver indicates that polynucleotides and
 polypeptides corresponding to this gene are useful for the detection and treatment of

liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). In addition the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various wound-healing models and/or tissue trauma. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:68 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 602 of SEQ ID NO:68, b is an integer of 15 to 616, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:68, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 59

The gene encoding the disclosed cDNA is believed to reside on chromosome 8. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 8.

This gene is expressed primarily in infant brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural or developmental disorders, particularly ischemic damage to the CNS. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the Central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. neural, developmental, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:142 as residues: Met-1 to Ser-6, Pro-51 to Ser-57, Ser-78 to Asp-93.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered bahaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:69 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1005 of SEQ ID NO:69, b is an integer of 15 to 1019, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:69, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 60

The gene encoding the disclosed cDNA is believed to reside on chromosome 7. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 7.

This gene is expressed primarily in the immune system including T helper II cells, neutrophils, buffy coat and lymph nodes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly inflammation, autoimmunity, and immunodeficiencies such as AIDS. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell

types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in T-cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:70 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 817 of SEQ ID NO:70, b is an integer of 15 to 831, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:70, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 61

This gene is expressed in the medulla region of Kidney.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, urogenital or renal disorders, particularly kidney failure. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the renal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. urogenital, renal, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:144 as residues: Lys-8 to Thr-13, Glu-39 to Gly-46.

The tissue distribution in kidney indicates that this gene or gene product could be used in the treatment and/or detection of kidney diseases including renal failure, nephritis, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilms Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:71 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 736 of SEQ ID NO:71, b is an integer of 15 to 750, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:71, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 62

This gene is expressed primarily in a prostate cells and testes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive disorders, particularly prostatic hyperplasia, prostatic cancer

and testes cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. reproductive, urogenital, endocrine, and cancerous and wounded tissues) or bodily fluids (e.g. seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:145 as residues: Lys-19 to Asn-32.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various disorders of the reproductive system, including cancers of the prostate or testes. Alternatively, the expression within testes may suggest that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:72 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 700 of SEQ ID NO:72, b is an integer of 15 to 714, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:72, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 63

This gene is expressed primarily in hepatocellular tumors, skin tumors, osteoclastoma, and to a lesser extent in kidney and lung.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, tumors particularly of the hepatic, integumentary or skeletal system.

- 5 Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skin and hepatic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. integumentary, hepatic, 10 skeletal, urogenital, endocrine, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, bile, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those 15 comprising a sequence shown in SEQ ID NO:146 as residues: Pro-10 to Pro-17.

- The tissue distribution in skin indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. 20 keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, 25 pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. Moreover, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athlete's foot, and ringworm). Alternatively, expression within bone would suggest a role in the 30 detection and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis as well as disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and 35 specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the

protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:73 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1391 of SEQ ID NO:73, b is an integer of 15 to 1405, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:73, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 64

This gene is expressed primarily in meningioma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, meningioma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the Central Nervous System, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. neural, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating tumors of the meninges. Similarly, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered bahaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo,

sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence
5 databases. Some of these sequences are related to SEQ ID NO:74 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence
10 described by the general formula of a-b, where a is any integer between 1 to 893 of SEQ ID NO:74, b is an integer of 15 to 907, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:74, and where b is greater than or equal to a + 14.

15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 65**

This gene is expressed primarily in Wilm's tumor.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are
20 not limited to, urogenital or renal disorders, particularly tumors of the kidney. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the renal, expression of this gene at significantly higher or lower levels may be routinely detected in certain
25 tissues or cell types (e.g. renal, urogenital, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those
30 comprising a sequence shown in SEQ ID NO:148 as residues: Glu-6 to Cys-12.

The tissue distribution in kidney indicates that this gene or gene product could be used in the treatment and/or detection of kidney diseases including renal failure, nephritis, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria,
35 renal colic and kidney stones, in addition to Wilms Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Protein, as well as, antibodies directed against the protein may show utility

as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:75 and may have been publicly available prior to conception of the present invention.

- 5 Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 673 of SEQ ID NO:75, b is an integer of 15 to 687, where
10 both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:75, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 66

This gene is expressed primarily in neutrophils.

- 15 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, such as autoimmune disease or inflammatory disease. Similarly, polypeptides and antibodies directed to these
20 polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample
25 taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

- The tissue distribution indicates that polynucleotides and polypeptides
30 corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in neutrophils indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other
35 processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also

used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:76 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 778 of SEQ ID NO:76, b is an integer of 15 to 792, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:76, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 67

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, such as diseases resulting from chronic or acute inflammatory response. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:150 as residues: Pro-43 to Ser-49, Met-56 to Gly-66, Gln-69 to Pro-75.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in neutrophils indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:77 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 742 of SEQ ID NO:77, b is an integer of 15 to 756, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:77, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 68

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, such as inflammation or autoimmune diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may

be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:151 as residues: Pro-24 to Glu-29, Glu-31 to Pro-37, Pro-48 to Asp-55, Arg-87 to Pro-93, Pro-100 to Ser-106.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in neutrophils indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:78 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 737 of SEQ ID NO:78, b is an integer of 15 to 751, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:78, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 69

The gene encoding the disclosed cDNA is believed to reside on chromosome 12. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 12.

5 This gene is expressed primarily in the fetal ear, and to a lesser extent, in osteoclastoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are
10 not limited to, skeletal or developmental disorders, particularly abnormal bone formation such as bone tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal system, expression of this gene at significantly higher or
15 lower levels may be routinely detected in certain tissues or cell types (e.g. skeletal, epithelial, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not
20 having the disorder.

In addition, the expression of this gene product in osteoclasts would suggest a role in the detection and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis as well as disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the
25 diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the
30 protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:79 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded
35 from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of

a-b, where a is any integer between 1 to 1397 of SEQ ID NO:79, b is an integer of 15 to 1411, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:79, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 70

The translation product of this gene was found to have homology to the human kidney epidermal growth factor precursor (See Genbank Accession No. R51437). The gene encoding the disclosed cDNA is believed to reside on chromosome 3.

Accordingly, polynucleotides related to this invention are useful as a marker in linkage
10 analysis for chromosome 3.

This gene is expressed primarily in brain, and to a lesser extent, in prostate.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are
15 not limited to, neural or reproductive disorders, particularly prostate disease such as tumors of the prostate and benign prostatic hypertrophy. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine, neural or reproductive
20 systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. reproductive, neural, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the
25 expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:153 as residues: Ser-49 to Arg-54.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative
30 disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, the gene or gene product may also play a
35 role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Alternatively, expression within the prostate indicates that the translation

product of this gene is useful for the detection, treatment, and/or prevention of a variety of reproductive disorders, including prostate cancer, and infertility. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:80 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 852 of SEQ ID NO:80, b is an integer of 15 to 866, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:80, and where b is greater than or equal to a + 14.

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	5' NT 3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	HCUDK80	209178 07/24/97	ZAP Express	11	392	1	392	80	80	84	1	26	27	29
2	HCWFFV11	209178 07/24/97	ZAP Express	12	465	1	465	126	126	85	1	33	34	33
3	HCWHN10	209178 07/24/97	ZAP Express	13	674	1	674	85	85	86	1	25	26	65
4	HCWHT35	209178 07/24/97	ZAP Express	14	297	1	297	36	36	87	1	16	17	26
5	HDTAE40	209178 07/24/97	pCMVSPORT 2.0	15	604	1	604	110	110	88	1	34	35	48
6	HE2BX71	209178 07/24/97	Uni-ZAP XR	16	1146	203	1146	276	276	89	1	27	28	32
7	HE2EO70	209178 07/24/97	Uni-ZAP XR	17	678	1	678	150	150	90	1	15	16	22

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
8	HE8DY08	209178 07/24/97	Uni-ZAP XR	18	1305	393	1305	734	734	91	1	23	24	54
9	HE9NB19	209178 07/24/97	Uni-ZAP XR	19	1060	1	1060	174	174	92	1	26	27	38
10	HE9ND27	209178 07/24/97	Uni-ZAP XR	20	1170	95	1170	353	353	93	1	27	28	52
11	HCE3G69	209878 05/18/98	Uni-ZAP XR	21	2084	1	2084	165	165	94	1	19	20	336
11	HEAAA85	209178 07/24/97	Uni-ZAP XR	81	2078	1290	2065	1295	1295	154	1	58	59	118
12	HEAAX57	209178 07/24/97	Uni-ZAP XR	22	643	1	643	127	127	95	1	38	39	48
13	HEEAG93	209178 07/24/97	Uni-ZAP XR	23	647	1	647	334	334	96	1	21	22	37
14	HEGAI9I	209178 07/24/97	Uni-ZAP XR	24	825	1	825	179	179	97	1	18	19	28

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
15	HEIAU93	209178 07/24/97	Uni-ZAP XR	25	541	1	541	96	96	98	1	24	25	35
16	HEMGDI5	209178 07/24/97	Uni-ZAP XR	26	852	1	711	20	20	99	1	31	32	181
17	HEQBR95	209178 07/24/97	pCMVSPORT 3.0	27	4598	2673	3242	2767	2767	100	1	50	51	83
18	HFCWE42	209178 07/24/97	Uni-ZAP XR	28	585	1	585	95	95	101	1	18	19	24
19	HFIXC91	209178 07/24/97	pSport1	29	824	1	824	244	244	102	1	19	20	31
20	HFKFN45	209178 07/24/97	Uni-ZAP XR	30	773	153	721	428	428	103	1	25	26	27
21	HFKGE44	209178 07/24/97	Uni-ZAP XR	31	969	141	969	363	363	104	1	29	30	86
22	HFPYC39	209178 07/24/97	Uni-ZAP XR	32	1355	1	606	362	362	105	1	14	15	127

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
23	HFTBS49	209178 07/24/97	Uni-ZAP XR	33	536	1	362	232	232	106	1	30	31	30
24	HFVHE58	209178 07/24/97	pBluescript	34	1123	594	1123	762	762	107	1	17	18	31
25	HFXDX75	209178 07/24/97	Lambda ZAP II	35	587	1	587	300	300	108	1	29	30	96
26	HFXFZ81	209178 07/24/97	Lambda ZAP II	36	842	1	842	129	129	109	1	16	17	21
27	HFXJC53	209178 07/24/97	Lambda ZAP II	37	953	1	953	707	707	110	1	42	43	46
28	HFXJW48	209178 07/24/97	Lambda ZAP II	38	2211	63	635	356	356	111	1	17	18	355
29	HGBGO11	209178 07/24/97	Uni-ZAP XR	39	682	1	682	58	58	112	1	36	37	70
30	HGBHM10	209178 07/24/97	Uni-ZAP XR	40	685	18	665	36	36	113	1	17	18	170

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
31	HSSAO72	209194 08/01/97	Uni-ZAP XR	41	550	1	550	28	28	114	1	34	35	35
32	HSSEO83	209194 08/01/97	Uni-ZAP XR	42	602	1	602	233	233	115	1			13
33	HSWAY58	209194 08/01/97	pCMVSPORT 3.0	43	1627	702	1627	815	815	116	1	18	19	155
34	HSXAR64	209194 08/01/97	Uni-ZAP XR	44	1457	1000	1457	1191	1191	117	1	24	25	38
35	HTECE72	209194 08/01/97	Uni-ZAP XR	45	888	1	888	184	184	118	1	46	47	45
36	HTEIM65	209194 08/01/97	Uni-ZAP XR	46	752	1	752	109	109	119	1	19	20	146
37	HTHBX95	209194 08/01/97	Uni-ZAP XR	47	1788	1025	1788	1054	1054	120	1	25	26	43
38	HTLDQ56	209194 08/01/97	Uni-ZAP XR	48	660	1	660	174	174	121	1	36	37	80

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	5' NT 3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
39	HTOFU06	209194 08/01/97	Uni-ZAP XR	49	1321	300	1321	255	255	122	1	16	17	98
39	HTOFU06	209194 08/01/97	Uni-ZAP XR	82	1064	15	1064	227	227	155	1	27	28	27
40	HTPDX06	209194 08/01/97	Uni-ZAP XR	50	548	1	548	216	216	123	1	21	22	31
41	HTWCE16	209194 08/01/97	pSport1	51	658	1	658	208	208	124	1	19	20	21
42	HTWEE31	209194 08/01/97	pSport1	52	622	1	622	27	27	125	1	41	42	121
43	HTWEL91	209194 08/01/97	pSport1	53	723	1	723	154	154	126	1	23	24	25
44	HTXDE07	209194 08/01/97	Uni-ZAP XR	54	908	1	908	84	84	127	1			23
45	HUFBO40	209194 08/01/97	pSport1	55	822	1	816	172	172	128	1	24	25	38

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
46	HUSAO56	209194 08/01/97	Lambda ZAP II	56	1951	839	1947	922	922	129	1	26	27	73
47	HUSIJ08	209194 08/01/97	pSport1	57	663	1	663	351	351	130	1	50	51	54
48	HAGBD57	209194 08/01/97	Uni-ZAP XR	58	778	1	778	221	221	131	1	29	30	43
49	HAICJ56	209194 08/01/97	Uni-ZAP XR	59	982	1	982	68	68	132	1	24	25	36
50	HBFAFA04	209194 08/01/97	pSport1	60	406	1	406	96	96	133	1	33	34	49
51	HBJES16	209194 08/01/97	Uni-ZAP XR	61	813	1	813	309	309	134	1	56	57	84
52	HBMTA15	209194 08/01/97	Uni-ZAP XR	62	846	1	846	116	116	135	1	19	20	22
53	HCEFZ05	209194 08/01/97	Uni-ZAP XR	63	1442	548	1442	587	587	136	1	15	16	44

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
54	HCFMX95	209194 08/01/97	pSport1	64	1004	1	1004	186	186	137	1	16	17	46
55	HL YHA71	209852 05/07/98	pSport1	65	1683	156	1683	55	55	138	1	25	26	288
55	HDTAR09	209194 08/01/97	pCMVSPORT 2.0	83	1126	355	1126	602	602	156	1	15	16	45
56	HE9FC17	209194 08/01/97	Uni-ZAP XR	66	1441	590	1087	780	780	139	1	17	18	23
57	HEBAL06	209194 08/01/97	Uni-ZAP XR	67	622	1	622	93	93	140	1	18	19	53
58	HEIAB33	209195 08/01/97	Uni-ZAP XR	68	616	1	616	269	269	141	1	43	44	60
59	HEPBC02	209195 08/01/97	Uni-ZAP XR	69	1019	15	829	137	137	142	1	36	37	100
60	HFTBY96	209195 08/01/97	Uni-ZAP XR	70	831	1	831	150	150	143	1	17	18	41

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
61	HKMMM61	209195 08/01/97	pBluescript	71	750	1	750	130	130	144	1	37	38	62
62	HL3AA35	209195 08/01/97	Uni-ZAP XR	72	714	1	714	56	56	145	1	24	25	32
63	HLQBQ38	209195 08/01/97	Lambda ZAP II	73	1405	453	1405	472	472	146	1	39	40	41
64	HMKCP66	209195 08/01/97	pSport1	74	907	1	907	353	353	147	1	19	20	40
65	HWTAL40	209195 08/01/97	Uni-ZAP XR	75	687	51	687	124	124	148	1	31	32	43
66	HNHDR03	209195 08/01/97	Uni-ZAP XR	76	792	1	792	184	184	149	1	45	46	54
67	HNHFH41	209195 08/01/97	Uni-ZAP XR	77	756	1	756	52	52	150	1	24	25	165
68	HNHFI81	209195 08/01/97	Uni-ZAP XR	78	751	1	751	46	46	151	1	18	19	113

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
69	HOSFQ28	209195 08/01/97	Uni-ZAP XR	79	1411	219	987	304	304	152	1	20	21	39
70	HPRAL78	209195 08/01/97	Uni-ZAP XR	80	866	128	866	148	148	153	1	42	43	63

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X and the translated SEQ ID NO:Y are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used to generate antibodies which bind specifically to the secreted proteins encoded by the cDNA clones identified in Table 1.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid
5 sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide
10 sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by
15 sequencing the deposited clone in accordance with known methods. The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its
20 sequence.

The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed sequence and
25 identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are species homologs. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for the desired
30 homologue.

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well
35 understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below).

It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

5 The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural or recombinant sources
10 using antibodies of the invention raised against the secreted protein in methods which are well known in the art.

Signal Sequences

Methods for predicting whether a protein has a signal sequence, as well as the
15 cleavage point for that sequence, are available. For instance, the method of McGeoch, Virus Res. 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, Nucleic Acids Res. 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1
20 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. (von Heinje, supra.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide
25 was analyzed by a computer program called SignalP (Henrik Nielsen et al., Protein Engineering 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results
30 shown in Table 1.

As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., +
35 or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely

uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

10 **Polynucleotide and Polypeptide Variants**

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

By a polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown in Table 1, the ORF (open reading frame), or any fragement specified as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are:

Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization

Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query

amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions,
5 interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequences shown in Table 1 or to the amino acid sequence encoded by deposited DNA clone can be
10 determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and
15 subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window
20 Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity.
25 For subject sequences truncated at the N- and C-termini, relative to the the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of
30 the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are
35 considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired
5 residues represent 10% of the sequence (number of residues at the N- and C- termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence.
10 This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query
15 sequence are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or
20 activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in
25 the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level.
30 Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be
35 deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., J. Biol. Chem. 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after

deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as to have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. (Cunningham
5 and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the
10 protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues
15 Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues,
20 where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino
25 acids, such as an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins
30 with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

35

Polynucleotide and Polypeptide Fragments

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence contained in the deposited clone or shown in SEQ ID NO:X. The short nucleotide fragments are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in the deposited clone or the nucleotide sequence shown in SEQ ID NO:X. These nucleotide fragments are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments having a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X or the cDNA contained in the deposited clone. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein.

In the present invention, a "polypeptide fragment" refers to a short amino acid sequence contained in SEQ ID NO:Y or encoded by the cDNA contained in the deposited clone. Protein fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-

60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred.

5 Similarly, polynucleotide fragments encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-
10 forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotide
15 fragments encoding these domains are also contemplated.

Other preferred fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.
20

Epitopes & Antibodies

In the present invention, "epitopes" refer to polypeptide fragments having antigenic or immunogenic activity in an animal, especially in a human. A preferred embodiment of the present invention relates to a polypeptide fragment comprising an
25 epitope, as well as the polynucleotide encoding this fragment. A region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." In contrast, an "immunogenic epitope" is defined as a part of a protein that elicits an antibody response. (See, for instance, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998- 4002 (1983).)

30 Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985) further described in U.S. Patent No. 4,631,211.)

In the present invention, antigenic epitopes preferably contain a sequence of at least seven, more preferably at least nine, and most preferably between about 15 to
35 about 30 amino acids. Antigenic epitopes are useful to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe, J. G. et al., Science 219:660-666 (1983).)

Similarly, immunogenic epitopes can be used to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow, M. et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle, F. J. et al., J. Gen. Virol. 66:2347-2354 (1985).) A preferred immunogenic epitope includes
5 the secreted protein. The immunogenic epitopes may be presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if it is long enough (at least about 25 amino acids), without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a
10 denatured polypeptide (e.g., in Western blotting.)

As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab')₂ fragments) which are capable of specifically binding to protein. Fab and F(ab')₂ fragments lack the Fc fragment of intact antibody, clear more rapidly from
15 the circulation, and may have less non-specific tissue binding than an intact antibody. (Wahl et al., J. Nucl. Med. 24:316-325 (1983).) Thus, these fragments are preferred, as well as the products of a FAB or other immunoglobulin expression library. Moreover, antibodies of the present invention include chimeric, single chain, and humanized antibodies.

20

Fusion Proteins

Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the
25 polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention
30 include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino
35 acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the

polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., *Nature* 331:84-86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., *J. Biochem.* 270:3958-3964 (1995).)

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., *J. Molecular Recognition* 8:52-58 (1995); K. Johanson et al., *J. Biol. Chem.* 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., *Proc. Natl. Acad. Sci. USA* 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., *Cell* 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

Vectors, Host Cells, and Protein Production

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods
5 In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography,
10 phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also
15 be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production
20 procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein
25 after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

30 **Uses of the Polynucleotides**

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

The polynucleotides of the present invention are useful for chromosome
35 identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat

polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be
5 selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the
10 polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome
15 specific-cDNA libraries.

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al.,
20 "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides
25 correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage
30 analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease
35 could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined.

First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the
5 mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected
10 individuals as compared to unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

In addition to the foregoing, a polynucleotide can be used to control gene
15 expression through triple helix formation or antisense DNA or RNA. Both methods rely on binding of the polynucleotide to DNA or RNA. For these techniques, preferred polynucleotides are usually 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science
20 251:1360 (1991)) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model
25 systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the
30 present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of
35 restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying

personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

5 The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set
10 of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

 Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as
15 tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more
20 restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

 There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of
25 unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

30 In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using
35 DNA immunization techniques, and as an antigen to elicit an immune response.

Uses of the Polypeptides

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

5 A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell . Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay
10 (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (^{125}I , ^{121}I), carbon (^{14}C), sulfur (^{35}S), tritium (^3H), indium (^{112}In), and technetium ($^{99\text{m}}\text{Tc}$), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

15 In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for
20 NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example, ^{131}I ,
25 ^{112}In , $^{99\text{m}}\text{Tc}$), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human
30 subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of $^{99\text{m}}\text{Tc}$. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The
35 Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder.

Moreover, polypeptides of the present invention can be used to treat disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B), to inhibit the activity of a polypeptide (e.g., an oncogene), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

Biological Activities

The polynucleotides and polypeptides of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides could be used to treat the associated disease.

Immune Activity

A polypeptide or polynucleotide of the present invention may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the

proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune deficiencies or disorders
5 may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotide or polypeptide of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

A polynucleotide or polypeptide of the present invention may be useful in
10 treating or detecting deficiencies or disorders of hematopoietic cells. A polypeptide or polynucleotide of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat those disorders associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to:
15 blood protein disorders (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

20 Moreover, a polypeptide or polynucleotide of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, a polynucleotide or polypeptide of the present invention could be used to treat blood coagulation disorders (e.g., afibrinogenemia, factor deficiencies), blood platelet
25 disorders (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotide or polypeptide of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment of heart attacks (infarction), strokes, or scarring.

30 A polynucleotide or polypeptide of the present invention may also be useful in treating or detecting autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polypeptide or polynucleotide of the
35 present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Examples of autoimmune disorders that can be treated or detected by the present invention include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, 5 Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

10 Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by a polypeptide or polynucleotide of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotide or polypeptide of the present invention may also be used to 15 treat and/or prevent organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of a polypeptide or polynucleotide of the present invention that inhibits 20 an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polypeptide or polynucleotide of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide may inhibit the proliferation and differentiation of cells involved in an inflammatory 25 response. These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel 30 disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

Hyperproliferative Disorders

A polypeptide or polynucleotide can be used to treat or detect hyperproliferative 35 disorders, including neoplasms. A polypeptide or polynucleotide of the present invention may inhibit the proliferation of the disorder through direct or indirect

interactions. Alternatively, a polypeptide or polynucleotide of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

Examples of hyperproliferative disorders that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but are not limited to neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstrom's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

Infectious Disease

A polypeptide or polynucleotide of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, the polypeptide or polynucleotide of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of viruses, include, but are not limited to the following DNA and RNA viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes

Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza), Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiollitis, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following Gram-Negative and Gram-positive bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Norcardia), Aspergillosis, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia, Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, Enterobacteriaceae (Klebsiella, Salmonella, Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Meningococcal), Pasteurellaceae Infections (e.g., Actinobacillus, Haemophilus, Pasteurella), Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis, and Staphylococcal. These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis, Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Moreover, parasitic agents causing disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following families: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas. These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), Malaria, pregnancy complications, and toxoplasmosis. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Preferably, treatment using a polypeptide or polynucleotide of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

Regeneration

A polynucleotide or polypeptide of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vascular (including vascular endothelium), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue

regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide of the present invention to proliferate and differentiate
5 nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized
10 neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotide or polypeptide of the present invention.

15 **Chemotaxis**

A polynucleotide or polypeptide of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of
20 hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system
25 disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that a polynucleotide or polypeptide of the present
30 invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, a polynucleotide or polypeptide of the present invention could be used as an inhibitor of chemotaxis.

Binding Activity

35 A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit

(antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.

Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a candidate binding compound with a polypeptide of the invention; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying
5 agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the invention, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

Other Activities

10 A polypeptide or polynucleotide of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

A polypeptide or polynucleotide of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color,
15 skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, a polypeptide or polynucleotide of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

A polypeptide or polynucleotide of the present invention may be used to change
20 a mammal's mental state or physical state by influencing biorhythms, circadian rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

25 A polypeptide or polynucleotide of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

Other Preferred Embodiments

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

35 Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of

positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous
5 nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of
10 contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide
15 sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide
20 sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

A further preferred embodiment is a nucleic acid molecule comprising a
nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ
ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the
First Amino Acid of the Signal Peptide and ending with the nucleotide at about the
25 position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in
Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising
a nucleotide sequence which is at least 95% identical to the complete nucleotide
sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under
30 stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which
35 comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1,
which DNA molecule is contained in the material deposited with the American Type

Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous
5 nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete
10 open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising
15 a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.

20 A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone
25 identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95%
30 identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of
35 comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in
5 Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as
10 defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an
15 amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method
20 comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence
25 selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an
30 amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is
35 performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as
5 defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type
10 of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel
15 is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number
20 shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a
30 polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table
35 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide
5 comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

10 Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

15 Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid
20 sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human
25 cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an
30 individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of
35 illustration and are not intended as limiting.

Examples**Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample**

5 Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector. Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For
10 example, where a particular clone is identified in Table 1 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited Plasmid</u>
	Lambda Zap	pBluescript (pBS)
	Uni-Zap XR	pBluescript (pBS)
15	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSPORT 2.0	pCMVSPORT 2.0
	pCMVSPORT 3.0	pCMVSPORT 3.0
20	pCR [®] 2.1	pCR [®] 2.1

 Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res.
25 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS.
30 The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the f1 origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the f1 ori generates sense strand DNA and in the other, antisense.

35 Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain

DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., *Focus* 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into *E. coli* strain XL-1 Blue. Vector pCR[®]2.1, which is available from Invitrogen, 1600 Faraday Avenue,
5 Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into *E. coli* strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., *Nuc. Acids Res.* 16:9677-9686 (1988) and Mead, D. et al., *Bio/Technology* 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the
10 corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone
15 identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited
20 sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported.
25 The oligonucleotide is labeled, for instance, with ³²P-γ-ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as
30 those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory*
35 *Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 μ l of reaction mixture with 0.5 μ g of the above cDNA template. A convenient reaction mixture is 1.5-5 mM MgCl_2 , 0.01% (w/v) gelatin, 20 μ M each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., *Nucleic Acids Res.* 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is

used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

5

Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

10

Example 3: Tissue Distribution of Polypeptide

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P³² using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

15

20

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70°C overnight, and the films developed according to standard procedures.

25

Example 4: Chromosomal Mapping of the Polynucleotides

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95°C; 1 minute, 56°C; 1 minute, 70°C. This cycle is repeated 32 times followed by one 5 minute cycle at 70°C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on

30

35

either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

5 **Example 5: Bacterial Expression of a Polypeptide**

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as
10 BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site
15 (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses
20 the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml).
25 The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

30 Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4°C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from
35 QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high

affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed
5 with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The
10 recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer
15 plus 200 mM NaCl. The purified protein is stored at 4° C or frozen at -80° C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a
20 neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with NdeI and
25 XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or
30 Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

35 **Example 6: Purification of a Polypeptide from an Inclusion Body**

The following alternative method can be used to purify a polypeptide expressed in *E coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10°C.

Upon completion of the production phase of the *E. coli* fermentation, the cell
5 culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a
10 high shear mixer.

The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M
15 NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.

20 Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.

25 To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 µm membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted
30 with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem

columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column
5 volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A_{280} monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above
10 refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 μ g of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

15 **Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System**

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus
20 (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The
25 inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as
30 long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., Virology 170:31-39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the
35 AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring

signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures,"
5 Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

10 The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("Geneclean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue
15 (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

20 Five µg of a plasmid containing the polynucleotide is co-transfected with 1.0 µg of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One µg of BaculoGold™ virus DNA and 5 µg of the plasmid are mixed in a sterile well of a
25 microtiter plate containing 50 µl of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 µl Lipofectin plus 90 µl Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then
30 incubated for 5 hours at 27° C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27° C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life
35 Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture

and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 μ l of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4° C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 μ Ci of ^{35} S-methionine and 5 μ Ci ^{35} S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

Example 8: Expression of a Polypeptide in Mammalian Cells

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

5 The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and
10 Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a
15 chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No.209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et
20 al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse
25 DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol
30 outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially
35 available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five μ g of the expression plasmid pC6 is cotransfected with 0.5 μ g of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 μ M, 2 μ M, 5 μ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 μ M. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

Example 9: Protein Fusions

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

5 For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that
10 the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a
15 heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

GGGATCCGGAGCCCAAATCTTCTGACAAACTCACACATGCCCACCGTGCC
CAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCAAACC
20 CAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGCGTGGT
GGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACG
GCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAAC
AGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTG
AATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAACCCCC
25 ATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGT
GTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCT
GACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGTGGAGTGGGA
GAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCTCCCGTGCTGG
ACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCA
30 GGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGC
ACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGC
GACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

Example 10: Production of an Antibody from a Polypeptide

35 The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) For example, cells expressing a polypeptide of the present invention is administered to an animal to induce the production of sera

containing polyclonal antibodies. In a preferred method, a preparation of the secreted protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

5 In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., *Nature* 256:495 (1975); Köhler et al., *Eur. J. Immunol.* 6:511 (1976); Köhler et al., *Eur. J. Immunol.* 6:292 (1976); Hammerling et al., in: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures
10 involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at
15 about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

 The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line
20 (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (*Gastroenterology* 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

25 Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a
30 mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further protein-specific
35 antibodies.

It will be appreciated that Fab and F(ab')₂ and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments). Alternatively,
5 secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies
10 described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268
15 (1985).)

Example 11: Production Of Secreted Protein For High-Throughput Screening Assays

The following protocol produces a supernatant containing a polypeptide to be
20 tested. This supernatant can then be used in the Screening Assays described in Examples 13-20.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates)
25 and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

30 Plate 293T cells (do not carry cells past P+20) at 2×10^5 cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine
35 (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in

Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37°C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl₂ (anhyd); 0.00130 mg/L CuSO₄·5H₂O; 0.050 mg/L of Fe(NO₃)₃·9H₂O; 0.417 mg/L of FeSO₄·7H₂O; 311.80 mg/L of KCl; 28.64 mg/L of MgCl₂; 48.84 mg/L of MgSO₄; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO₃; 62.50 mg/L of NaH₂PO₄·H₂O; 71.02 mg/L of Na₂HPO₄; .4320 mg/L of ZnSO₄·7H₂O; .002 mg/L of Arachidonic Acid ; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitric Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine-H₂O; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL-H₂O; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-H₂O; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2H₂O; 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and 0.680 mg/L of Vitamin B₁₂; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine;

0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37°C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

Example 12: Construction of GAS Reporter Construct

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are
5 generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, *Ann. Rev. Biochem.* 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-
10 12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN- α , IFN- γ , and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

15 Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the
20 proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

<u>Ligand</u>	<u>tyk2</u>	<u>JAKs</u> <u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>	<u>STATS</u>	<u>GAS(elements) or ISRE</u>
<u>IFN family</u>						
IFN-a/B	+	+	-	-	1,2,3	ISRE
IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
IL-10	+	?	?	-	1,3	
<u>gp130 family</u>						
IL-6 (Pleiotrohic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
IL-11(Pleiotrohic)	?	+	?	?	1,3	
OnM(Pleiotrohic)	?	+	+	?	1,3	
LIF(Pleiotrohic)	?	+	+	?	1,3	
CNTF(Pleiotrohic)	-/+	+	+	?	1,3	
G-CSF(Pleiotrohic)	?	+	?	?	1,3	
IL-12(Pleiotrohic)	+	-	+	+	1,3	
<u>g-C family</u>						
IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
IL-7 (lymphocytes)	-	+	-	+	5	GAS
IL-9 (lymphocytes)	-	+	-	+	5	GAS
IL-13 (lymphocyte)	-	+	?	?	6	GAS
IL-15	?	+	?	+	5	GAS
<u>gp140 family</u>						
IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
IL-5 (myeloid)	-	-	+	-	5	GAS
GM-CSF (myeloid)	-	-	+	-	5	GAS
<u>Growth hormone family</u>						
GH	?	-	+	-	5	
PRL	?	+/-	+	-	1,3,5	
EPO	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)
<u>Receptor Tyrosine Kinases</u>						
EGF	?	+	+	-	1,3	GAS (IRF1)
PDGF	?	+	+	-	1,3	
CSF-1	?	+	+	-	1,3	GAS (not IRF1)

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

5':GCGCCTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCG
 10 AAATGATTTCCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

5':CTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCGAAATG
 20 ATTTCCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCC
 CTA ACTCCGCCCATCCCGCCCCTA ACTCCGCCCAGTTCCGCCCATTCTCCGC
 CCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGC
 CTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCCTAGGCTTT
 TGCAAAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using Sall and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

Example 13: High-Throughput Screening Assay for T-cell Activity.

The following protocol is used to assess T-cell activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies)

with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells (10^7 per transfection), and resuspend in OPTI-MEM to a final
5 concentration of 10^7 cells/ml. Then add 1ml of 1×10^7 cells in OPTI-MEM to T25 flask and incubate at 37°C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentamicin, and 1% Pen-Strep. These cells are treated with supernatants containing a polypeptide as produced by the protocol described in Example 11.

10 On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

15 Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12
20 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples
25 from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at -20°C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4°C and serve as a source of material for repeating the assay on a specific well if desired.

30 As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

35 **Example 14: High-Throughput Screening Assay Identifying Myeloid Activity**

The following protocol is used to assess myeloid activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest 2×10^7 U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 1 mM MgCl_2 , and 675 uM CaCl_2 . Incubate at 37°C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37°C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

These cells are tested by harvesting 1×10^8 cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of 5×10^5 cells/ml. Plate 200 ul cells per well in the 96-well plate (or 1×10^5 cells/well).

Add 50 ul of the supernatant prepared by the protocol described in Example 11. Incubate at 37°C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon

activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or
5 differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

10 The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)

5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

15 Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

20 To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker)
25 containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

30 Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

35 To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS

(Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count
5 the cell number and add more low serum medium to reach final cell density as 5×10^5 cells/ml.

Add 200 μ l of the cell suspension to each well of 96-well plate (equivalent to 1×10^5 cells/well). Add 50 μ l supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR
10 can be used, such as 50 ng/ μ l of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

Example 16: High-Throughput Screening Assay for T-cell Activity

15 NF- κ B (Nuclear Factor κ B) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF- κ B regulates the expression of genes involved in immune cell activation, control of apoptosis (NF-
20 κ B appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- κ B is retained in the cytoplasm with I- κ B (Inhibitor κ B). However, upon stimulation, I- κ B is phosphorylated and degraded, causing NF- κ B to shuttle to the nucleus, thereby activating transcription of target
25 genes. Target genes activated by NF- κ B include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF- κ B promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF- κ B would be useful in treating
30 diseases. For example, inhibitors of NF- κ B could be used to treat those diseases related to the acute or chronic activation of NF- κ B, such as rheumatoid arthritis.

To construct a vector containing the NF- κ B promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF- κ B binding site (GGGGACTTTCCC) (SEQ ID NO:8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

5 5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC
TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5':GCGGCAAGCTTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

10 PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene) Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

15 5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCC
ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCA
TCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTTCTCCGCCCCATGGCTGACT
AATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTC
20 CAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTT:
3' (SEQ ID NO:10)

Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF- κ B/SV40 fragment using XhoI and HindIII.

25 However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF- κ B/SV40/SEAP cassette is removed from the above NF- κ B/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the
30 NF- κ B/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

Once NF- κ B/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described

in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

Example 17: Assay for SEAP Activity

5 As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

10 Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 µl of 2.5x dilution buffer into Optiplates containing 35 µl of a supernatant. Seal the plates with a plastic sealer and incubate at 65°C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 µl Assay Buffer and incubate at room
15 temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 µl Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

20 Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

Reaction Buffer Formulation:

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25

28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-3, used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO₂ incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-3 is made in 10% pluronic acid DMSO. To load the cells with fluo-3, 50 ul of 12 ug/ml fluo-3 is added to each well. The plate is

incubated at 37°C in a CO₂ incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-5x10⁶ cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-3 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37°C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1x10⁶ cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-3. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular Ca⁺⁺ concentration.

Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating

tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately
5 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from
Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with
100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr
with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine
(50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or
10 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed
with PBS and stored at 4°C. Cell growth on these plates is assayed by seeding 5,000
cells/well in growth medium and indirect quantitation of cell number through use of
AlamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento,
CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are
15 used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture
plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of
Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium.
Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20
20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example
11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH
7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na₃VO₄, 2 mM Na₄P₂O₇
and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim
(Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for
25 5 minutes at 4°C. The plate is then placed in a vacuum transfer manifold and the extract
filtered through the 0.45 mm membrane bottoms of each well using house vacuum.
Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum
manifold and immediately placed on ice. To obtain extracts clarified by centrifugation,
the content of each well, after detergent solubilization for 5 minutes, is removed and
30 centrifuged for 15 minutes at 4°C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many
methods of detecting tyrosine kinase activity are known, one method is described here.

Generally, the tyrosine kinase activity of a supernatant is evaluated by
determining its ability to phosphorylate a tyrosine residue on a specific substrate (a
35 biotinylated peptide). Biotinylated peptides that can be used for this purpose include
PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and

PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg₂₊ (5mM ATP/50mM MgCl₂), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl₂, 5 mM MnCl₂, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30°C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37°C for 20 min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37°C for one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity

As a potential alternative and/or compliment to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4°C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky, D., et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR

products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton, T.A. and Graham, M.W., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7
5 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-
10 triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson, Cg. et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and
15 propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson, Cv. et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and
20 chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

25

Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is
30 a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with
35 specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10.

The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to
5 validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove
10 unbounded conjugate.

Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on
15 the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

Example 23: Formulating a Polypeptide

The secreted polypeptide composition will be formulated and dosed in a fashion
20 consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of secreted polypeptide administered parenterally per dose will be in the range of about 1 µg/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and
25 most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the secreted polypeptide is typically administered at a dose rate of
30 about 1 µg/kg/hour to about 50 µg/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending
35 on the desired effect.

Pharmaceutical compositions containing the secreted protein of the invention are administered orally, rectally, parenterally, intracistemally, intravaginally,

intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes
5 of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules.
10 Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., Biopolymers 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and R. Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D- (-)-3-hydroxybutyric
15 acid (EP 133,988). Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008;
20 U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, the secreted polypeptide is
25 formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are
30 known to be deleterious to polypeptides.

Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood
35 of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The secreted polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

Example 24: Method of Treating Decreased Levels of the Polypeptide

It will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

Example 25: Method of Treating Increased Levels of the Polypeptide

Antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

Example 26: Method of Treatment Using Gene Therapy

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

5 The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the
10 presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

15 The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

20 Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media
25 from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

30 The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

35 It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

 The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other

disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties.

WO 99/09155

PCT/US98/17044

178

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>94</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet ☐	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit July 24, 1997	Accession Number 209178
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet ☐	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only ☒ This sheet was received with the international application Authorized officer 972 PAUL F. URRUTIA	For International Bureau use only ☐ This sheet was received by the International Bureau on: Authorized officer
--	---

WO 99/09155


PCT/US98/17044

179

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>95</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet ☐	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit May 18, 1998	Accession Number 209878
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet ☐	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only	
☒ This sheet was received with the international application	
Authorized officer PAUL F. URRUTIA 	

For International Bureau use only	
☐ This sheet was received by the International Bureau on:	
Authorized officer	

WO 99/09155

PCT/US98/17044

180

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>98</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet ☐	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (<i>including postal code and country</i>) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit <u>August 1, 1997</u>	Accession Number <u>209194</u>
C. ADDITIONAL INDICATIONS (<i>leave blank if not applicable</i>) This information is continued on an additional sheet ☐	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (<i>if the indications are not for all designated States</i>)	
E. SEPARATE FURNISHING OF INDICATIONS (<i>leave blank if not applicable</i>)	
The indications listed below will be submitted to the International Bureau later (<i>specify the general nature of the indications, e.g., "Accession Number of Deposit"</i>)	

For receiving Office use only ☒ This sheet was received with the international application Authorized officer 972 PAUL F. URRUTIA	For International Bureau use only ☐ This sheet was received by the International Bureau on: Authorized officer
--	---

WO 99/09155

PCT/US98/17044

181

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>101</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet ☐	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit May 7, 1998	Accession Number 209852
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet ☐	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only ☒ This sheet was received with the international application Authorized officer PAUL F. URRUTIA PFU	For International Bureau use only ☐ This sheet was received by the International Bureau on: Authorized officer
--	---

WO 99/09155

PCT/US98/17044

182

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>101</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet ☐	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit <u>August 1, 1997</u>	Accession Number <u>209195</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet ☐	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

For receiving Office use only ☒ This sheet was received with the international application Authorized officer PAUL F. URRUTIA	For International Bureau use only ☐ This sheet was received by the International Bureau on: Authorized officer
---	---

WO 99/09155

PCT/US98/17044

1

<110> Human Genome Sciences, Inc. et al.

<120> 70 Human Secreted Proteins

<130> PZ014.PCT

<140> PCT/US98/17044

<141> 1998-08-18

<150> 60/089,510

<151> 1998-06-16

<150> 60/092,956

<151> 1998-07-15

<150> 60/056,555

<151> 1997-08-19

<150> 60/056,556

<151> 1997-08-19

<150> 60/056,535

<151> 1997-08-19

<150> 60/056,369

<151> 1997-08-19

<150> 60/056,629

<151> 1997-08-19

<150> 60/056,628

<151> 1997-08-19

<150> 60/056,728

<151> 1997-08-19

<150> 60/056,368

<151> 1997-08-19

<150> 60/056,726

<151> 1997-08-19

<160> 190

<170> PatentIn Ver. 2.0

<210> 1

<211> 733

<212> DNA

<213> Homo sapiens

<400> 1

gggatccgga gcccaaattct tctgacaaaa ctcacacatg cccaccgtgc ccagcacctg	60
aattcgaggg tgcaccgtca gtcttcctct tccccccaaa acccaaggac accctcatga	120
tctcccggac tcctgaggtc acatgctgtg tgggtggacgt aagccacgaa gaccctgagg	180
tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg	240
aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg caccaggact	300

WO 99/09155

PCT/US98/17044

2

ggctgaatgg	caaggagtac	aagtgcaagg	tctccaacaa	agccctccca	acccccatcg	360
agaaaaccat	ctccaaagcc	aaagggcagc	cccgagaacc	acaggtgtac	accctgcccc	420
catcccggga	tgagctgacc	aagaaccagg	tcagcctgac	ctgcctggtc	aaaggcttct	480
atccaagcga	catcgccgtg	gagtgggaga	gcaatgggca	gccggagAAC	aactacaaga	540
ccacgcctcc	cgtgctggac	tccgacggct	ccttcttctc	ctacagcaag	ctcaccgtgg	600
acaagagcag	gtggcagcag	gggaacgtct	tctcatgctc	cgtgatgcat	gaggctctgc	660
acaaccacta	cacgcagaag	agcctctccc	tgtctccggg	taaatgagtg	cgacggccgc	720
gactctagag	gat					733

<210> 2

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> Site

<222> (3)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 2

Trp Ser Xaa Trp Ser

1

5

<210> 3

<211> 86

<212> DNA

<213> Homo sapiens

<400> 3

gcgcctcgag	atttccccga	aatctagatt	tccccgaaat	gatttccccg	aaatgatttc	60
ccccgaaatat	ctgccatctc	aattag				86

<210> 4

<211> 27

<212> DNA

<213> Homo sapiens

<400> 4

gcggcaagct	ttttgcaaag	cctagggc				27
------------	------------	----------	--	--	--	----

<210> 5

<211> 271

<212> DNA

<213> Homo sapiens

<400> 5

ctcgagattt	ccccgaaatc	tagatttccc	cgaaatgatt	tccccgaaat	gatttccccg	60
aaatatctgc	catctcaatt	agtcagcaac	catagtcccc	cccctaactc	cgcccatccc	120
gccctaact	ccgccagtt	ccgccattc	tccgccccat	ggctgactaa	ttttttttat	180
ttatgcagag	gccgaggccg	cctcggcctc	tgagctattc	cagaagtagt	gaggaggctt	240
ttttggaggc	ctaggctttt	gcaaaaagct	t			271

<210> 6

<211> 32

<212> DNA

WO 99/09155

PCT/US98/17044

3

<213> Homo sapiens

<400> 6

gcgctcgagg gatgacagcg atagaacccc gg

32

<210> 7

<211> 31

<212> DNA

<213> Homo sapiens

<400> 7

gcgaagcttc gcgactcccc ggatccgcct c

31

<210> 8

<211> 12

<212> DNA

<213> Homo sapiens

<400> 8

ggggactttc cc

12

<210> 9

<211> 73

<212> DNA

<213> Homo sapiens

<400> 9

gcggcctcga ggggactttc ccgggggactt tccggggact ttccgggact ttccatcctg
ccatctcaat tag

60

73

<210> 10

<211> 256

<212> DNA

<213> Homo sapiens

<400> 10

ctcgagggga ctttcccggg gactttccgg ggactttccg ggactttcca tctgccatct
caattagtca gcaaccatag tcccgcacct aactccgccc atcccgcccc taactccgcc
cagttccgcc catttccgc cccatggctg actaattttt tttatttatg cagaggccga
ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg
cttttgcaaa aagctt

60

120

180

240

256

<210> 11

<211> 392

<212> DNA

<213> Homo sapiens

<400> 11

gaattcggca cgagcgctgt tgggtgtgtg tatgtttgcg ctgggcgcgc ttgccgtgcc
ggtgaccggt ttcggcagta tgcctgcgct ctcatgaggc ctgaccatgc tcggctgcta
cgcgatagcc atcctgctgt tcgtgacgct ggtgcgcaaa ccggettaac gttacttgat
gacagacagg caaaaaaaaa cccgcttcgg cggttttttt aagaattcgg ytaaagtcag
atagcgataa cgtagcagc cgacgggcct ttggcaccat tggtgatttc gaactctacg

60

120

180

240

300

WO 99/09155

PCT/US98/17044

4

cgctggcctt cagcgagggt cttgaagccc tggctggaaa tagcagagaa atgaacgaaa 360
 acatctttgc tgccatcttc aggggtaatg aa 392

<210> 12
 <211> 465
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (357)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (395)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (440)
 <223> n equals a,t,g, or c

<400> 12
 gaattcggca cgagctcact tgaaatccat gacactacat agaaaatgga ctctaaaatc 60
 tgcctggcaa tgattctaca tttccctaata cccttcactt tcctactctc ccctactctc 120
 ttagaatgtt ctgtatctcc ttatctttct tcaatctccc tgaatattct ccctgttcct 180
 tgctttcagt tcaggaattg gtgccccaat ttttttatgt tgtttgattt tttttttttt 240
 tttgagacag agtctggctc tgtcactggg gctggagtgc agtggtgcaa tcatggctca 300
 ctgcaatctc tgcctcccag gctcgagagt attctagagc ggccgcgggc ccatcgnttt 360
 tccaaccggg tggggtagca ggtaagtgt acccnattcg gcctatagtg agtccgtaat 420
 taaaattcaa ctgggcggtt ggtttaaaaa cgtccgtgga actgg 465

<210> 13
 <211> 674
 <212> DNA
 <213> Homo sapiens

<400> 13
 tgcccctgaa gagtaagaat gaatatgaca tgttgattct tgaagtggcc aaataaatca 60
 cccgacggtg aagttctgca atggatgaag gtggcagtga gaggaaagca gagagaatgc 120
 agagacagga tcctaggcaa gaagacaaag gcctggacac agagaaggag atcaaagtgt 180
 ggctctgggt acaaagttag agtgagtgtg caggaagtga acaagggtcag tagaactagg 240
 aaaagcmaaa ggtcaaggaa accagcattt ggagacagrt aatgatgtca ccttttgacc 300
 aagggagatt gaagcttctg taaggcraaa gtaaatgttc ctgggttagta atccagggtc 360
 ttggtaattg gtattaagtt tgtcatgtgc tgtggctcat gccaaagtcca tccatataaa 420
 gacaaccatg ttmgaataag aaagacaaag aactctcaga gtctgttcct gagatagagc 480
 aggtcctgag aggcttatca aaagttcaga aactaaggca aaattttggc catgatattc 540
 acaaaattga agagaaacag catttaataa tacagccaag cataaaaaaa accaagacaa 600
 cctaaaaccc caatgccatt tgtattgaag gtgagtgggg agctcaccgg tgggtctcaag 660
 aacttggcag atgc 674

<210> 14
 <211> 297
 <212> DNA

WO 99/09155

PCT/US98/17044

5

<213> Homo sapiens

<400> 14

gaattcggca	caggtctaaa	tgagatggca	cgggtatgct	tctgttcttt	ttctggacgt	60
tgtttagaga	gtcagtagat	cataataatt	cagacacttt	tttttckgga	ccataaaata	120
tctgarscca	yataataaca	aacatacagc	acggtgaata	agaacccaac	ttttgagcca	180
gatcactttg	catggaatcc	ccattctatc	attctatcat	ttctgggctg	tgggaacctc	240
agacaagtta	cttaacttct	tcaatgctca	gattaaaaaa	aaaaaaaaaa	aactcga	297

<210> 15

<211> 604

<212> DNA

<213> Homo sapiens

<400> 15

tcgacccacg	cgtccgcagg	gaaggaccct	ttaagaggac	atttactaaa	atgcactttg	60
caacattaaa	aagaagaccc	tggaatacat	ttctctcctt	ctaagtgaag	tgctctcaaa	120
gagctctaag	atgggtgtcag	ttaaaccgggc	tgacccgggg	tctctggggt	tcacttttct	180
gctgtcctcc	cttcccaagt	gtacagtggg	ggtctccaga	ggccgcccc	catgcaccag	240
ctgctctgat	ggctgagata	acgtctggca	ttcccggtct	tcaaattaaa	cagaaacact	300
attcagtgtt	ttcgggtttta	attaagaata	cggtaaata	cagtcaatac	agcccacatg	360
aacatggacc	cctttgggggt	cctcaatgac	ttcagaagt	attagtgtg	aggtcagaaa	420
accggaggac	aaaatcaatt	acacgtcctg	acaaggagct	gagcctggca	tcaactcaga	480
gaaggggttt	gcagataaca	gcattcacct	gaggttccac	taacacggaa	taaagctgtg	540
gtataaaata	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaagggc	600
ggcc						604

<210> 16

<211> 1146

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1140)

<223> n equals a,t,g, or c

<400> 16

cttaattatt	aataagccaa	tgtgttatga	taccaatayc	tgtttttaaaa	aactaaaacc	60
aaccatgctt	ctggcatgat	aaaatcatgg	aattaaatca	ggggtttaca	ttcttgtaga	120
gtgttcttga	aacactctct	gcaccatttt	taaaacttga	gaatagtttt	agtatctctg	180
atattttttg	ccagaatcat	catgtcatgt	atgaatgtgt	tatccctatc	taaggaaaaa	240
ggtgaatatg	tttttgtatg	aatgttttaac	tggaaatgtc	catggacttg	gctaattttat	300
atttactttt	tattgtacat	agattttctaa	tattttttcat	tctgtatca	tttaaacttc	360
cttcatttga	gtaaattcac	taaatatattc	tatttttttgc	tttttttaaat	tctgatttta	420
tatgaattct	aattcttttt	cactacatat	gttttaaaaga	gttacataca	gtgatttaga	480
atggtttaca	gttaatgctg	atcttgtatt	ttaaattcca	acactttgtg	tcactacctc	540
ctctaattgg	tagtatgata	tgctagcaga	ctgtatgagg	tctttttttta	aaataccact	600
tttagtgtca	gtgaacccaa	ttctgggaatg	tcttaacagc	tctaaatctt	acttgtcttg	660
aaaatgattg	gggttttaata	ccactgctgg	tggttcacac	atcatcccat	ccttaatatg	720
cctgacaggc	atctgagcaa	aggtttttag	taattgaatt	tctctgcagt	agtccttcaa	780
gcacttgaat	gtaaaccttt	agcattttatt	cgtttaatga	ctactgatac	gaatctcaag	840
cagatttctt	gctcttaaaa	gttatgtttc	actgagttct	ggttttgtgt	agctatatatt	900
tatatagcta	gatattcctc	acagtgaaca	tgaattgtaa	taattgggta	tttccttaag	960
tcttttagatt	ataataattt	cagattattg	cacgtctgtg	atttgagagg	tgagttattt	1020
aagaggccag	ttttcaggac	atgggaattt	gaattgtaaa	cctgttatct	ctgtgaaact	1080

SUBSTITUTE SHEET (RULE 26)

WO 99/09155

PCT/US98/17044

6

tttaacatga taaaatataa cctttctttg tgcttaaaaa aaaaaaaaaa aaaaaactcn 1140
aagggg 1146

<210> 17
<211> 678
<212> DNA
<213> Homo sapiens

<400> 17
ggcacgagggc ggaggtggag acgcagagct atatttggtg gactgtgaac agactcacct 60
gcctagagca gtgtattcac attgggatta ttagagtaaa gtgtggacaa gaggtataat 120
gcagaggtct taatgtgtca ggctggggaa tgtacttagt attctgtctc tcatgtgtct 180
caaaccaggg tccctattca cctggttggtg cttggtgaca aggataaaaa agctcctccc 240
tactctgcta gttttacttc aaataatgaa gggaaactta taattaattg ataagtcattg 300
ttaaataatct ctgtagcaac ttaaataagga aatatgatgc tgaattttct tgaattctta 360
aaataagggg tttccaaata atttgaagtt attactgctc ttttgagatt gttttcaaac 420
tctgacaatc actgatcatt ctctctgcct ttggaattct tgagagacaa agtgtgggta 480
tcacataagt attagggagt cattacaggt tgatgcatag aggaagagag agccacgttt 540
ctaataacac tcatacctga aatcattcca ttaccattct ttaatagttt cattctgact 600
tcattgtagc aactcttact ttattcttct taagttttta aggccaaatc atgggtttcat 660
aaaaaaaaaa aaaaaaaaaa 678

<210> 18
<211> 1305
<212> DNA
<213> Homo sapiens

<400> 18
cagcttgtgc agactccgag ccttcagtga caaaggcttt gctgtttgtc ctcttgacct 60
gtgtctgact tgctcctgga tgggcaccca cactcagagg ctacatatgg ccctagagca 120
ccaccttctt ctagggacac tggggctacc tacagacaac ttcacttaag tcctaactat 180
tacaatgatg gactcagcac ctccaaagca gttaattttt cactagaacc agtgagatct 240
ggaggaatgt gagaagcata tgctaaatgt acattttta ttagactac ttgaaaagggc 300
ccctaataag gctagaggtc taagtcccc acccctttcc ccactccctt ctagtgggta 360
acttttagagg aaaaggaagt aattgcacaa ggagtttgat tcttaccttt tctcagttac 420
agaggacatt aactggatca ttgcttcccc agggcaggag agcgcagagc tagggaaagt 480
gaaaggtaat gaagatggag cagaatgagc agatgcagat caccagcaaa gtgcactgat 540
gtgtgagctc ttaagaccac tcagcatgac gactgagtag acttggtttac atctgatcaa 600
agcactgggc ttgtccaggc tcataataaa tgctccattg aatctactat tcttggtttc 660
cactgctgtg gaaacctcct tgctactata gcgtcttatg tatgggttta aggaaattta 720
tcaggtgaga gagatgagca acgttgtctt ttctctcaaa gctgtaatgt gggttttgtt 780
ttactgttta tttgtttgtt gttgtatcct ttctctcctg ttatttgccc ttcagaatgc 840
acttgggaaa ggctgggttc tttagcctcct ggtttggtgc tttttttttt ttttttaaac 900
acagaatcac tctggcaatt gtctgcagct gccactgggt caaggcctta ccagccctag 960
cctctagcac ttctctaagt gccaaaaaca gtgtcattgt gtgtgttcct ttcttgatac 1020
ttagtcatgg gaggatatta caaaaaagaa atttaaatg tggtcatagt ctttcagagt 1080
agctcacttt agtcctgtaa ctttattggg tgatattttg tggtcagtggt aattgtcttc 1140
tctttgctga ttatgttacc atgggtactcc taaagcatat gcctcacctg gttaaaaaag 1200
aacaacatg tttttgtgaa agctactgaa gtgccttggg aaatgagaaa gttttaataa 1260
gtaaatgat tttttaataa tcaaaaaaaaa aaaaaaaaaa ctcga 1305

<210> 19
<211> 1060
<212> DNA
<213> Homo sapiens

WO 99/09155

PCT/US98/17044

7

<400> 19

gaattcggca	cgagaatcaa	tctacaccct	caagcagttt	gtagtctgct	ggaatgacag	60
acttaaaaat	gcttataact	aaaatatatt	atgtgcagga	ctagggtttt	taagctaaaa	120
ggctgctttt	taaattgtga	aataataagt	acatgtagaa	caatgcataa	aacatgtcaa	180
cagttaaaca	gatagttatg	ggattatact	ttgtgtatwt	ttatgtttgc	ttcttttatt	240
caacattctg	tggttcatct	gtgttgcttg	tagcatcatc	attactgtag	catactttat	300
ttgttctact	gttggtggac	attactgttg	cttccagttt	ttggctatca	ttaacaatga	360
tgctaagagt	gttcttgatt	atgtgtcttg	gtatgtttgt	gcacgcacca	ataatatata	420
tctaggaatg	gaatcgttgg	gtcatagaga	atatacgtag	cttttaagtt	tactagataa	480
gtgattttcc	aatttaaaaa	gacctttgaa	acgtttttct	acattgggtg	tttttaaagt	540
tatctatttt	ctcatggaat	ttggttttct	catgagaata	aggtaggaat	ggttgtatgt	600
tgctaatatg	tagttcaagt	gccctttcta	cctaactctg	attgccagga	atatgcttga	660
aatgccaaat	catgacttag	tattttmctg	tggtaattgg	agtagtcttt	gacacatcag	720
gaagtatggg	aatatgggaa	agatctttga	gagtggaaac	tataccacag	ttttgttttag	780
tgctaggtag	gaaaggtgaa	aaaaaaagcg	cgagagtata	ttaagtatac	aaaaagctta	840
gtggttttta	aatgttaagc	tcacatttgg	aagtgttaatt	ctattttaat	ctcttttccta	900
atggaggaag	aaagatgact	gatgtggtag	ggtaactctt	tttgaaaaat	tgacaactct	960
ggcatacggc	ccagatctct	tttcagattt	tgtgtgaaaa	agaaaaatgg	cagcctctta	1020
gtgctattca	ttggtgtaaa	aaaaaaaaaa	aaaaactcga			1060

<210> 20

<211> 1170

<212> DNA

<213> Homo sapiens

<400> 20

ggttaacatt	tgtggatgac	tgaagattga	tggaaatgcta	ctatgccaaa	ccttaattgt	60
gatattattt	tcataactga	attatttttag	aaatgtatca	attgactgct	gctcagcagt	120
aactaaaatt	cctcaagtat	ttgattaaac	agaataatgt	caaaaattta	accttccctt	180
aaaactttat	acataagaca	tttatgattg	ttcaattttt	ataatctatt	tgtggatttt	240
gttaaaaagat	ttcacatgaa	gatttattag	ttgccattta	aaatttttat	atgttttagtt	300
aaaagatttg	acatgaaaat	ttattagata	ccatttataa	attttatgtg	ttatgtgttt	360
attcttttgag	aatgttacct	tactgtttgt	aatagtgtca	catttttctg	ctttcaggcc	420
tctgtatttt	cacaaaacac	caaaaacagc	atttaattat	attatcatga	gtgtgtttct	480
ggacacaaac	ttctgcagta	gaatgacctt	acatgtcggt	ttcattgcag	tcattatagg	540
attgaaatac	gttcaaaaata	acctctctag	gaaagtcttc	tgctagaatt	tctcccctct	600
attcattata	atattctttg	tttttaaagc	cagtcaaata	taatagtctt	aataagatca	660
gaaactctcc	aggagagtga	gtctaccctc	acgtccttgt	aggatgatct	tgattatagt	720
cttattatag	gactataact	gtattctcaa	catttctcca	gaaaggacct	tgtaaaaagg	780
tcttttgtac	cacagtattg	gttttttccc	ctctctcttc	acttaaaaaa	aaaaatagca	840
aggcagaaat	agtgtattga	aaagtgtgtc	atctattatg	aagtccttga	gtggtgaaaa	900
atccgttgta	catgagaaca	tttctatgca	tttaagccag	aaacgaggta	catggctgtg	960
tgctcttctg	tcaaccaatg	aaatgtgttt	tcacatgtgt	ggcagtgcaa	gtaaataaca	1020
cattatttga	ctgaatcagg	catgatactg	caccaaagtg	ttggtacata	ttcacggtag	1080
taaatcagta	cccctgttaa	aggatttatc	ccattgcctc	atattaataa	aatgggttaca	1140
atatatcaaa	aaaaaaaaaa	aaaaactcga				1170

<210> 21

<211> 2084

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (2075)

WO 99/09155

PCT/US98/17044

8

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (2083)

<223> n equals a,t,g, or c

<400> 21

ggcacgagga	gttgtgcaga	tacctggctg	agagctggct	caccttccag	attcacctgc	60
aggagctgct	gcagtacaag	aggcagaatc	cagctcagtt	ctgcgttcga	gtctgctctg	120
gctgtgctgt	gttggctgtg	ttgggacact	atgttccagg	gattatgatt	tcctacattg	180
tcttgttgag	tatcctgctg	tggcccctgg	tggtttatca	tgagctgac	cagaggatgt	240
acactcgcct	ggagcccctg	ctcatgcagc	tggactacag	catgaaggca	gaagccaatg	300
ccctgcatca	caaacacgac	aagaggaagc	gtcaggggaa	gaatgcaccc	ccaggagggtg	360
atgagccact	ggcagagaca	gagagtgaag	gagagggcaga	gctggctggc	ttctccccag	420
tgggtggatgt	gaagaaaaca	gcattggcct	tggccattac	agactcagag	ctgtcagatg	480
aggaggcttc	tatcttggag	agtgggtggc	tctccgtatc	ccgggccaca	actccgcagc	540
tgactgatgt	ctccgaggat	ttggaccagc	agagcctgcc	aagtgaacca	gaggagaccc	600
taagccggga	cctaggggag	ggagaggagg	gagagctggc	ccctccccga	gacctactag	660
gccgtcctca	agctctgtca	aggcaagccc	tggactcgga	ggaagaggaa	gaggatgtgg	720
cagctaagga	aaccttgttg	cggctctcat	ccccctcca	ctttgtgaac	acgcacttca	780
atggggcagg	gtccccccaa	gatggagtga	aatgctcccc	tggaggacca	gtggagacac	840
tgagccccga	gacagtgagt	ggtggcctca	ctgctctgcc	cggcacccctg	tcacctccac	900
tttgcccttgt	tggaaagtgc	ccagccccct	ccccttccat	tctcccacct	gttccccagg	960
actcacccca	gcccctgcct	gcccctgagg	aagaagaggc	actcaccact	gaggactttg	1020
agttgctgga	tcagggggag	ctggagcagc	tgaatgcaga	gctgggcttg	gagccagaga	1080
caccgccaaa	accccctgat	gctccacccc	tggggcccga	catccattct	ctggtacagt	1140
cagaccaaga	agctcaggcc	gtggcagagc	catgagccag	ccgttgagga	aggagctgca	1200
ggcacagtag	ggcttcttgg	ctaggagtgt	tgctgtttcc	tcctttgcct	accactctgg	1260
ggtggggcag	tgtgtgggga	agctggctgt	cggatggtag	ctattccacc	ctctgcctgc	1320
ctgcctgcct	gctgtcctgg	gcattgggtg	gtacctgtgc	ctaggattgg	ttttaaat	1380
gtaaataatt	ttccatttgg	gttagtggat	gtgaacaggg	ctagggaagt	ccttcccaca	1440
gcctgcgctt	gcctccctgc	ctcatctcta	ttctcatctc	actatgcccc	aagccctggt	1500
ggtctggccc	tttctttttc	ctcctatcct	cagggacctg	tgctgctctg	ccctcatgtc	1560
ccacttggtt	gtttagttga	ggcactttat	aattttttct	ttgtcttgtg	ttcctttctg	1620
ctttatttcc	ctgctgtgtc	ctgtccttag	cagctcaacc	ccatcctttg	ccagctcctc	1680
ctatcccgtg	ggcactggcc	aagctttagg	gaggctcctg	gtctgggaag	taaagagtaa	1740
acctggggca	gtgggtcagg	ccagtagtta	cactcttagg	tcactgtagt	ctgtgtaacc	1800
ttcactgcat	ccttgcccca	ttcagcccgg	cctttcatga	tgcaggagag	cagggatccc	1860
gcagtacatg	gcgccagcac	tggagttagt	gagcatgtgc	tctctcttga	gattaggagc	1920
ttccttactg	ctcctctggg	tgatccaagt	gtagtgggac	cccctactag	ggtyaggaag	1980
tggacactaa	catctgtgca	ggtgttgact	tgaaaaaata	agtgttgatt	ggctagaaaa	2040
aaaaaaaaaa	aaaaaaaaaa	actcgagggg	gggcnccggt	acnc		2084

<210> 22

<211> 643

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (115)

<223> n equals a,t,g, or c

<400> 22

gaattcggca	cgagaaacta	tctacaagga	tgatgtttcc	acaaagaact	tctcacaagc	60
agaaatggga	ggccaagaca	cacatctaaa	cagaccttcc	agaagcactt	gcaangcaca	120

WO 99/09155

PCT/US98/17044

9

caggacatgt	tgccgtacag	cctgcctttt	cacatttcct	gtactttctt	tctgagccac	180
catcttcayc	ctcatctgtt	gtctctgttg	ctttcttttt	cgcctaaggg	agtcacagct	240
gatgttaaaa	tttcaactgat	gatggcaaaa	tgactaagga	tgaaggttca	ctactgaaat	300
cacagctgag	ttctaaacat	gaagggtcaaa	aacwtcatgg	cagtaggtta	gggatgacaa	360
tacagcaatt	tcctgggtgac	tgcatgtgtc	aagtaattta	ctaacttgct	agagatatag	420
aatagcatt	ttaacaacag	atgtctaagc	caagaactaa	attcatatga	gtctttctta	480
gaaaaaagt	acatcagctg	gggtgtgggtg	ctcatgcctg	taatccccag	cactttgggt	540
ggctgaggtg	gaaggatcac	ttaagctcag	gagtccaaga	ccagcctggg	caacataccg	600
agacctcctc	tctactaaaa	aaaaaaaaaa	aaaaaaaaact	cga		643

<210> 23

<211> 647

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (69)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (614)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (632)

<223> n equals a,t,g, or c

<400> 23

nccaaagttc	gaaattaccc	ctcactaaag	ggaaccaaaa	gctggagctc	caccgcgttg	60
gcggccgcnt	ctagaactag	tggtatcccc	gggctgcagg	aattcggcac	gagagctgcc	120
ttggctcggc	ttgggtctgcg	gcctgtcaaa	caggttcggg	ttcagttctg	tcccttcgag	180
aaaaacgtgg	aatcgacgag	gaccttcctg	cagacgggtga	gcagtgagaa	gggccgctcc	240
actaatctca	actgctcagt	gattgcggac	gtgaggcatg	acggctccga	gccctgcgtg	300
gacgtgctgt	tcggagacgg	gcctgcctg	attatgcgcg	gcgctcatct	caccgctctg	360
gaaatgctca	ccgccttcgc	ctcccacatc	cgggccaggg	acgcggcggg	cagcggggac	420
aagccggggc	ctgatactgg	tcgctgacag	cgccaaagag	accaacaaga	tgatttttagc	480
gtggactagg	acacttaacc	taagaagagt	ttcacttaat	cattcaaatac	actatctgaa	540
gggtcacgga	gcgcaaaaata	aagtttataa	ccctgctacc	aaaaaaaaaa	aaaaaaaaaa	600
ctcgaggggg	gggnccggta	ccccaatctt	gncctatagt	ggagtcg		647

<210> 24

<211> 825

<212> DNA

<213> Homo sapiens

<400> 24

gaattcggca	cgagattaca	cagcagtatg	tggtttattgt	agaaatgatt	gaaatcgaaa	60
tggttaaaatt	aaaaaataat	ttctgttcta	actcccaatt	tgataaatag	ctctctatcc	120

WO 99/09155

PCT/US98/17044

10

atatctctat	atattatctat	ttctctgtat	ctatttgttg	tttttgtcca	gttagatcat	180
gctattttaa	ctgtttttta	gcttgattct	tttttcattt	gttgtctcgt	gcatcttttc	240
tgtatcaata	aatattcccc	tgtaaggaca	tttgaaaagg	ttttatagca	ttctgtttat	300
ggacatacca	taattttattg	aatctaattt	cttttgccaa	acacttaagt	tgttccaaat	360
ttctggttat	tataaacagg	gcttcacaac	tctccttgtg	catcattttg	acattcattt	420
ctgattattt	tcttatgaaa	atttcccaat	tttggtttta	ctgagtcaga	gtgtttccct	480
agaatattta	aaaatatgtg	gctgaaaaat	gaacttattg	ctgggtgcag	tggcttatgc	540
ctgtgatact	ggcaccttgg	gaggctgagg	tgggcagggtg	gcttgaagtc	aggagttcga	600
gaccagcctg	gccaacatgg	tgaaacccgt	ctctactaaa	aatacaaaaa	gtagtcaggt	660
gtggtggcgc	atgcctgtag	tcccagctac	tcaggaggct	gaggcacgtg	aatcacttga	720
gctagggaga	cggaggttgc	agtgagctga	gatcgtgcca	ctgcattcca	gcctgggtga	780
cagagtgaga	ctctgtttta	aaaaaaaaaa	aaaaaaaaaa	ctcga		825

<210> 25

<211> 541

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (11)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (12)

<223> n equals a,t,g, or c

<400> 25

ggacccccgg	nncaggaatc	cccccccccc	ccccccatct	gtctctccag	atcttaccca	60
tcttgtcctt	ccacacgtcc	cagatgcctc	tgaagatgcc	attcatgttt	ctctcccttc	120
cccgggacac	attcctaattg	ttggagttgg	tgtaggttac	tttcaactgc	aatgggagtt	180
tctttattca	caaagcctct	tgagtgttgc	tctcatacta	ttttgtgtgt	ccttccaggg	240
cagtgcacctt	gacagttatt	tgtcttgttc	tcccaagcgc	gggtgctaag	gacatagtct	300
gtgggcatgc	agatgtgtgt	gacttgttca	cacgaactgt	gaggatgagg	acttggtgaa	360
tgggtggaaat	tcagatccaa	actgtatctc	cagggcatga	tggcgcctgt	ctgtagtgca	420
gttacttgag	aacttgggag	ggtgagttgg	gaggatttct	tgaggttcca	ggagttcgag	480
accaacttgg	gcaacatagc	aagatcctgt	ctctataaaa	aaaaaaaaaa	ggatccctcg	540
a						541

<210> 26

<211> 852

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (719)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (834)

<223> n equals a,t,g, or c

<220>

WO 99/09155

PCT/US98/17044

11

<221> SITE

<222> (840)

<223> n equals a,t,g, or c

<400> 26

gaattcggca	cgagaagtca	tggcggcgct	gtgtcggacc	cgtgctgtgg	ctgccgagag	60
ccattttctg	cgagtgtttc	tcttcttcag	gccctttcgg	ggtgtaggca	ctgagagtgg	120
atccgaaagt	ggtagtcca	atgccaaagga	gcctaagacg	cgcgagggcg	gtttcgcgag	180
cgcgttgagg	cggcactcgg	agcttctaca	gaagggttct	ccaaaaaatg	tggaatcctt	240
tgcacttatg	ctgagacatt	ctcctcttac	acagatggga	cctgcaaagg	ataaactggg	300
cattggacgg	atctttcata	ttgtggagaa	tgatctgtac	atagattttg	gtggaaagtt	360
tcattgtgta	tgtagaagac	cagaagtggg	tggagagaaa	taccagaaag	gaaccagggt	420
ccggttgagg	ctattagatc	ttgaacttac	gtctagggtc	ctgggagcaa	caacagatac	480
aactgtacta	gaggctaata	cagttctctt	gggaatccag	gagagtaaag	actcaagatc	540
gaaagaagaa	catcatgaaa	aataaatgaa	ctttgcttag	tggattgact	cctttgctga	600
agtcagttat	tcatacaaga	tgcaattaga	ctaattgtga	ataaatgatt	gaatgaagat	660
ataataaata	aaagctataa	ttatagataa	ctcttattag	aattttcttt	agcaatatnc	720
ccacccccca	ccccttgttt	tgctcttaata	ggttttttcc	ttgggtgggg	atagtataca	780
ctgtactaag	aaatgtcatt	caataaatac	gttttgagtg	ctgtctaaaa	aaanaaagan	840
ttgggtgggg	gg					852

<210> 27

<211> 4598

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (948)

<223> n equals a,t,g, or c

<400> 27

tactgattgg	aacactttcc	tcctcttcct	tcctagcccc	agctattcac	tggggactgt	60
catagctggg	attctaaagg	tgccacattt	ttcagtttca	tctccactag	gttggttccc	120
gggcaggaag	tcaggcagca	gggaaggaca	cgggaacagc	aggtggagaa	ttcctacagt	180
ctttcttacc	ctgctagcaa	tagctctcag	tttcagaggc	acagtctttg	gagaccattc	240
agcactgaga	aagcaatatt	tagaacctat	tgcaaaaactg	ggcctgagtt	aggcatgggtg	300
atgaatgcat	cagcaaggaa	tagaaagttc	ttatcgtgaa	acccttcaac	ctcaactatg	360
ccttcataga	cacacacggt	catgcacatg	taggcacatg	taccatctca	catcttcaact	420
ttcccagagat	gccatataca	attacctaca	ttaataactg	tagcactatr	ccttttgagc	480
ccgagagagg	gaattagtga	ctctaagtga	aggtcactga	cacagagaag	cagtatgtgt	540
ctgggggcttc	caggacctgc	aggcccacta	gcgtgcactt	accagaatgg	catacacagg	600
acctgatcat	gaggaagacc	aggtttccag	tgtaaactac	tcttggtccc	accacctctg	660
gagcactcag	ggagccccat	acagtactta	caatgtcttt	aatggacttg	attctgttta	720
attttttggt	ttatattagg	cacactgtat	taattttcca	aaatggtata	ccacactatg	780
ttcttggtcc	tgacctattg	ctctggagga	aagagttgta	taagaacgtg	gctcatgtga	840
acttttgcta	gcttcatttg	aggacctgag	aatcatgggg	aaaggggaag	taatgttttc	900
attgaaatca	tcacagtgat	ttttattccc	tgggaacaca	gcgtgtanct	aaaaatacat	960
gagaaaatag	catgtatatg	aaagctattc	tcaaaagtca	cctgagctca	ccatcttcat	1020
agccaaccct	accagttata	aagatggcag	ctctatcact	tgattaagtg	ggaggtggtc	1080
aaatattttg	gtgcctcatt	ttcttcatct	gtgagatggg	aactgttatg	cctggcttac	1140
taagagtctt	gtgagagact	gagaagttga	ttttgttcat	atccaatctg	taaatgcgaa	1200
gtcaggggaa	gtaatgtccc	tgaaataaac	gggttcatgc	catctaggga	caataaatgg	1260
ttttcttggt	gtaacttctg	gttaatatca	gtaccttgat	gtcatcaccg	tgatgacaaa	1320
gagaagagtt	attgttgatc	ttcttggttt	tggtctgtct	cttttcttag	gataaagaaa	1380
aacttccaaa	ctagaaaaac	aggccctggg	tcccttagtt	tgcacttgaa	cccaatatgt	1440
tgccctgtac	atacttggtc	cctgtcacat	tgactgcttg	ggaggcttcc	agggagaagt	1500

WO 99/09155

PCT/US98/17044

12

atgagaccct	gaggggtgag	aatgggagc	tagcaagaac	atggaaattc	tgcttggtcac	1560
tacagtcata	aatagaaaac	actgtgtgtg	ctcaggggag	caggggatgc	cactgaagaa	1620
actcaagga	atgtgtattt	gaaggaaatg	caaaaactaa	gtatttagca	aaatgaaatt	1680
atgccttgat	gactaaaagg	cactagaaag	gttgtgtcta	ctaacttcag	ccctaatacag	1740
aacagatgcc	tagaaggagc	atTTTTgtga	caacttcata	gtgattagaa	tcagtggaga	1800
actccatctt	agtggcagga	atataatgaa	actaccacg	caagaacatg	gttgaatcac	1860
atttgcttga	cttagggcaa	agtacgaaag	agagacaaaa	gggttctctt	ggaaacaaga	1920
agagtkactc	cagatgtggc	ctgaataatt	gccatgttaa	gttaatgcaa	aagatcagaa	1980
cagggctaca	tttgcacagg	cagtttctct	ccgggccgta	gttttctactg	atgatcacct	2040
ttcacagcat	tttccccaac	cagcatttca	cttagtcttc	tctataccca	gcacctcccc	2100
cggcaccccc	ggcaagccca	ctatcacttc	cgacttccaa	cgtggcatcc	gtgagatctg	2160
tccacattag	gcgaagcagg	agaacactga	gagcagcagg	atgggtttgg	aaagagcatg	2220
cctctggaaa	cacagcttcc	tgggaattca	catgaggcca	gtcctacaga	gagcaagatg	2280
caccccagga	tttcttcatt	ttctaataga	tgtgggagtg	ctccattttc	cccagacagc	2340
aatttccct	gagaaacgat	actagaccct	gggtttgccc	accttgtaac	tcttctcttat	2400
ctcctccttt	tcatccctaa	ttcatcctcc	ctctggcatg	gaattgacgc	ccgtgcagta	2460
catttgccaa	gtggcacctt	ctttcaattt	atgttttatt	ttgctatgg	ggtgattctt	2520
tatttgctgg	ttgtcttttc	tcacacatct	ttctctctgt	ctctctcttt	cctgctcttt	2580
gtttttctgc	ccagaaaaac	ctgacttcga	tacaaaaaaa	gatgaaacta	cagaaactca	2640
aatttaaaaa	aaactttaaa	agaaacaaaa	aaataactca	cgattctttc	agctttatta	2700
acattttcca	ttgtttcttg	cgacttgtgt	ctcgttcttt	gtagtattga	tgatgaacat	2760
ttgataatga	atgttcttgt	atattcagat	aaagaaaaaa	aaaacaaaaa	aagcggctctg	2820
aatttaatat	tgtttataat	aaaaatttta	aaaatgacct	tcatagcacg	caaaacagga	2880
tggggaattt	ccctctctct	ttctgtgaca	atgcgcacat	ttcctgcatt	agtttttaac	2940
accagactac	ctacattcat	catttccctc	atttttcttt	tattttcttg	catttgtgaa	3000
ttagttcaag	aatgctagaa	aagtgtcgag	ttgtgcacat	ccatttcttg	tttcacaatg	3060
tttaaaagt	acagtaattc	attttgtaaa	ctaaaaaaa	aaaaaaaag	gttggaatag	3120
tgagcataat	aggtacaacc	taacacatta	ttatgtttat	taactttgag	acccagaaat	3180
aaattctttt	cttttcttga	ttcttgctct	taaaaataca	aaaaaaaaaa	tgttttgttt	3240
tgtgttattt	ttgggttggt	tattgggggg	ctttttttta	ttgtcaggat	tatgatcttg	3300
ctgtttttct	tcaatatgta	tacaagggtga	tgtgaaaaga	tgacttgggc	agaggagtaa	3360
gaacaagtag	gcttggttctt	ctactttgct	tcagaattca	gttaatgcca	aaagcgaaga	3420
tcaagcccat	gttgatgtct	cgttgctcac	ctgcatttcc	agagagtgtg	acactcatgc	3480
agtccctgag	aaaaataaaa	tcaggagacat	acttctcctt	ttagcctttt	aaaaattcaa	3540
aaacgttttag	tccaagggaa	cttttttatgc	tatcaggaaa	ggtttttgct	gtttttgatt	3600
ctgattatca	cagccaagta	ctttgtttta	ttctccctaa	ttaataacta	cattccatga	3660
ggcctcttcc	aaccaaagag	gccttttctt	ccaggagagt	cccgcagaga	tgctggtag	3720
atgggcacca	ttgggttaagt	aaactacatg	caggaagaag	tccttggggc	cagtctgcca	3780
gctgagtcct	ggttttggat	gaagagttaa	tgagatattg	ggccaggctc	aatgctgtag	3840
ttttaatgct	aagagggttac	gtttacttca	cagagtacac	ctcttagtaa	cctctgactt	3900
aggcagctgc	ttaaagcaaa	ttgcaaaact	ggcttgattt	ggaatgtttt	tatttagagga	3960
aaaaagaaag	ccatattatc	tggaaaaaaa	ttcattttta	ataccatcat	tcaacaaatt	4020
atgttcagaa	agtggtcaga	acttaagcaa	gaaaagtaaa	gaaagaatgc	agaattgtgg	4080
agcaatgctt	taggaaatat	ttctacctga	acacttgtag	tcttgaagtc	acaacaaaat	4140
aatgatgagc	ttttcacatc	acctttatgg	tttcaatccc	tagctcaaag	cttcttgga	4200
tcttttattt	tttgtaaact	tttttttctt	ttgttaaaat	aaataaaaaca	ttcaatgttt	4260
ttctcctttt	ctctcttatt	acttctttcc	tttggcattt	tcaatttgaa	atgctttcct	4320
ttgggttggtg	gttttattct	ccccctaccc	ctcccccttt	cttattattc	agaatataaa	4380
cctgcaaagc	tctgctctgt	tttgggtttg	aaagtttaag	cttttctgct	tctgtgagag	4440
cacaggcttc	tgtccctttt	gattccaact	gaacttttgt	gttctctaata	gataactaaca	4500
cgggtgtaggt	tttacagctc	cctaatttgt	actggtaatg	catattccaa	ataaatagtt	4560
tcttttggtg	caaaaaaaaa	aaaaaaaaaa	aaaaaaaa			4598

<210> 28

<211> 585

<212> DNA

<213> Homo sapiens

WO 99/09155

PCT/US98/17044

13

<400> 28

gaattcggca	cgaggtgaag	tggcatttct	tataaagaaa	aaaaagtcct	ctagtattgt	60
ctatgggaaa	ttcttccagg	ctacaatacc	tagtatgcaa	gttttaaatgc	tggcacattt	120
tttgatcttg	ctagaacatg	ttcaggggaag	gtgttcagac	aacaactagg	actaatattc	180
cttcaaggggt	cattaaatgg	ttgattaact	gaaacatcaa	gggattatag	atcaggcatg	240
tgtaggcaat	gacaactatg	tcattgactgc	tgtgtggcca	acagtaattg	aaggctgcca	300
tcaattataa	gacacattcc	atttcagaga	tggtacagtg	tgggggtgggg	gaaagtctgt	360
ctggaattag	tagtaaggga	cctgtcttat	aataggcaga	aatgtgtgt	aattgaatct	420
taagtatata	acatctaaag	aattataaga	ttttagagcc	aggaataaaa	aaacacatgt	480
taccatccct	tagaatctta	gaaaatgtta	ttggtgaaat	aaacttttagt	gatgatcata	540
cagaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	ctcga		585

<210> 29

<211> 824

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (759)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (791)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (792)

<223> n equals a,t,g, or c

<400> 29

ggtcgaccca	cgcggtccgag	agactggggt	tactgtgtgt	agcctggatg	gtctcgattt	60
tctgatctta	tgattcaccc	acctctacct	cccgaagtgc	tgagattatg	ggcgtgagca	120
ccgtgactgg	cctgtttttt	gtttctttta	caaaaagtta	tggggatttc	tatgagtatt	180
gtgttgaatc	taaatcacat	tcggttatat	aatcattgag	caataactaat	ttttccaatc	240
aatatggatt	gtatgtgtat	ttatatgttt	ttaatcattt	tgatcaatgt	ttgtagattt	300
caaggtacaa	acttctcacc	tttatatgtt	tattcctaaa	tatttcttac	tttaagctct	360
ttagcaaattg	gaagtgggtt	ttaattttat	tttaaaatta	tttaattgta	atgtatggaa	420
attcaactaa	tttttggtgc	tattattcta	ttctgcaa	acactgaata	tgtttattag	480
ttccagttgt	attttggttg	actgtgatat	tcttcacaga	tcattgtcatc	tacaaacaaa	540
taaaatttga	cttcttttct	tctgaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	600
aaaaaaaaaa	gggcggccgc	tctaaaggat	ccaagcttac	gtacgcgtgc	atgcgacgtc	660
atagctctyc	tatagtgtca	cctaaattca	attcactggc	cgctggttta	caacgtcgtg	720
actgggaaaa	cctggcgtta	cccaacttaa	tcgccttgna	gcacatcccc	ctttcgccag	780
ctgggggttat	nncgaaaagg	ccgcaccgat	cggcccttcc	ccaa		824

<210> 30

<211> 773

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

WO 99/09155

PCT/US98/17044

14

<222> (2)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (773)

<223> n equals a,t,g, or c

<400> 30

gnagcgcgcc	ggcggcccgc	gtctccctag	gacccgagtc	gggcggccgg	cagcgctccg	60
cctcctccty	ctgctgggcg	ctgtcctgaa	tccccacgag	gccctggctc	agmctcttcc	120
caccacaggc	acaccagggg	cagaaggggg	gacgggtgaag	aactakgaga	cagctgtcca	180
atthttgctgg	aatcattata	aggatcaaat	ggatcctatc	gaaaaggatt	ggtgcgactg	240
ggccatgatt	agcaggcctt	atagcaccct	gcgagattgc	ctggagcact	ttgcagagtt	300
gtttgacctg	ggcttcccca	atcccttggc	agagaggatc	atctttgaga	ctcaccagat	360
ccactttgcc	aactgctccc	tggtgcagcc	caccttctct	gacccccag	aggatgtact	420
cctggccatg	atcatagccc	ccatctgcct	catccccctc	ctcatcactc	ttgtagtatg	480
gaggagtaaa	gacagtgagg	cccaggccta	ggggggccacg	agcttctcaa	caaccatggt	540
actccacttc	cccacccccca	ccaggcctcc	ctcctccctc	cctactccct	tttctcactc	600
tcacccccac	cacagatccc	tggattgctg	ggaatggaag	ccagggtggg	tcatggcaca	660
agttctgtaa	tcttcaaaaat	aaaacttttt	ttttgtaaaa	aaaaaaaaaa	aaaaaaaaaa	720
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aan	773

<210> 31

<211> 969

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (36)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (123)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (347)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (525)

<223> n equals a,t,g, or c

<400> 31

gggaggaaca	tgatggtgtc	cgtgacaaca	tctgtngggc	acttgcccgc	ctggtgatgg	60
ccagtcccac	caggaaacca	gagccccagg	tgctggctgc	cctactgcat	gccctgccac	120
tgnaaggagg	acttgaggga	gtgggtcacc	attgggcgcc	tcttcagctt	cctgtaccag	180
agcagccctg	accaggttat	agatgtggct	cccagagctt	tgcgtatctg	cagcctcatt	240
ctggcagaga	ctattcaggg	cctgggtgct	gcctcagccc	agtttgtgtc	tcggctgctc	300
cctgtgctgt	tgagcaccgc	ccaagaggca	gacccccagg	tgcaanaaat	gccatcttcg	360
ggatgggctg	gctggcagag	catggggggc	accctgccc	ggaacacttc	cccaagctgc	420
tggggctcct	ttttccctc	ctggcgcggg	agcgacatga	tcgtgtccgt	gacaacatct	480

WO 99/09155

PCT/US98/17044

15

gtggggcact	tgcccgcctg	ttgatggcca	gtcccaccag	gaaanccaga	gccccagggtg	540
ctggctgccc	tactgcatgc	cctgccactg	aaggaggact	tggaggagtg	ggtcaaccat	600
tgggcgcctc	ttcagcctcc	tgacgttcct	ggccaaacag	cacaccgaca	gctttcaagc	660
agctctgggc	tcactgcctg	ttgacaaggc	tcaggagctc	caggctgtac	tgggcctctc	720
ctagactgca	ggctgcagcc	agtccagaga	gaatagagcc	tgcccaggcc	ttaagaccac	780
ctctcagccc	agttcagttc	tgctttacca	aagattctga	gactcatacc	catttggagc	840
cagccccact	tgctgcctta	cagggctgtc	cctgaggctg	gatctgttac	aaatgagtca	900
tgacatcata	ctgtaataaa	agcagcttgt	tttctgcttg	aacaataaaa	aaaaaaaaaa	960
aaaactcga						969

<210> 32

<211> 1355

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (7)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (12)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (111)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (113)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1332)

<223> n equals a,t,g, or c

<400> 32

ggaattngtg	ancgattaca	atttcaccac	aggaaaccag	ctatgaccat	gattacgcaa	60
agctcgaaat	taaccctcac	taaagggaac	maaagctgga	ctccaccscg	ntngcggccs	120
ctctagaact	agtggatccc	ccgsgetkca	ggaattcggc	acgagatttg	cgcacctgtc	180
ttttcctggg	ttgggggggtg	gcatctgatg	gtggcagagt	gcctgttggt	tcgcccgtgg	240
gtctcatggt	tcagacagag	ggaggtggac	ggcagggatc	aggagagccag	gagcgcgcct	300
cagacttgca	gcaaccattg	tgatttgggt	tgttcgggaat	atttaaatta	ctgatcagaa	360
gatgaaagta	gctttttctct	tgggaagtct	tgagcccgt	gggagtgata	ccaggagcaa	420
cacagagctc	agcagcggcg	ccaaggtgtt	ccctgtttcc	tcagcacgtg	agccttcacc	480
gcctgcttca	ttcaggagcc	agtgcagcag	taatacagtc	tatacattgt	tctgttttca	540
aatttatcct	gaggctttgt	tgagcataaa	tgattatacg	ataaagggtat	ccgttatattt	600
ggaactcatt	tcagttggga	tctcctgtat	gcagagtgtt	gcatttagag	gtttgagtcc	660
catcttggtt	tcttgccgtg	ctgactgtag	ccttcacctt	gacttgaatg	aaggctctgtg	720
gttggaatgt	gtgaggagcc	gctgaggtgt	tcaggaggtg	ctgcctggag	gtcggtttct	780
tcctgggtgt	tacgggcaac	tgctcacaca	gttggtttctc	tgtgaacatt	tccagtgttt	840
aatccaaaat	gaaaaccac	caatgctttt	gctaacttca	gtgcctttta	taaatcattt	900
ttaaatttcc	tgaacttgct	ttttgaggat	atacagggat	attaagtaga	cgcaggattg	960

SUBSTITUTE SHEET (RULE 26)

WO 99/09155

PCT/US98/17044

16

tttttgtttg	taaaaattct	gaattgaaac	tttgttttaa	aaaaaggctt	ctttctttca	1020
tatgacaaga	gataggtcag	gaatattgga	atcaagattt	aatgtttaa	attcgatttt	1080
gttacacagg	gtgtgttcac	ttgttttgta	gcagacaaga	tctagatccc	agacagaaac	1140
aacacatgct	attctaataa	gccgcatttt	aaaaggcacc	ttggtttctca	aaagaaatca	1200
gaatatggat	attcgtagtg	atgatctgtt	ttctctaata	tcttaccata	ttgtctgtat	1260
atggttgtaa	attcaaattg	aaagtaaaac	gttttggccc	tgawaaaaaa	aaaaaaaaaa	1320
aaaaaaaaaa	tnactgcggt	ccgtcaaggg	aattc			1355

<210> 33
 <211> 536
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (4)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (20)
 <223> n equals a,t,g, or c

<400> 33	
cctngctaca	aggagctggn agctccaccg cgggtggacgg gccgctctag aactagtgga 60
tcccccgggc	tgcaggaatt cggcacgagc tcaacatgtg gggattacaa ttcaagatga 120
gatttggtgc	aggaaacaga gccaaaccat atcaagagcc tctggtaacc actgttctac 180
tcaatacttc	tatgaggtga acttcttttg attccacata tgatcaagat catgaggaag 240
gaggagcaag	tcttctttgt catgctatta agaaaatacc cagagtcaca gcaccatgat 300
ctccttgtga	agcagaacaa gtaatatata actgatctaa agaggcctcc cctctactct 360
tatctgtctg	gtcgagtcac ttgggtccaa gtgggcacca ttgtgggagg gtgggaggac 420
tcatcactgg	gggcccaggc atcattggca tgtggcctcc tgtgttagtt tgttctcatg 480
ctgcaaataa	agacaacttg agactggata atttaaaaaa aaaaaaaaaa aaaaaa 536

<210> 34
 <211> 1123
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (78)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (79)
 <223> n equals a,t,g, or c

<400> 34	
aatccctatg	gtctctaatt tcagctcttg ctgtaaactg caagccaaat gctctttctc 60
agaaagagct	atatttttnt cttcttacag gcaacccaat atttatttca taaagtgtta 120
taaatattga	gaagatacac tggggagata gcatataaaa atgatgctcc aaaatgagaa 180
ttctatatgg	ggctttccct aagaagaatc catcccagca catattttga aaagggtgctg 240
aattaaaaag	tacaagagtt tgctcatata aatcaagttg cccaggaaac ctgaggtgat 300
gctatcattt	gtctcataat ttagaaacgt gatctcttga gagagagact acgcattgcc 360

WO 99/09155

PCT/US98/17044

17

tgggcacttt	cagattcctt	aggaagtgcc	cctttgatat	ttggaatgtg	gatataattta	420
taaaacaaat	ggattgttat	tccaaatcca	catggattta	taaccaagcc	ccagaagaat	480
aggcagcttt	gaaatagcta	gttcgtggaa	ttgaacagaa	ccttgatgga	atgcagttgc	540
ctgtgtgagg	acagaaaaca	aagaggctgc	ctcagaccas	atgcctatct	agagattaag	600
tggaatttgt	gagggacatt	ttgtggatgc	cttaaagatg	accagtgggtg	ggttctgatg	660
ggaatatata	cactcatctg	gactaggcca	atggaagcag	tctctttcag	ttcacctccg	720
tacagcacia	gttgttcctg	ctcatgacct	cattgaggaa	aatgagaatt	gtggtgctgg	780
tgactttcat	gtgtcttggg	aggttgaggt	gttcaacatc	gttaaggcac	tcccaaaacg	840
caaacctcct	tttttaaagt	ccaattgtac	atctacatta	attcatctat	gcaaacttgt	900
gttttcatgg	tttgtttttt	acactatatt	tctcattagg	ttcttttaaac	atcagggtta	960
atattgatat	tatgaataat	ttttaaacca	aagtattcta	taagtctgtg	tgctttgttt	1020
tcctggatgg	tttgaccaag	gtaaacatca	gtcttgtcct	tctctcttaa	taaagtcac	1080
catttggtta	gaaaaaaaaa	aaaaaaaaaa	aaaaaaaaact	cga		1123

<210> 35

<211> 587

<212> DNA

<213> Homo sapiens

<400> 35

gaattcggca	cgagcttctt	tgcaggaagc	ccccccagga	gtttgcatag	tcaatctgtc	60
atttgaaatc	atttattcag	tttaaagcat	taccatcaga	gagtaagaag	gaatctgttt	120
ataaggagat	tttagataat	ggggaaaaat	ccagaaaaaa	aattttacaat	aatcttgcta	180
ctgattataa	catcatctct	tgctgacatt	tctttaaggg	gttagtctag	tatgtcaagc	240
atatgcagct	gcttggagct	cttgattttt	agaaatgaat	aatacaagag	aaccaactaa	300
tgttccttag	ctcttcaaac	cagtctagta	cctgcatgaa	aacattgggt	attttgggtat	360
ccagttggag	agcacagggc	catgcagcag	gatttctgaa	aatcaaagct	ctcttcctga	420
aatatatggc	cacaaaggat	gcatttctgg	gatctgatgt	ttcctggctt	attcaaataa	480
taatgatggg	gttaggaaac	ttttacaact	ataggcctct	tcttttcttt	atgctcaatg	540
cctcgtgccg	aattcgatat	caagcttata	gataccgtcg	acctcga		587

<210> 36

<211> 842

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (823)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (826)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (831)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (832)

<223> n equals a,t,g, or c

SUBSTITUTE SHEET (RULE 26)

WO 99/09155

PCT/US98/17044

18

<220>

<221> SITE

<222> (838)

<223> n equals a,t,g, or c

<400> 36

gttgtagtt	gacatgtggt	ttgataagtc	atttagatac	tattgaaggg	aaatataagc	60
agcatataca	gatttccttg	ggaaatctgt	ggtattaaat	tctttccatg	aagattaaaa	120
tcattaaaaat	gtatttttatt	tacttaaaaat	atatttttatt	gactccagga	gtaggcatga	180
atgagacaag	atagaatgaa	aaacaaaaac	agctagccct	ctgtcctgtc	ttttgctgag	240
gtcctctgac	tctctctgag	atggaaaagg	tgaagggtca	agcagcctag	ttcaggcaca	300
cgaggggact	actaatatta	catcagttaa	aagtkgcaac	atttccaagg	agaattctac	360
acttagatca	gaaaataggc	aagagcaggg	aakggycata	gtttttatttg	kcacctcatt	420
tkgtccacaa	ccaaatgaat	ggataattgt	ccatgtcggg	gttctaagtg	ctactcttaa	480
agagcagtta	attcagagga	gtggtgggtg	gactgagata	taccttaagt	aactaaagca	540
cacctaggaa	ccctgacatt	cttctgcttt	cctaggagaa	ggagagtcag	agctaacaaa	600
ttaatttttaa	aaaggctctg	aacaagaatt	ttatcaaatt	accactttga	ttttgcctgc	660
taggatgtca	taacctagaa	tctcatccct	taatataata	cagtttagtt	taaccgaggc	720
attttttcagc	ctatgagacc	gaagtgacat	ctaacaaact	ggctttatta	gaatttgcct	780
gtatgggagg	cctcgtgccg	ctcgtgccga	attcgatatc	aanttnaagc	nnacctanta	840
ct						842

<210> 37

<211> 953

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (952)

<223> n equals a,t,g, or c

<400> 37

gaattcggca	cgagaacaac	ctctgccttg	ccccttctcc	accttcaggt	ccccttccca	60
gatacaataa	tttttagctt	tttattttta	attattcttg	ttgttaccta	cataactctg	120
ggcaatatgg	aaaagttatt	gattttgtat	attaatttca	taatcagtta	ccttgatgaa	180
ttctcttggt	tctagtagtt	tttcttttagg	gttttaaagg	gatacaatca	taccatttgc	240
agttagtaac	catttatctc	ctcttatctc	caacttcgta	ctgttttctc	ttgtctaatt	300
tgttttttaat	tggtgggtac	ttctagaaca	aggttaaata	aaagtgggtg	tggtgggcgt	360
ccttatttct	gatattaatg	ggaatgagta	taatgtataa	atatataacc	atgattttgg	420
tttttttcca	agtttttata	agtaatgatt	gctgagtttt	atcaaaaattt	ttttggcatc	480
cattgagagg	attatatatt	actctttgac	acattaatgt	ggttaattaa	agtaaccaac	540
ttattaacct	tgaaatagtc	ttagttaaata	aamccctact	tgtcaatgct	atatcattat	600
tttaatatgt	tactgaacat	tttaciaaagg	tgtttcacca	taaggcatat	tgatctgtaa	660
tttttttttt	tctgttgaac	ttgctattgt	caggtttttg	tgtattatgt	tggttttgga	720
gaataaattt	aaaagtttcc	tttatgttat	ctatacattg	cctgaaaaga	gtttaaatag	780
cattgaaaat	gatctcttct	ttgaagattt	aaccaatttc	acctgtaaat	ctgtctgtgc	840
tttgtaattt	tggtgatact	gttgactcaa	attccaaaag	cagtaaattgc	agtgttttat	900
atttttctat	taaaaatgta	aatcaaat	ataaaaaaaa	aaaaaaaaaa	cnc	953

<210> 38

<211> 2211

<212> DNA

<213> Homo sapiens

<220>

WO 99/09155

PCT/US98/17044

19

<221> SITE

<222> (2181)

<223> n equals a,t,g, or c

<400> 38

ggcacaggaa	agaagctgtc	tccatcttgt	ctgtatccgc	tgctcttgtg	acgttgtgga	60
gatggggagc	gtcctggggc	tgtgctccat	ggcgagctgg	ataccatggt	tgtgtggaag	120
tgccccgtgt	ttgctatgcc	gatgctgtcc	tagtggaac	aactccactg	taactagatt	180
gatctatgca	cttttcttgc	ttgttggagt	atgtgtagct	tgtgtaatgt	tgataccagg	240
aatggaagaa	caactgaata	agattcctgg	atthttgtgag	aatgagaaag	gtgttgtccc	300
ttgtaacatt	ttggttggct	ataaagctgt	atatcgtttg	tgctttgggt	tggtatggtt	360
ctatcttctt	ctctctttac	taatgatcaa	agtgaagagt	agcagtgatc	ctagagctgc	420
agtgcacaat	ggatttttgt	tctttaaatt	tgctgcagca	attgcaatta	ttattggggc	480
attcttcatt	ccagaaggaa	cttttacaac	tgtgtgggtt	tatgtaggca	tggcagggtgc	540
cttttgtttc	atcctcatac	aactagtctt	acttattgat	tttgacatt	catggaatga	600
atcgtgggtt	gaaaaaatgg	aagaaggga	ctcgagatgt	tggtatgcag	ccttggttatc	660
agctacagct	ctgaattatc	tgctgtcttt	agttgctatc	gtcctgttct	ttgtctacta	720
cactcatcca	gccagttgtt	cagaaaacaa	ggcgttcac	agtgtcaaca	tgctcctctg	780
cgttggtgct	tctgtaatgt	ctatactgcc	aaaaatccaa	gaatcacac	caagatctgg	840
tttgttacag	tcttcagtaa	ttacagtcta	cacaatgtat	ttgacatggt	cagctatgac	900
caatgaacca	gaaacaaatt	gcaacccaag	tctactaagc	ataattggct	acaatacaac	960
aagcactgtc	ccaaaggaag	ggcagtcagt	ccagtgggtg	catgctcaag	gaattatagg	1020
actaattctc	tttttgttgt	gtgtatttta	ttccagcatc	cgtacttcaa	acaatagtca	1080
ggttaataaa	ctgactctaa	caagtgatga	atctacatta	atagaagatg	gtggagctag	1140
aagtgatgga	tcactggagg	atggggacga	tggtcaccga	gctgtagata	atgaaaggga	1200
tggtgtcact	tacagttatt	ccttctttca	cttcatgctt	ttcctggctt	cactttatat	1260
catgatgacc	cttaccact	ggtacaggta	tgaacctct	cgtgagatga	aaagtcagtg	1320
gacagctgtc	tgggtgaaaa	tctcttccag	ttggattggc	atcgtgctgt	atgtttgga	1380
actcgtggca	ccacttggtc	ttacaaatcg	tgattttgac	tgagtgagac	ttctagcatg	1440
aaagtcacc	tttgattatt	gcttatttga	aaacagtatt	cccaactttt	gtaaagtgtg	1500
gtatgttttt	gcttcccatg	taacttctcc	agtgttctgg	catgaattag	atthttactgc	1560
ttgtcatttt	gttattttct	taccaagtgc	attgatattg	gaagtagaat	gaattgcaga	1620
ggaaagttht	atgaatatgg	tgatgagtta	gtaaaagtgg	ccaytattgg	gcttattctc	1680
tgctctatag	ttgtgaaatg	aagagtraaa	acaaatttgt	ttgactatth	taaaattata	1740
ttagacctta	agctgtttta	gcaagcatta	aagcaaatgt	atggctgcct	tttgaaatat	1800
ttgatgtggt	gcctggcagg	atactgcaaa	gaacatgggt	tatttttaaaa	tttataaaca	1860
agtcacttaa	atgccagttg	tctgaaaaat	cttataaggt	tttacccttg	atacgggaatt	1920
tacacaggta	gggagtgttt	agtggacaat	agtgtagggt	atggatggag	gtgtcgggtac	1980
taaattgaat	aacgagtaaa	taatcttact	tgggtagaga	tggcctttgc	caacaaagtg	2040
aactgttttg	gttggtttta	actcatgaag	tatgggttca	gtggaaatgt	ttggaactct	2100
gaaggattta	gacaagggtt	tgaaaaggat	aatcatgggt	tagaagggaag	tgthttgaaag	2160
tcactttgaa	agttagtttt	ngggcccaca	cggttgggtc	acccctgtaa	t	2211

<210> 39

<211> 682

<212> DNA

<213> Homo sapiens

<400> 39

gaattcggca	cgaggtgatt	cgaaagtctt	agaactggga	gtgaaggccc	acatgggatg	60
cactggctcg	gaaggggggtg	gaggttgctg	gaggggtggag	agaaggagct	gccaacctgg	120
tcactgttgt	tgctgtatcc	agggtgcctc	cagtcctgct	ccaccacacc	atggaccact	180
ccatcccaga	tgctgaagc	cactggaggg	cagggcaggc	aggggggggt	tcccgcctc	240
ctgcagcaaa	gggcaaccac	cctcggatga	tgggttgca	ccggcctgct	gcttaagggtg	300
ggggctgcca	tgaggggggc	gtgtccagga	gggtgaccat	gggatggctt	atacacacag	360
gcctccttgg	agcctcagac	tccaagctag	gctgaggctc	aggcagggcc	cacaggcagc	420
cgattctctt	gtgctgattt	aatgctgga	cacggaggca	ggctgtttaa	acgctgctta	480

SUBSTITUTE SHEET (RULE 26)

WO 99/09155

PCT/US98/17044

20

aagtcgcaac	tgggcccctt	tcaagaaatt	ttgctctacc	aggaaaacag	ttacacattt	540
taagagaaca	gagctacgtt	ctttgtgaga	gctttttcct	tgscttgact	tgctctttgt	600
cacagactgc	ataagttgtc	agccttgact	atcttttgaa	taaagatttg	attttaaaca	660
aaaaaaaaaa	aaaaaaactc	ga				682

<210> 40

<211> 685

<212> DNA

<213> Homo sapiens

<400> 40

tcgacccacg	cgtccgagca	gacacaatgg	taagaatggt	gcctgtcctg	ctgtctctgc	60
tgctgcttct	gggtcctgct	gtcccccagg	agaaccaaga	tggtcgttac	tctctgacct	120
atatctacac	tgggctgtcc	aagcatgttg	aagacgtccc	cgcgtttcag	gcccttggct	180
cactcaatga	cctccagttc	tttagatata	acagtaaaga	caggaagtct	cagcccatgg	240
gactctggag	acaggtggaa	ggaatggagg	attggaagca	ggacagccaa	cttcagaagg	300
ccagggagga	catctttatg	gagaccctga	aagacatygt	ggagtattac	aacgacagta	360
acgggtctca	cgtattgcag	ggaaggtttg	gttgtgagat	cgagaataac	agaagcagcg	420
gagcattctg	gaaatattac	tatgatggaa	aggactacat	tgaattcaac	aaagaaatcc	480
cagcctgggt	ccccttcgac	ccagcagccc	agataaccaa	gcagaagtgg	gatgcctgtc	540
ttgagtagac	ttggacccaa	aaaatcatct	caccttgagc	ccacccccac	cccattgtct	600
aatctgtaga	agctaataaa	taatcatccc	tccttgccca	gcaaaaaaaaa	aaaaaaaaaaa	660
aaaaaaaaaa	aaaaaaaaaa	aaaaa				685

<210> 41

<211> 550

<212> DNA

<213> Homo sapiens

<400> 41

gaattcggca	cgagggttca	gattagaatg	ggtctgttta	atcagtgtga	ttacagtgat	60
ccaagtttgc	agttagtttt	ttttttaatg	gctctattcc	acattttgtt	ttcattaact	120
actttgatca	tgtaaacctt	taggttaata	aattttctcc	ccttactgtt	cctctttcct	180
ctctaccact	ttttttcata	attggttttc	attctagaat	ggaaaagaaa	atgggtgtagt	240
aacatgagcc	atggatttag	gggcagaaat	atttgggttc	ctccgtttat	tagtaaagtg	300
tctttggact	attgtctcga	ccttttttaa	aaaaaatagg	ctatcatttt	tactaagatt	360
gtggtgagat	ttccatgaaa	taatctaggg	gaaagacttc	atactgttct	tcattcttgt	420
gctttactta	tcctcaattt	tgaaaaaatg	ttttaaaaaa	aaattttatt	ggctgggtgc	480
aggctcattg	cattgcagcc	tttgtgacaa	gagcgagacc	ctttctcaaa	aaaaaaaaaaa	540
aaaaacacga						550

<210> 42

<211> 602

<212> DNA

<213> Homo sapiens

<400> 42

tggatctcca	ccgcggtggc	ggccgctcta	gaactagtgg	atcccccggg	ctgcaggaat	60
tcggcacgag	attgtatcca	ggaagtaact	aacctgcttt	tgattttaca	ggctcatagg	120
tggaagggac	ttgccttgte	tcagatgaga	ctttagactg	tggacttttg	agttaatgct	180
gaaatgagtt	aagactttgg	gggactgtta	gaaaggcatg	attggttttg	aaatgcgaga	240
tcattgagatt	tgggaggggc	caggggcaga	atgatatggt	ttggctgtgt	ccccatccga	300
atctcatctt	gaattttctgt	gtgttggtgg	agggacaggt	gggaggtcat	tgaatgatgg	360
gggcaagtct	tttctgtact	gttcttgatg	tagtgaataa	gtctcatgag	atctgatggt	420
tttaaaaaga	ggagtttccc	tgctcaagtt	ctctctcttt	gcctgctgcc	atccatgtaa	480

WO 99/09155

PCT/US98/17044

21

gatgtgactt gctcctcctt gccatctgcc atgatgtgag gcttccccag ccacgtggaa	540
ctgtaagtcc aattaaacct cttttctttg taaattaaaa aaaaaaaaaa aaaaaaactc	600
ga	602

<210> 43
 <211> 1627
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (618)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (627)
 <223> n equals a,t,g, or c

<400> 43	
agctgtgaca gtgcggggcgg ccttggtccg ctccagtcctg gccgagttca tttccgagcg	60
gggtggaggtg gtgtccccac tgagctcttg gaagagagtg gttgaaggcc tttcactggt	120
gggacttggg agtatctccg tattctggag cagtatttca tggaaactcc attaaataaa	180
tatacctctt tcatttccta attgactatg ctgaattggt gtttatgata actgrtgcac	240
tcactgctat tgccctgtat tttgcaatcc aggacttcaa taaagttgtg tttaaaaagc	300
agaaactcct sctagaactg gaccagtatg ccccagatgt ggccgaactc atccggaccc	360
ctatggaaat gcgttacatc cctttgaaag tggccctggt ctatctctta aatccttaca	420
cgattttgtc ttgtgttgcc aagtctacct gtgccatcaa caacaccctc attgctttct	480
tcattttgac tacgataaaa ggcagtgctt tcctcagtcg tatttttctt gccttagcga	540
cataccagtc tctgtaccca ctacacttgt ttgtcccagg actcctctat ctctccagc	600
ggcagtacat acctgtgnaa aatgaangag caaagccttc tggatctttt cttgggagta	660
tgccatgatg tatgtgggaa gcctagtggg aatcattttg ctctccttct tccttctcag	720
ctcttgggat ttcattcccc cagtctatgg ctttatactt tctgttccag atctcactcc	780
aaacattggg cttttcttgt acttctttgc agagatgttt gagcacttca gcctcttctt	840
tgtatgtgtg tttcagatca acgtcttctt ctacaccatc cccttagcca taaagctaaa	900
ggagcacccc atcttcttca tgtttatcca gatcgctgtc atcgccatct ttaagtccta	960
cccgacagtg ggggacgtgg cgctctacat ggccttcttc cccgtgtgga accatctcta	1020
cagattcctg agaaacatct ttgtcctcac ctgcatcatc atcgtctgtt ccctgctctt	1080
ccctgtcctg tggcacctct ggatttatgc aggaagtgcc aactctaatt tcttttatgc	1140
catcacactg accttcaacg ttgggcagat cctgctcatc tctgattact tctatgcctt	1200
cctgcggcgg gagtactacc tcacacatgg cctctacttg accgccaagg atggcacaga	1260
ggccatgctc gtgctcaagt aggcctggct ggcacagggc tgcatggacc tcagggggct	1320
gtggggccag aagctgggcc aagccctcca gccagagttg ccagcaggcg agtgcttggg	1380
cagaagaggt tcgagtccag ggtcacaagt ctctggtacc aaaagggacc catggctgac	1440
tgacagcaag gcctatgggg aagaactggg agctcccca cttggacccc caccttgtgc	1500
tctgcacacc aaggagcccc ctcccagaca ggaaggagaa gaggcagggt agcagggctt	1560
gtagattgt ggctacttaa taaatgtttt ttgttatgaa gtctaaaaaa aaaaaaaaag	1620
ggcggcc	1627

<210> 44
 <211> 1457
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE

WO 99/09155

PCT/US98/17044

22

<222> (879)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1397)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1425)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1448)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1455)

<223> n equals a,t,g, or c

<400> 44

ctgatcccct	gctcatcaat	gacttcaagg	atgtgacgca	cacatgcccc	agctgcaaag	60
ctacatctac	acgtacaagc	gcctgtgcta	acggagctgg	gactcggggac	tccccgcct	120
gtcagtctgg	ccccctgtgc	tttgctccct	gygctcagtg	gtcactttcc	cgctcccact	180
tggggctggg	agccgtgcca	ccatccccta	gaagtcctgt	cctcttcacc	ctgccctacc	240
tgagccgctg	actcttctgg	caaaaattct	gttgggattt	aaggccaagg	gtcagtgggt	300
ggcagggggc	tgrcaatgag	cttgtgtgtt	gttgggtctgc	ttgggtgtgtg	tgatcgggaa	360
gataagctgg	gaggggtctc	ctgctggggg	cctgatgcct	ctggtttcaa	acaaggtaca	420
ggttcagtcc	agactctttc	cccctgggac	caacagcagc	cagagcagtt	agccagttag	480
tccccaggcc	tgtggcacag	gcgttttctg	acctgctggg	ccgagaatgg	gtaagttgtc	540
tggagtcagg	tgggcccacg	taggacaggg	tcacaaagcc	tgggtttgtt	tctgggtact	600
ttgcgcctct	ggggtgctag	aggtggggca	tggtggctgg	aagtaaaact	gccaaactytg	660
gccctcagaa	ctctcaggta	tagaagccca	ggatgtctaa	taccctgtcc	cagtgcgccga	720
ragctgcctg	gtgtcaggta	gagaggacac	tgtacctggg	tgaatgatca	gaccctggta	780
gctaagaagg	aacttgtccc	tttgagtcag	tgtgcagacc	ccctttcagg	ccatgcctct	840
gtgaaccctg	tattgctggg	gccggaagga	gcccctgang	cctagccctt	tcccgtctgc	900
cctgtgtcct	cactgcgtgt	gggtatgacc	tctgcctggg	ggctgggtgta	tcccaactgg	960
gcaagagatg	gcagaggggc	ccccttgtgg	gtgcgccttg	atgtgcagag	ccttctccat	1020
ggattttctt	ccctgtaagt	gccgggcccc	tcaccccagc	tgacaggctg	ttgctgtgcc	1080
tgctcacacc	tgctcctgca	ggcacactgg	gctagggagc	aggaaggagc	agccacaagt	1140
ggtagaactg	ccttggtgga	caccagcctc	gccctgtctt	tatttcctga	atggtttgtg	1200
aacttgctca	cctggaccac	tgtatcctgc	cactgtcctt	cctgggtctcg	cactgccact	1260
gcatggcctc	ctgtcactgt	gaatcgtggc	ccagtctcag	tttgtagttt	ctcattaaat	1320
tggccctttc	actccccgc	aaaaaaaaaa	aaaaaaaaaac	tcgagggggg	gcccgggtacc	1380
caatcgccct	atatgantcg	tattacaatt	catggccgct	gtttnacaaa	gtcgtgactg	1440
gggaaaanct	ggcgnta					1457

<210> 45

<211> 888

<212> DNA

<213> Homo sapiens

<400> 45

gaattcggca	cgagacagag	tgtgggatag	atcatatatg	catccacagg	cactgtgtcc	60
------------	------------	------------	------------	------------	------------	----

WO 99/09155

PCT/US98/17044

23

atataacccat	cttgaatagt	aattgctcac	ctgcattttg	taacaagagg	ggcatctgca	120
acaataaaca	tcactgccat	tgcaattatc	tgtggggacc	tcccaactgc	ctgataaaaag	180
gctatggagg	tagtggtgac	agtggcccac	cccctaagag	aaagaagaaa	aagaagttct	240
gttatctgtg	tatatgtgtg	cttattgttt	tgtttatttt	attatgttgt	ctttatcgac	300
tttgtaaaaa	aagtaaacca	wtaaaaaagc	agcaagrtgt	tcaaactcca	tctgcaaaaag	360
aagaggaaaa	aattcagcgt	cgacctcatg	agttacctcc	ccagagtcaa	ccttgggtga	420
tgccttccca	gagtcaacct	cctgtgacgc	cttcccagag	tcatectcag	gtgatgcctt	480
cccagagtca	acctcctgtg	acacctccc	agagtcaacc	tcgggtgatg	ccttctcaga	540
gtcaacctcc	tgtgatgcct	tcccagagtc	atcctcagtt	gacgccttcc	cagagtcaac	600
ctcctgtgac	acctcccag	aggcaacctc	agttgatgcc	ttcccagagt	caacctcctg	660
tgacgcctc	ctagagccaa	cctcagttga	tgccttccca	gagtcaacct	cctgtgacgc	720
cctcccagag	ccaacctcgg	gtgacacctc	cccagagtca	acctcatgtg	acaccttacc	780
ggagtaaaag	tggtaaacia	aagcaatcag	taccaattcc	aaaaactgta	tccagaaaag	840
gtacattaaa	aaaataattc	ctaaaaaaa	aaaaaaaaa	aaactcga		888

<210> 46

<211> 752

<212> DNA

<213> Homo sapiens

<400> 46

gaattcggca	cgaggaaaaa	ccaaggaac	cagatagaac	cagtgtccct	gtgactccac	60
ccactcatct	ggccaccgtt	gccctgacct	gccaggagcc	tggagaagat	gaaggcatcc	120
gtggttctct	ccctccttgg	ctacctggtg	gttccaagtg	gtgcttacat	cttggggcgt	180
tgcacagtgg	ctaagaaact	ccacgatgga	ggcctggatt	attttgaggg	ctatagcctt	240
gagaactggg	tgtgcctggc	ctacttcgag	agcaagttca	accccatggc	catctacgag	300
aacacacgtg	agggtamac	tggctttggc	ctctttcaga	tgcgtggcag	tgactgggtg	360
ggcgaccatg	gcaggaaccg	ctgccatatg	tcattgttccg	ctttactgaa	tcctaattta	420
gagaagacaa	ttaaatgtgc	caagaccatt	gtaaaaggaa	aagaagggat	gggagcatgg	480
cccacctggt	cccggtactg	ccagtactcc	gataccctgg	cacgggtggc	ggatgggttg	540
aagctgtagc	ckcctgcatg	gcccctgcag	cactcaccag	ttgcatcttg	tgaatgaagg	600
tgcttttctg	cttgctgctt	cagtcaatcc	ttttgatgat	ctcaccactt	taagagttcc	660
agatggaaaa	agacaaaagt	ttgcttcac	cggggatgca	ggatgcagaa	taaaccaaac	720
tagttactca	aaaaaaaaa	aaaaaaactc	ga			752

<210> 47

<211> 1788

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (12)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1490)

<223> n equals a,t,g, or c

<400> 47

gtatgttcct	gnatttttatt	ctctaaattg	tactcaattt	catggtaatt	acatgaagaa	60
gttacctgca	attattctta	acactacatg	gtaattcact	gggtaattgt	gggtcattta	120
tttcttgaag	tcacgtgaaa	tccttagctg	gttgaatgtt	gcacagtatt	tgagaattac	180
ggtttgaagt	gatttctgtg	ggagggaatc	attgcaatgt	atattctaaa	taaagtcac	240
taactattaa	aaaaaaaaa	cccttcctaa	cccttctttt	cttaaaattc	cacattcatc	300

WO 99/09155

PCT/US98/17044

24

cacaatctca	tccctttgta	gaaattcttg	cctgaattct	caccaagttt	tgaattccta	360
aggtagcccc	gatctaggat	gtgaaggctg	cccagaaaaa	gtttatggct	ggaggagtat	420
catacagtgt	ctacatatga	tagtacttac	agattaggtc	ttkggatgct	ttaacacaaa	480
agatttttgt	tatccttatt	agtcaaataa	cgctattctt	ttgtggttct	agaccctggc	540
ttctatctcc	ctgtgatttg	ttttaatgct	gaaatgactt	ggctatccaa	agcttctagt	600
ctagaggtct	gttggttgaa	ggcagacatt	tccaagtttg	ttgaaataat	acgaagctga	660
ctagcttacg	tgaatgatgt	tgccctcatt	tgttttgggt	gaggactcat	tactgcagta	720
tattgatctc	ttcaccaa	gctttttcty	tttctgaata	aatgctgtat	tagaggttct	780
atttatatat	gattttttaa	actttggttt	ccttctatcc	accaaatact	gtgaattggt	840
tttccattta	tttttcttag	ctaagtgaac	tttattcttc	actttttttt	agccctagac	900
ttcctagatt	ttctgtggca	ttctgtagga	cattgtattg	cttggaaaaa	aaaagatcaa	960
aatcattckg	gggcaaakgc	tctattatcc	ttatttatga	caagagaata	atgaaattca	1020
taagaaatta	ataacattca	gatattgcta	taaatgtact	tgagtcattt	tcatttgggg	1080
atagtaataa	tggctgtggc	agctttaatg	gagaaacctg	tgttggcctc	tttttctggc	1140
attaggatct	cttgtcatag	aactattggt	aaagtacagg	tttgatagca	gagttcctga	1200
attcagcata	tcatcagaat	ttccatttac	cttttgtctt	ttctttttat	kgattttttt	1260
aacctttttg	tttctattcc	tacctcccat	gagtaacatt	gatttctgct	gaagttagaa	1320
tttgtgttaa	gaattgactt	taaacttctg	aaatagttga	atattagaag	tggcttcagt	1380
tgccatgaaa	tgattgcttt	tctttttctt	tttttttctt	taaataaaaa	taatgcagcc	1440
ttatatatgt	ctcttccctt	caagaatgtg	aatttaggct	gggcatagtn	actcacgcct	1500
gtaatcccg	acctttggga	ggctgacacg	ggaagattgc	ttgagcccag	gaatttcaga	1560
ccagcctggg	caacacagga	agactccatc	tctacttaaa	atatttttgt	tttttagcca	1620
gggtgtgggtg	tatgtgcctg	tagtcccagc	tacttggggag	gctgagggtg	gaggatcact	1680
tgaaccag	agtttggggg	gcagtgaagc	atgattgcga	cactgcactc	cagcctgggc	1740
aacagagcaa	gaccctgtct	caaaaaaaaa	aaaaaaaaaa	aaactcga		1788

<210> 48

<211> 660

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (393)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (401)

<223> n equals a,t,g, or c

<400> 48

gaattcggca	cgaggagatg	cacatggccc	tgaacaacca	ggccaccggg	ctcctgaacc	60
tcaagaagga	catccggggc	gtgctggacc	agatggagga	catccagctg	gagattctca	120
gggagcgggc	ccagtgccgc	actcgagcca	ggaaggagaa	gcagatggca	agcatgtcga	180
aagggaggcc	aaagctggga	agytccaagg	gcctggcagg	ccagctctgg	ctgctgaccc	240
tgaggctgct	gctgggcgcc	ctgctggtct	ggaccgytgc	ctacgtgtac	gtggtgaacc	300
ccacaccttt	cgaggggctg	gtgccamccc	tgctgagccg	tgccaccgty	tggaagctcc	360
gggccctgct	ggacccttct	ctgcgcctca	aantggacgg	nttctgccc	ttctaggcca	420
raggcccagc	ggccccagca	aggaggccag	gcgaccagca	ctgccccgga	tgcccagtg	480
ccgtgccagc	cccctgcaca	tggcaccact	gtgcaccatc	cttgccagaa	gctgcagaga	540
aggggtggagg	tgggggtctgt	cctgagggct	gggcctgtgg	ctggacatag	agtcatgaca	600
taaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaactcga	660

<210> 49

<211> 1321

WO 99/09155

PCT/US98/17044

25

<212> DNA

<213> Homo sapiens

<400> 49

ccggatcacc	aggtcaggag	atcgagacca	tcctagctaa	cacagtgaaa	tcctgtctct	60
actaaaaata	caaaacttat	ccaggcatgg	tggtgcatgc	ctgtaatccc	agctactcag	120
gaggctgagg	caggagaata	gcttgaacct	gggaggtgga	gattgcaatg	agatgacatc	180
gccccactgc	actccagcct	ggcgacagag	caagactcca	tctcaaaaaa	aagaaaaagt	240
catttggaag	agatatgtgt	agtgtgttgc	tggtaaaaga	ctgtccactg	ttttcttttt	300
cagtaattaa	tggtcacaca	ctgtgtttac	ggctgttgct	agaaattgca	gacaaccctg	360
aggcggtcga	tgtgaaagat	gccaaaggac	aaacaccact	gatgcttgca	gtagcatatg	420
gacatattga	cgctgtttca	ttgttacttg	aaaaggaagc	caacgtagac	actgttgaca	480
tcctaggatg	cacagcttta	cacagagggg	tatgtacatc	tttctcagct	ctagtcaagc	540
aattttttta	atgagcttgt	tttctttttt	agcaaacaat	tacaaagggc	ctactttgat	600
tggattttta	gcaaaaaatg	tttagcaaaa	attgtttcct	aatacaacca	attaacctta	660
ttcagtccaa	aagaaattac	aaaatccttg	gcaaaggcaa	aataatggaa	ggtttttgctc	720
ttaagatttc	atgttagatt	gtgataatag	atgcatgaac	acctactgct	ggtgaaattg	780
gttctgcttt	ctgactacaa	aatacaagta	tatcatagaa	aatttgcaga	atattttttt	840
ttaaagccca	gagaagaaaa	tcacaatcac	cagtaatcat	acctcctgga	gataaccact	900
at ttgatgta	tattatctcc	aatctttttt	ctatatatag	atttgtttta	gatttttaaaa	960
agagaatact	gaagatatca	tttggattct	gctttttttt	cttagtatat	caaggatctt	1020
ttttcatttc	at tttttttct	gcatcatgat	ttttaatgcc	tcattgtggt	caagtgtcat	1080
agttttatttc	aatgattacc	tggtttttcag	tagttatgca	atttctaatt	gtttgtcctt	1140
acaaataatg	ccaaaatatg	tatcctgtgg	gcaattat tt	gcacacatct	gttgaagtgt	1200
ttgggtttttt	ttttttttaat	ctcactctta	tcacccaggt	tgcagtgagc	cgagatcaca	1260
ccactgcatt	ccagcctggg	tgacacagcg	agactccatc	tcaaaaaaaaa	aaaaaaaaaaa	1320
a						1321

<210> 50

<211> 548

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (10)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (14)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (27)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (68)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (533)

<223> n equals a,t,g, or c

WO 99/09155

PCT/US98/17044

26

<220>

<221> SITE

<222> (539)

<223> n equals a,t,g, or c

<400> 50

ctcgaaattn	accntcacta	aagggancaa	aagctggagc	tccaccgcgg	tggcggccgc	60
tctagaanta	gtggatcccc	cgggctgcag	gaattcggca	cgagcggaat	ttgcggcttt	120
ggcagattga	aatcatggca	gggccagaaa	gtgatgcgca	ataccagttc	actggtatta	180
aaaaatat	caactcttat	actctcacag	gtagaatgaa	ctgtgtactg	gccacatatg	240
gaagcattgc	attgattgtc	ttatatattca	agttaaggtc	caaaaaaact	ccagctgtga	300
aagcaacata	aatggatttt	aaactgtcta	cggttcttaa	cctcatctgt	taagttccca	360
tgcctggaga	agctaatagcc	aactcatcat	gtgataattc	aatttgtaca	ataaattatg	420
aacctggaaa	aaaaaaaaaa	aaaaaaactc	gagggggggc	ccsgtaccm	attsgccctt	480
gkgrgkcggt	twccattcat	ggcctsgttt	tacaacgtcg	tgactgggga	aancctggng	540
ttacccaa						548

<210> 51

<211> 658

<212> DNA

<213> Homo sapiens

<400> 51

ggtcgaccca	cgcgcccggt	ttctagtcta	tgcataaact	agaagaatgt	gagaaaagac	60
tatttttcagt	tgctcatgtt	tacctggatg	aactagttta	atttttgtct	tttaaaacag	120
acatatattat	tttaaaatta	aaatagcttg	aaatttttaa	atacaccca	aagcaagatg	180
atcgtttaag	ttaagttaaa	caatacaatg	aatggctctt	tatttttggt	gatgattgcc	240
aaaaacctct	tgccttcagg	aaataagcaa	taaacctgat	gaattgggca	tagttgaggg	300
ggaaaataaa	aatcaatggc	ttctatttaa	aaaacacagt	atgtaatatc	taaaaaagaa	360
aggcattggt	tctgaattgg	ggtgaatgta	ccaaacatat	accaaagga	aggcattttg	420
ttagaaaatt	tgattaatta	ttagaatctt	cctgactgga	gatgtaaatt	atcttgtttt	480
aaatctaact	cactctaatt	tggttttaat	gttgactgta	atccaggctg	tttctgggga	540
caacagaaca	caatatacct	ctttattcaa	accacacaat	cttggccagc	tattccctac	600
tccagcctga	atgacagaaa	gagaccttgt	ctcgaaaaaa	aaaaaaaaaa	gggcggcc	658

<210> 52

<211> 622

<212> DNA

<213> Homo sapiens

<400> 52

ggtcgaccca	cgcgcccggt	ctcatcatgt	tatgggtgaa	aacaaggaga	gaagagctgc	60
ggcccttcgg	ggaaccgaga	cctggaagct	ccctgaggca	gggctgtgac	tccctctttg	120
gacctcttaa	gttcctggag	tctcaagctt	ccagccgcca	ccatgtttcc	tggtggcagc	180
tgtggaagct	gcttctgggt	tgcctgggcc	agctgcagcc	ttgcagagag	ccggcaccga	240
tgcagacacc	ttgtgctggc	tgccccgctg	cagcagctgg	ggtgcctcac	tgtgtgcagt	300
ggctggaccc	catgctcact	tgctcacaca	cccctcactg	ctccacacct	ggcttgccgt	360
tggcagtgat	gggatccagg	ctggtagcgt	gagctgagca	cagcctgctc	aagccaaatg	420
gatggaacaa	accagtgagg	ccagagcaga	actcaggcaa	aggtgccacc	agccacagag	480
gcttctggsc	agaaaagcaa	caccctgagg	atcctgcaac	agtagtttta	caaagtgttt	540
attttgtcat	ataaaaatct	ggtttttaat	atttgcaaaa	ataaaagtaa	ggatgaaaaa	600
aaaaaaaaaa	aaaagggcgg	cc				622

<210> 53

WO 99/09155

PCT/US98/17044

27

<211> 723
 <212> DNA
 <213> Homo sapiens

<400> 53
 gggcgaccca cgcgtccgct cagcctttgt tgagagtgct gtgccccaaa tctgggttggc 60
 ttattctagg cattcgagtc tcttcccaaa taccaccttc tcaagtgcag cttttcctta 120
 ctacttaatt ttatagtccc ccatcaatgt acgatgttac cctcttttcc ttcattgaga 180
 gtgtttgtaa tttttttttg tctgcttggt tattgtcttt ttgccccata agtccaaggt 240
 ttacatgaac agggaaactg tctgttttgt ttattactgt atcccctatg ctggcacata 300
 ctatgtaata agtgtttggt gagtgcata gtgaataacc attctaataa actctgatgt 360
 ttaaagccct ttgctttata taagaatttt acttggaacc ctgggtatttt cgtttgtatt 420
 tgtttgtaa taaatgtcaa gagttcagta gtaagatagg tttcagaaat gctaagttaa 480
 acagaataaa gaaagaatat gtattacagg tcttggcaga gccttgaata tgctaacatt 540
 tgacagtggg agtctttgag aattatcaca tgaagctgct gtacattaca acacattcta 600
 ggaaatgctg tcttagacaa aaacctgtca tattagaatt ggggtaaggg gcacgatact 660
 gaccgtgagg cagcagattc ctatggacta cattaaaaaa aaaaaaaaaa aaaaaggggcg 720
 gcc 723

<210> 54
 <211> 908
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (361)
 <223> n equals a,t,g, or c

<400> 54
 gaattcggca gaggggaggc ctgccctgcc ctctctcttg cagagagcca ggttcacagc 60
 agggcgkcct gcaggacatt agcatgccta gtagatacac agtgtcgttg gggcgtgggc 120
 attttgwttt ctgttctctc tttttcccta tttaactatc atgtttgggg acctttgcct 180
 ctcaattttt aagagattaa aaaaaaatga grgcggcctt tattatacac tacatgtgtt 240
 ttctcccagt ttgtcagttg tcttttgctt ttttggtaat tttgccaggt acttatgtca 300
 acttgcatta agatgtcccc ttattaataa aagtaatttg ctctcattgt atgcaattaa 360
 nagaatacta aaatttctaa tgatcctacc acttaaagct gtataaacgc tgctaacata 420
 ccaggatatcc cattccaggc ttgcttggtat gtgtatatat attaataatt atctgtagct 480
 gtatgtctgk gacactctaa attattaaaa atttgtccca gtggcttaca aatttttttt 540
 tgtagtagca gcagctttta aaaaatacaa atcttagcat agttaacaga aaaaaagagt 600
 tgctccgggt aaggtagatt ctaatcccca ccaggggccc tgagacatgt ccttaaattg 660
 ctacaaaatg tacaacaaac cactagtaaa gtttattcta tttgataact ctgtttgctt 720
 ttaaaaactt catgtatagt gattattttc ctgttattct gtattcttca cctgcttcat 780
 atttagtgac tgccaagtat tctattgtat gtttatgaca caagtaattt aactattttc 840
 ttatcattga acatttacat ttgtatatac ttttactggt ttgccaaaaa aaaaaaaaaa 900
 aaactcga 908

<210> 55
 <211> 822
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (813)
 <223> n equals a,t,g, or c

WO 99/09155

PCT/US98/17044

28

<220>
 <221> SITE
 <222> (817)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (822)
 <223> n equals a,t,g, or c

<400> 55
 tcgatccacg cgtccgcgga cgcgtggrgt tgaaaattca tagtaagatt gatatctata 60
 aaatagatat aaatttttaa gagaaagaat ttagtattat caaagggata aagaaaaaaa 120
 tactatttaa gatgtgaaaa ttacagtcca aaatactggt ctttccaggc tatgtataaa 180
 atacatagtg aaaattgttt agtgatatta catttattta tccagaaaac tgtgatttca 240
 ggagaacctt acatgctggg gaatatattc aactttttcc ctcactaatt ggtactttta 300
 aaaacataac ataaattttt tgaagtcctt aataaatamc ccataattga agtgtataat 360
 ataaaaaatt ttaaaaatct aagcagctta ttgtttctct gaaagtgtgt gtagttttac 420
 tttcctaagg aattaccaag aatatccttt aaaatttaaa aggatggcaa gttgcatcag 480
 aaagctttat tttgagatgt aaaaagattc ccaaacgtgg ttacattagc cattcatgta 540
 tgtcagaagt gcagaattgg ggcacttaat ggtcaccttg taacagtttt gtgtaactcc 600
 cagtgatgct gtacacatat ttgaagggtc tttctcaaag aaatattaag catgttttgt 660
 tgctcagtgt ttttgtgaat tgcttggttg taattaaatt ctgagcctga tattgatatg 720
 gttttaagaa gcagttgtac caagtgaat tattttggag attataataa atatatacat 780
 tcaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aanaagnaaa gn 822

<210> 56
 <211> 1951
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (28)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1636)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1947)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1951)
 <223> n equals a,t,g, or c

<400> 56
 ggccctgggc tcgcggcggt gccgsgngg atggcgggag ccggagctgg agccggagct 60
 cgcggcggaac ggccggcggg gtcgaggctc gagctcgca tccaccgcc gcgcaccgcg 120
 cacatcctcg ccaccctcgg cctgcggctc agccctcggc ccgcagatgg atggcgggctc 180
 agggggcctg ggggtctgggg acaacgcccc gaccactgag gctcttttcg tggcactggg 240

WO 99/09155

PCT/US98/17044

29

cgcgggcggtg	acgggcgctca	gcaccccctg	ctctacgtga	agctgctcat	ccaggtgggt	300
catgagccga	tgccccccac	ccttgggacc	aatgtgctgg	ggaggaaggt	cctctatctg	360
ccgagcttct	tcacctacgc	caagtacatc	gtgcaagtgg	atggtaagat	agggctgttc	420
cgaggcctga	gtccccggct	gatgtccaac	gccctctcta	ctgtgactcg	gggtagcatg	480
aagaaggttt	tccctccaga	tgagattgag	caggtttcca	acaaggatga	tatgaagact	540
tccctgaaga	aagttgtgaa	ggagacctcc	tacgagatga	tgatgcagtg	tgtgtcccgc	600
atgttggccc	accccctgca	tgtcatctca	atgcgctgca	tggtccagtt	tgtgggacgg	660
gaggccaagt	acagtgggtg	gctgagctcc	attgggaaga	ttttcaaaga	ggaagggctg	720
ctgggattct	tcgttggatt	aatccctcac	ctcctgggcg	atgtgggttt	cttgtggggc	780
tgtaacctgc	tggcccactt	catcaatgcc	tacctgggtg	atgacagcgt	gagtgaacac	840
ccaggggggc	tgggaaacga	ccagaatcca	ggttcccagt	tcagccaggc	cctggccatc	900
cggagctata	ccaagttcgt	gatgggggatt	gcagtgaagc	tgctgaccta	ccccttctctg	960
ctagttggcg	acctcatggc	tgtgaacaac	tgcgggctgc	aagctgggct	cccccttac	1020
tccccagtg	tcaaatacctg	gattcactgc	tgggaagtacc	tgagtgtgca	gggcccagctc	1080
ttccgaggct	ccagcctgct	tttccgccc	gtgtcatcag	gatcatgctt	tgccctggag	1140
taacctgaat	catctaaaaa	acacggtctc	aacctggcca	ccgtgggtga	ggcctgacca	1200
ccttgggaca	cctgcaagac	gactccaacc	caacaacaac	cagatgtgct	ccagcccagc	1260
cgggcttcag	ttccatattt	gccatgtgtc	tgtccagatg	tggggttgag	cgggggtggg	1320
gctgcaccca	gtggattggg	tcacccggca	gacctaggga	aggtgaggcg	aggtggggag	1380
ttggcagaat	ccccatacct	cgcagatttg	ctgagctctg	cttgtgcaga	gggcccagaga	1440
atggcttatg	ggggcccagg	ttggatgggg	aaaggctaata	ggggtcagac	cccaccccgt	1500
ctacccctcc	agtcagccca	gcgcccattc	tgcagctcag	ctgggagcat	cattctcctg	1560
ctttgtacat	agggtgtggt	cccctggcac	gtggccacca	tcattgtctag	gcctatgcta	1620
ggaggcaaat	ggccangctc	tgccctgtgt	tttctcaaca	ctacttttct	gatatgaggg	1680
cagcacctgc	ctctgaatgg	gaaatcatgc	aactactcag	aatgtgtcct	cctcatctaa	1740
tgctcatctg	tttaatgggtg	atgcctcgcg	tacaggatct	ggttacctgt	gcagttgtga	1800
atacccagag	gttgggcaga	tcagtgtctc	tagtcctacc	cagttttaaa	gttcatggta	1860
agatttgacc	tcattctccc	caaataaatg	tattgggtgat	ttggaaaaaa	aaaaaaaaaa	1920
aaaaaaaaaa	aaaaaaaaaa	gggggggnccc	n			1951

<210> 57

<211> 663

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (43)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (64)

<223> n equals a,t,g, or c

<400> 57

ccaatcggct	aattcaactc	acatagtagg	gaaacgtggg	acnccctgca	ggtacccggg	60
ccgnaattcc	cgggtcgacc	cacgcgtccg	gctattgtaa	tcttttctac	ctatacttct	120
tcattggctc	agaatgaagc	aaggcatgtg	ctgcttttct	atatgtcatt	tatgccataa	180
atcccattgt	tagaaggtaa	tgcttctaac	ggattccatt	catgcttttg	agataaatgg	240
cattgacttt	catattgatc	acatggaaag	ctgttacctg	attcctttcc	tgagatcact	300
tccagcctaa	tgtgcatttg	gctggaatat	ggttgtctca	gaataacatc	atgcactcgg	360
gctttttatac	ttctgccttt	aggggactgt	ggcagcatgg	catgggtcaa	gaagtacttc	420
tccttcatct	tcctttgatg	tcggtaactc	atcctttctg	cactgcggga	gttggttaatg	480
cttttgtgtc	ctccagttca	catgctgatt	gctaagaaga	aatgagcat	gagtgaaccc	540
aaagctgctg	aaacattctg	cgtttatgca	acttccttgc	cctctataca	aggaagatgg	600
tttcattgtc	ttgtctagag	aataaagtct	tttttaaaaa	taaaaaaaaa	aaaaaaggcg	660

WO 99/09155

PCT/US98/17044

30

gcc

663

<210> 58

<211> 778

<212> DNA

<213> Homo sapiens

<400> 58

ggcagagtca	gctctgtgct	gagcctcctg	gcctggcccc	caccggtgca	tccgcccagt	60
gcgtccacct	gccctggcta	gcatgctgct	gggccacacc	ccaagatcag	gggccctggg	120
gacggcaagt	gaataaagca	catttccacc	caattttgtc	atccgagaga	gagcacaaac	180
tgcaggccct	tggtgcagct	gaaggaagac	cctacagaga	atggaattga	gagtggagac	240
aggacacttc	acaggacact	tgagcacagt	caagatttta	ttcacacttt	tggttcctgt	300
gttttatatc	gaagacttag	ctatgaattg	ctatctaaat	ctcagagctt	agaagccaac	360
ccagtgacta	gaccttccag	tgaagaaagt	gatctcaaga	gggccaggga	cttaacagcc	420
aagccacacc	acccgcacag	gttcttctgt	gacaccgaga	gatctaacc	aaggcctggg	480
ttatgtctta	gtcgagacat	catcatctga	gaagcaccac	atcctttcag	acacatcctc	540
ggacacacat	gcggtccttg	gtgccccag	gttcaatcct	gcgttagctc	ttttgatgag	600
aaggaaataa	accaaaccag	ccacttgcac	tatggcttcc	aagccaatgt	tattgactca	660
ataagtgctt	agcaattggc	ttcctctttt	gtcttcctat	tttcagctcc	atttaaacca	720
ggagttattt	ataaagacct	cttcctctca	aaaaaaaaaa	aaaaaaaaaa	aaactcga	778

<210> 59

<211> 982

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (360)

<223> n equals a,t,g, or c

<400> 59

gaattcggca	cgagcatatg	tccaagtgtt	accttgtcta	gccccagga	acacagtccc	60
caggaccatg	ttttttgggg	caccacagc	aggggcagtg	caggtctggt	tgctcctgct	120
ctcacctgca	gcatctcccg	tagaggaatt	gtcagttctg	gttccctgtg	ggcagtaaag	180
gtttccttgt	aggtcactgg	ggcattggcc	agaaaaaggt	tgtgaaaatc	acatgctaata	240
ttctcaaaat	tcctgctttc	aatgttgatg	tccaataaag	atgttcataa	tttcagctgg	300
atattcttaa	taggatttcc	tccaataaccg	atgctgtaaa	gcatattgaa	tggaacaggn	360
attcaaattt	gaaactctct	ctctagaagg	gtccatgtgg	gagatgggtg	atcacttgag	420
gtcgggaatt	cgagmccaga	ctggscaaca	tggtgaacc	ccatctgtac	taaaaattac	480
aaaaaattgg	ccaggagtct	aggcatgtgc	ctgtagtccc	agytactcag	gatgctgagc	540
ccrggrgaat	tgcttgagcc	caggaggcag	atgttgcagt	gagccgagat	cactgccact	600
gtactccagc	ctgggtgaca	gaatgagact	ccatctaaaa	aaatttttaa	atttaaaaag	660
ttgacacact	tttacaagct	gcatcccatc	tcagataagg	aggtgatgta	actgagttct	720
tttagatcca	tctgctttca	tcttatcttt	ttgtaggtaa	tattttgaca	agcatgtttg	780
tacataaaga	ttctcctatg	gttgggattt	taaaaattca	tagactactc	aggccagggtg	840
cggtgcctca	agcctgtaat	ctcaacacat	tggaaggcca	aggagggtgg	attgtctgag	900
cccagaagtt	caagaccagc	ctgggcaaca	tggcaaaatc	ctgtctctac	aaaaaataca	960
aaaaaaaaaa	aaaaaaactc	ga				982

<210> 60

<211> 406

<212> DNA

<213> Homo sapiens

WO 99/09155

PCT/US98/17044

31

<400> 60

tcacacaacg	ggtgatctca	caaaactggt	aagttttctta	tgctcatgag	ccctcccttt	60
tttttttttaa	tttggtgcct	gcaactttct	taacaatgat	tctacttcct	gggctatcac	120
attataatgc	tcttggectc	tttttttgctg	ctgttttgct	attctttaaac	ttaggccaaag	180
taccaatggt	ggctgttaga	agggattctg	ttcattcaac	atgcaacttt	agggaatgga	240
agtaagtcca	tttttaagtt	gtgttggtcag	taggtgcggt	gtctagggtta	gtgaatcctg	300
taagttcaaa	tttatgatta	ggtgacgagt	tgacattgag	attgtccttt	tccctgatca	360
aaaaatgaat	aaagcctttt	taaacaaaaa	aaaaaaaaaa	aaaaaa		406

<210> 61

<211> 813

<212> DNA

<213> Homo sapiens

<400> 61

gaattcggca	cgagtctcag	gtatgttttaa	acccaatggt	tctttgttaa	ttttctctct	60
agatgatcta	attctgagag	agagggaaaa	tgaatatggg	gaagtctaaa	aaatgaaaaa	120
ggggaaaaat	gaaggaatat	gcctgctggt	tcctaataag	tagctgaaag	tcttcaacct	180
atgaagcctc	ctggatcatc	tgccaattgt	tcaacacaac	tcccaccctt	gccttcatcc	240
tctttccctg	attcacaccc	tcatggcctc	ttttcattac	agtcaagggtc	catcccagct	300
ttgacctcat	gaatccatta	tgccctcctc	tgttactgct	agacctgcag	acccagtgtc	360
cacaaagatg	ctcctatat	ctttattcct	gcttctctgg	aatgggttta	atgcccccta	420
aagcaccagc	wtgtgaatcg	acctttgtgt	tcatatcatg	gagtcctctt	agctccttgg	480
tgccctccaag	gccaagcttc	catcacctgc	caagacacag	cgagctggac	caatatttgt	540
gtggcagggt	gggtgtgaca	tgaatgtcaa	agccaccctg	aattgaggga	ttctgtctcc	600
ctttgttgaa	cttcctttgg	gtggttaagcc	agacattgtc	attcagcaaa	catgggtttca	660
ataaatatct	agatgcaatc	aagagaaaca	tgaaaatgac	atggcctcag	tcctccaaga	720
gttcaaactct	aacagaagg	acaaaaagt	tcttagccta	agatgattaa	aaaaaaaaaa	780
aaaaaactcg	agggggggcc	cgtaccctct	cgc			813

<210> 62

<211> 846

<212> DNA

<213> Homo sapiens

<400> 62

gaattcggca	cgagtctttc	tgttttttaat	gctttattac	atatgcctag	ttttgcttaa	60
gcttgtctaa	attttatgac	ggaactataa	aaaatgtatt	tcactttttac	gtgacatggt	120
attggtgaat	cttgtgtttg	tatgtttttt	tcttttttgaa	aggagagtgc	atttaaaatg	180
ctgaattgaa	caggacatct	tgagagaatg	ttttaatttg	agctcatgta	tctgctgac	240
gatttctaagt	gcaggatatt	ttctgtttgt	catagatatt	tgaatgggtg	tacttccata	300
agcatggcac	atctttttatt	gagcaagtat	ctgtaagcca	tttgcaacca	ctgatgggag	360
gaacagagag	cagcatttca	gaaccagggt	ctccttcgag	gaacagagaa	aatgaaacca	420
gcagacagaa	tttgtcagg	gactactttt	ctaattgtgt	ttcagagctg	tgtattttaag	480
attgagtttg	gctctgggag	atagaaaact	caaaacagca	gagtgtgtgt	gtgtgcatgt	540
ttgtgtttcc	cccaaaattc	taatcaccaa	tgtgatgtta	cgaggtaggg	tctttgggag	600
gtgatcagg	catgagggca	gtgccctcag	ggatgtgatg	aatgccctta	tgagagaccc	660
cagagagctg	cttgccactt	ctaccgtggg	aggacaccac	gagaaggcgc	cgtctgtgaa	720
ccagaaagca	gaccctcacc	agacaccaaa	tttgttggtta	ccttggtcat	agacttccca	780
gcctccagaa	ctgttaaaaa	taaatttata	ctgtttataa	tctaaaaaaa	aaaaaaaaaa	840
actcga						846

<210> 63

<211> 1442

WO 99/09155

PCT/US98/17044

32

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (933)

<223> n equals a,t,g, or c

<400> 63

catgaagatg	tgaaaatata	atcttaacca	gtttcattct	atgaacataa	tattctggca	60
rctttttcta	taactgmga	tggatatct	ttttatacac	tgcctaaatc	agtactactg	120
ccagtcacct	gaggtcaggt	ctgcacaaca	ctaaattggg	caataacata	gaacatctag	180
gcagtcctga	cagtcaca	gtgtaatcac	taggggaagr	aaaagtaggc	ctaccctttt	240
acttattaac	ttaagtaata	aaaattgtat	aaaaatatga	atggtsgctg	cagaggagcc	300
tttacaatga	gataatttga	agcagtcctt	gaaaataaca	aaaattattc	catttaataa	360
agggtttgtt	ttgttttagt	tttctctttt	attcagaaaa	catacctgtg	ccttttgaaa	420
gggcttaatc	ccaaacaggt	aatatgtgtg	gatcaatcat	ctctcctccc	atgaaattaa	480
tcattcatgg	taatatatta	aggctggaac	gtagctctta	gtgacttaaa	acatgacagt	540
aagcattttac	actgttggaa	ggtaatttca	ttgctatgtt	attaaaaatga	tgggaatcct	600
atttatacat	ttattttatt	atttattttac	agaagattgg	ttccttccag	ttcaatttaa	660
cagcttcagt	gaagttagta	taatgataag	aaaaattgac	tgtagctatt	attccaagtg	720
aaaatcatgc	agctgagtc	tgctgcaccc	tgggagcaaa	gcattaattc	aatgaggag	780
tagtcagtc	tagcactgta	gacgccgact	ttaccaacca	agatattgta	tgtgtgtgac	840
attcagctaa	cattgatcta	gggcacttag	tttgctacca	cattgttccc	ttcatgattg	900
aaactgtaaa	taacataaca	ctttaaggca	gcnaagcaaa	tattttaata	agccagaaag	960
gcaagatgtc	agagaaaatc	tgtatatatt	gctattttgga	gaactcgtgt	tttccacaaa	1020
ttaaactgga	gatgtcattt	gaaattttct	tcccttaaac	atgctgtcac	aacatggatt	1080
ccttctcatg	gatgtctttc	taggcttata	aatatatggg	gtgattgcta	taattttgtg	1140
aaatttttatt	cagcaattaa	tagtgatttc	agcaatatgt	actaagattc	caaggcagaa	1200
ataaatgtat	aaaggatttg	agcctgtatg	tgtagaaga	aactctctct	tcagtcatat	1260
ttcctaaatt	cagtgttaagt	acctcgctga	tttagcactg	gagttattcc	ttgaatgtgt	1320
aaataatgat	gttctattct	gacctaata	attcctgtaa	tgtgaatatt	taaaataaaa	1380
gaattcaatt	taaatgtata	aaaaaaaaaa	aaaaaaaaact	cggagggggg	gcccggtacc	1440
ta						1442

<210> 64

<211> 1004

<212> DNA

<213> Homo sapiens

<400> 64

ccgggtcgac	ccacgcgtcc	ggggcgccca	tgcatacacag	ctgtgtccac	aggatgcacg	60
atggccattg	agaaatggat	tttgagtgca	gaagacctgg	gtgctgcatg	cttaactcat	120
ctgggtcctt	tggacaaatc	acatcacctc	tcatggcctc	catatgttcc	ttctgtgcat	180
gaaggatgat	gttacttctt	gcctctgcct	tctcatagg	gacagtgtta	ggatcaaaaca	240
gatcatgtat	gagtcagtg	tgtgggcacc	ataaatcaca	gaaagcccag	aagacatcgt	300
catttattac	agccccagtc	aagtaaaagc	ccattttacc	aggcacattg	gttccaacag	360
taagcctttt	tggctgatga	aagctgtgta	aagtttggtc	tctggagaga	agctgtttta	420
tttttttaaa	ccaagtctgt	aaaaccttgg	atgagaagct	cttttagctc	ttttatgttt	480
tgatcaataa	tcaatgaagg	cccaatataa	gatctcctcc	cccgaaccgtg	tatgcaacac	540
atttccaagg	cccatccaca	gcaactttgt	tacttctgcc	tgccgcatgc	atggtttgaa	600
atttggcagc	tcatattggg	gtaaaaatca	catatcactg	taggctaaac	ttacctctgc	660
acactcctcc	atgtccactg	agcatctgct	gaagtctgct	ttttcttcat	tttttatgga	720
atgtaaagct	catccatgtg	tacattattc	atgcattttac	ttttctgcca	cctccaaagc	780
attcaattaa	agcaggaatt	aaggctcaac	tatcttactt	tagcacagtt	ttggcagaga	840
tgttacagtg	agatgatttt	tttctgtctg	tcaaagttgt	ttcttcatgt	tttccaagat	900
ggtctagaac	atcatttaga	gtaaattttc	attttggagg	aaatttttat	gaaaagtctc	960

WO 99/09155

PCT/US98/17044

33

tgtaggtatc tcctgtgaat agagggtttta aaaaaaaaaa aaaa

1004

<210> 65

<211> 1683

<212> DNA

<213> Homo sapiens

<400> 65

tgctctttct	ggttcgctg	ctgtgggccc	cggctgcggt	ccgggccggc	ccagatgaag	60
accttagcca	ccggaacaaa	gaaccgccgg	cgccggccag	cagctgcagc	cgcagcctgt	120
gstgtgcagg	gccccgagcc	ggccccgggtc	gagaaaatat	ttacaccagc	agctccagtt	180
cataccaata	aagaagatcc	tgctacccaa	actaatcttg	gatttatcca	tgcatttgct	240
gctgccatat	cagttattat	tgtatctgaa	ttgggtgata	agacattttt	tatagcagcc	300
atcatggcaa	tgcgctataa	ccgcctgacc	gtgctggctg	gtgcaatgct	tgccttgga	360
ctaatacat	gcttgctcag	tttgtttggc	tatgccacca	cagtcacccc	caggggtctat	420
acatactatg	tttcaactgt	attatctgcc	atttttgcca	ttagaatgct	tcgggaaggc	480
ttaaagatga	gccctgatga	gggtcaagag	gaactggaag	aagttcaagc	tgaattaaag	540
aagaaagatg	aagaatttca	acgaacccaa	cttttaaata	gaccgggaga	tgttgaaacg	600
ggtacaagca	taacagtacc	tcagaaaaag	tgggtgcatt	ttatttcacc	catttttggt	660
caagctctta	cattaacatt	cttagcagaa	tgggggtgat	gctctcaact	aactacaatt	720
gtattggcag	ctagagagga	cccctatggt	gtagccgtgg	gtggaactgt	ggggcactgc	780
ctgtgcacgg	gattggcagt	aattggagga	agaatgatag	cacagaaaat	ctctgtcaga	840
actgtgacaa	tcataaggag	catcgctttt	ttggcgcttg	cattttctgc	actattttata	900
agccctgatt	ctgggtttta	acaagctggt	tgttcactca	tatttagttt	aaaataggta	960
gtattatctt	tctgtacata	gtgtacatta	caactaaaag	tgatggaaaa	atactgtatt	1020
ttgtagcact	gattttgtga	gtttgaccca	ttattatgtc	tgagatataa	tcattgatcc	1080
tatttgtaac	aaggagtgtt	aaaagaaacc	tgacttctaa	gtgtgggttt	ttcttctctc	1140
caacataatt	atgttaatat	ggctctcatt	tttcttttgg	tgcagaaccg	ttgtgcagtg	1200
gggtctacca	tgcaattttc	tttcagcact	gaccctttt	taaggaatac	aaattttctc	1260
cttcactcact	taggtgtttt	aagatgttta	ccttaaagtt	tttcttgggg	aaagaatgaa	1320
ttaattttcta	tttcttaaaa	catttccctg	agccagtaaa	cagtagttta	atcattgggtc	1380
ttttcaaaac	taggtgttta	aaaaaagaga	catatatgat	attgctgtta	tatcaataac	1440
atggcacaac	aagaactgtc	tgccagggtca	ttcttcctct	ttttttttta	attgggtagg	1500
acaccaata	taaaaacagt	caatattttga	caatgtggaa	ttaccaaat	aaaagagaat	1560
actatgaatg	tattcatatt	ttttctatat	tgaataaaca	atgtaacata	gataacaata	1620
taaataaaag	tggtatgacc	aaaaaaaaaa	aaaaacaaaa	aaaaaaaaaa	aaaaagggcg	1680
gcc						1683

<210> 66

<211> 1441

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1362)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1364)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1421)

WO 99/09155

PCT/US98/17044

34

<223> n equals a,t,g, or c

<400> 66

aagttgggtt	cggctgcaga	ggggaaggcg	gctaccagtg	taaagccaga	gctgaggttc	60
ttgatagtcc	acaatgggtg	aaccacagca	agtgagtgca	cttccaccac	ctccaatgca	120
atatatcaag	gaatatacgg	atgaaaatat	tcaagaaggc	ttagctccca	agcctcccc	180
tccaataaaa	gacagttaca	tgatgttttg	caatcagttc	caatgtgatg	atcttatcat	240
ccgccctttg	gaaagtcagg	gcatcgaacg	gcttcaccc	atgcagtttg	atcacaagaa	300
agaactgaga	aaacttaata	tgtctatcct	tattaatttc	ttggaccttt	tagatatatt	360
aataaggagc	cctggggagta	taaaacgaga	agagaaacta	gaagatctta	agctgctttt	420
tgtacacgtg	catcatctta	taaatgaata	ccgacccccc	caagcaagag	agaccttgag	480
agtcatgatg	gaggtccaga	aacgtcaacg	gcttgaaaca	gctgagagat	ttcaaaagca	540
cctggaacga	gtaattgaaa	tgattcagaa	ttgcttggtt	tctttgcctg	atgatttgcc	600
tcattcagaa	gcaggaatgc	agagtaaaaa	ctgaaccaat	ggatgctgat	gatagcaaca	660
attgtactgg	acagaatgaa	catcaaagag	aaaattcagg	tcataggaga	gatcagatta	720
tagagaaaga	tgctgccttg	tgtgtcctaa	ttgatgagat	gaatgaaaga	ccatgaaaga	780
tgtttctttt	tctttttttt	cttttgataa	tagcatcata	tattagttca	ttttcttttg	840
gacagtctta	agagaagttt	cactaaaaat	gtaaacagct	ttaatcttga	ctccaaattt	900
ttcaattatg	agatgtcata	ggcagtaatt	tcgctgtata	acaagcatag	acaaatgagt	960
gtccctgcac	taagaagaat	cacttttaaaa	agcaaagtgt	tagctgctgt	tgtatgggac	1020
attcctatgt	tttagagttg	cagtaaaact	ttgatgataa	cctcaataat	agcaaagttt	1080
tcgtctttga	aaaggggatt	tagcatttgc	tttaagaatg	atagataaat	ggatattaag	1140
ctctctacat	gtaaaactat	gaaatcttta	gacttattcc	attaaaaatt	ttgcttaagc	1200
tccaaaaagt	agcataacat	gttgatagag	aggagcccag	tagagttata	aaatagaaac	1260
ttcatttttt	cctcatgact	gcttctgtaa	accactagc	tcagtctttt	ctccctatcc	1320
tgaatggact	cttgcagggg	agtccccata	aatgttggtt	tntngccagt	cactccaggg	1380
gaataagtcc	tttggggcac	tttaaagtta	cagacattaa	ntttaagtaa	ttaagatggc	1440
c						1441

<210> 67

<211> 622

<212> DNA

<213> Homo sapiens

<400> 67

gcaattcggc	acgagggggc	ctctcctctg	ctgactcttg	ccattttttc	aggcctcccc	60
tcagtgagga	gaccaggcga	tgggagacag	gcatgggtgt	gcttctgctg	ctccagagaa	120
accctgggac	acctttgttc	tgcttggttt	tctgggctgg	gctcaggaaa	cctgcccagt	180
tcaggcctat	attgggtcca	agctgccctt	gtgctgcttc	tgtcaagcga	ggtgtggaca	240
ttccaagttc	gtaagcatga	acaaaagaaa	agaggaaccc	agcagatgta	acagaactga	300
ctccagttgt	gtagagtttt	gctaaactgt	ttatccccct	ttgctgtggt	ttacattaat	360
ggcaatagtt	agccaggtgt	ggggaatgag	agtgcattgc	tcgatagggt	ctgatgaact	420
gggagtaacc	caccattgca	attggggatt	gttttgcaag	gaaatagtat	ttttatgtgg	480
gggaccagca	aaatctctac	attagtgtaa	aatttcaaat	agttgtttta	tcgttggttt	540
ggttttacca	caaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	ctcgaggggg	ggcccgtacc	600
caatagccct	ctcatgtatc	gt				622

<210> 68

<211> 616

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (2)

<223> n equals a,t,g, or c

WO 99/09155

PCT/US98/17044

35

<400> 68

gncccaacgc aattaatggg rgtagctma cycattaggc acccaaggct ttaaacttta	60
tgcttccggc tcgtatgttg tgtggaattg tgagcggata acaatttcac acaggaaaca	120
gctatgacca tgattacgcc aagctcgaaa ttaaccctca cttaaaggga caaaagctgg	180
agctccaccg cggtaggggc cgctctagaa ctagtggatc ccccgggctg caggaattcc	240
ccccccccc cccacacccc cttcagctat gcttttggag tcctggatgg gaatctgggg	300
ggagagagga aggacaggtc aggtctcccc cagccccctc tgctcctgtc tcctcgtgtc	360
cgcattgctg gagctccacc tccctcttgg tttctccgca cccgccatt ttccttctgy	420
ctttacctgc ttcgtatcct ttcctctgtg atgtggctga cccctctccc acccctccct	480
gcaggcggct ggccagggtg gcaggtgcca gccggagctg taaatagasc gtgcgctttt	540
gtgctggttt gtgcgtgtgc tgtatttctg tgttttgata gaagtcacac aaaaaaaaaa	600
aaaaaggatc cctcga	616

<210> 69

<211> 1019

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (884)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (922)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (939)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (965)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1003)

<223> n equals a,t,g, or c

<400> 69

ggcgtccagg tccgctcggg aaccgtttcc cgcgcgcccc gccccgactc cgggggtaaag	60
agccccggag cggagcagcg ctggccgcgt gccgcctccg gagccggcag ccccatggc	120
tgggggttat ggagtgatgg gtgacgatgg ttctattgat tatactgttc acgaagcctg	180
gaatgaagcc accaatgttt acttgatagt tatecttgtt agcttcggtc tcttcattgta	240
tgccaaaagg aacaaaagga gaattatgag gatattcagt gtgccaccta cagaggaaac	300
tttgtcagag cccaactttt atgacacgat aagcaagatt cgtttaagac aacaactgga	360
aatgtattcc atttcaagaa agtacgacta tcagcagcca caaaaccaag ctgacagtgt	420
gcaactctca ttggaatgaa acctcagaaa aagagcaaca gaagtaattg tttcaagctc	480
ctgattcttt ctactaaatc atgaacagct ttaaaaacat ttctgtctgc ataaaattat	540
tttacttgta acttttcccc aattgttctg tgcattgttt tgccttttta aattacatct	600
ccaagtggct caaaaggcct tgacacaggg aacctgcaca tatccaggat atgtgtaacc	660
agcgatggtg acttgacctt gccaaagacct gtgattcctt caggatacaa tcagtgagaa	720

SUBSTITUTE SHEET (RULE 26)

WO 99/09155

PCT/US98/17044

36

ataaaaacac	atcttgggaa	gtgggaatcc	tggagtttat	gccatttgca	atattaaaaa	780
ataaaaatgc	aagttattat	ttcaataata	acttcctggt	tcattgtatt	ctgtgagtga	840
taagtgtcag	atcaataaca	gattaatttg	ttgttaacag	ctcntttttt	tttttttttt	900
tttggagaca	ggagtctggt	tngcccagac	ttggagtgnc	agtgggccaa	atcctctggc	960
tcaantggca	aacttccaac	ctccccgggg	tttaaacgga	ttntctcctg	gccacagcc	1019

<210> 70

<211> 831

<212> DNA

<213> Homo sapiens

<400> 70

gaattcggca	cgagaatttc	ttatggctga	ataatatattc	attgtgtaga	taaaccacat	60
tatttgtcag	ataatagaca	tttgggttat	tgctgtcttt	tggctattat	gagtgttata	120
aatatttgtg	cacaagtatt	tgtgtagaca	tgtttgcatt	tctcttgggt	atatacctag	180
gagtgaatt	gctggataat	atgtttaact	atgtgaggac	tgatagacta	ctttgtaaag	240
tggccaacat	gagtaagttt	tcatcacatt	tataaaatgt	tagtgtactt	acattagctt	300
gcaaagcatt	taataagcag	caagagttaa	accacgttgg	tccaagtga	ctgaaagcag	360
acttctgtgt	tacatgtgta	tgagttactg	aacatgttcc	ataatacagg	agtgtgagca	420
cactaacagg	taagtgcagg	aaamcaagaa	gaaatatattt	cagagtatag	tcaaaagtac	480
actgagcatg	ggagaattgt	tttgacattt	tgctcaaaac	tatttctgaa	gaaaattcaa	540
catttctttc	acggaaagtt	ttaggaacag	gtaaatacaa	ttatataaag	tactggtaga	600
atatgttcgt	tcagatgacc	ttgaagtgtt	ttttcagact	tatctgaact	tgagatctga	660
actgaatttt	tattagaaac	tgtaaagcc	tctggcattg	aagggttagt	cataattggt	720
gagttctgaa	tcacttcatt	tcckgcagtg	gttcctgaga	gaatcttagt	tmaaaggact	780
gcccccgcca	acccttgccc	cgccaaaaaa	aaaaaaaaaa	aaaaaactcg	a	831

<210> 71

<211> 750

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (734)

<223> n equals a,t,g, or c

<400> 71

gaattcggca	cgagcgggaa	ggctgggggtc	cgtgggggatg	ggcagggtct	gtggggacac	60
gcagggtgtc	ccacatgatg	cagcctgtcc	tcatatgggg	actctgagct	ctgagactcc	120
ctgtgtgaga	tgtttgggtg	cagagctgtg	aagacacaga	aggaaacgtt	gccgtctgca	180
ccaggctccc	caccgttggt	ggccctgttt	tccgtggccc	tgtggcctgt	ggccctgtct	240
aacgaggcca	caccacattc	atgtggacaa	gcaccaggag	ctccgggtca	gatgagaaca	300
ctgtttcctc	cgacctgact	gcctcttttc	ctggcggttt	ctaagccagc	atccagccgg	360
cctcggtgag	gatgacacca	gcattcccctt	gaccctccaa	ggtctcctgt	gacattgccc	420
cagaggctct	tgctgtgggg	ccgtccagtt	tatgtggagt	gacctgcacc	ctgagcacag	480
cccaacaktt	ggccacacct	tgggggcccg	aggggctgag	ttctacccag	agcggctgga	540
ggctcacaag	ggattttccc	accttgaggg	gagccaagtt	cccctggggg	gcagggtggc	600
tgctcagctc	tgaaagacct	cagtgccgtg	gagtgcgctc	tggaggaagg	gtactgagcc	660
gattccctga	cagtgactgt	aataaagatg	gctaaataga	gaaaaaaaaa	aaaaaaaaaa	720
aaaaaaaaaa	tagnaggggg	tcccgtaccg				750

<210> 72

<211> 714

<212> DNA

WO 99/09155

PCT/US98/17044

37

<213> Homo sapiens

<400> 72

gaattcggca	cgaggaggag	ttattcaggc	ctccgccagc	ttcaaggccc	tgggggatggt	60
ctttcacctc	cctctttctg	atctcttttt	catgctcctc	cttgctccaa	agaaaagccg	120
gatggcaaaa	gagcccagaa	cctattggaa	ctgacaaaat	caagtcacgg	cgcctacaaa	180
gatgaggggc	agattctggc	tgccttttaa	tttcgtcctt	cacctgatat	ctgtgccaga	240
gaatgtggca	tggttcagtc	ttccaggagt	tctgctacag	agaagagagt	aacccccatc	300
catcatggcc	aaagcaccca	gtcaggctcc	gctctggatc	cagcccgaca	aatgcaaccc	360
ttgaataggg	tttgtgcaag	caaactggat	gacgaccgaa	gaaaccctgt	cgcttctgag	420
aagacaccca	atccaagaat	gaaagcatca	ggttcaatac	ctaggaactc	ctgtagaggg	480
tgttgtggaa	tcttctttta	aagaacaaaa	caaggtaaaa	caaagttaa	tagggtagag	540
cagccaggtg	tgggtgggtca	tgcctgtaat	ctcagcaatt	tgggaggcca	aggcaggatc	600
tcagcaattt	gggaggcgaa	ggcaggcaga	tcacttgagc	ctaggagttc	aagaccagct	660
tgggcaacat	agcaagaccc	tgcctatacc	aaaaaaaaaa	aaaaaaaaact	cgta	714

<210> 73

<211> 1405

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (8)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (35)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (59)

<223> n equals a,t,g, or c

<400> 73

ccctcctncc	cttccttggg	ccttccaacc	ttaantcctt	tttccaaaaa	aaaaaagang	60
aactgtgaag	aacccccaaa	aaacttccca	cttcctggga	ggccagccca	caggaacagg	120
gaacaatatt	tatttgggtc	tcttcagttc	cccctttgag	aacaacatta	aatacatggt	180
agctgggggt	cccagggcac	tctccttccc	acagtagtgc	ggccaaattc	ccagtctggc	240
cagtctcttt	gttgagactg	aatagaagga	ctgcaggttt	ttttggagga	tgagataatt	300
tttctctgca	ggcatttttc	ccttgccctc	cttatgcatg	aatgggtccct	ttgaatatta	360
tttccaaaag	tgagagctaa	gacaaaagtca	tcaaaaagag	aggataacag	aagggtggggg	420
cggggggcggg	gtgcagtggg	gtaggggttac	ctgttaattg	ctgagactca	gatgaaagtc	480
cagctctccc	tgggcaaccc	tagagggcag	cagaggaccc	cagagctcat	tcaggccttg	540
ctgcttggtc	taaactacac	cttaggattt	tttcttcttt	ccaaaacatt	ccattgattt	600
tataaagact	ttctatagag	aggctttcac	ttttgagttc	tttgagttta	aagattgctt	660
ttcttgaaac	gctctttttt	taatgtagaa	aaattttact	ttttcaaata	tgcatacaat	720
ttttaaaaca	gtagaagcaa	attcatttta	atgaccatgt	aaagagcgaa	tgtcagacag	780
tattattacc	agtttattca	aattacatac	atgttcctac	caagggtggaa	agaaattcaa	840
acctcatggt	aaaacttaag	cacgatttaa	gataaaaagca	tagtatttct	tcagtgtaga	900
cttattaagt	gccttattga	acaggatctt	aacctgcttt	ttctgttttt	ttgaaagagt	960
taatgcaatt	gttgaagctt	ctaaccaaga	aacaacttaa	ggaattggga	gacttggtcc	1020
cctcgttgtc	agggttctgg	ctataagtac	ctccccacct	ttgggttttc	ttaaatatgc	1080
caaaaggaat	tctagttttt	ataaccaatg	gggtttttttg	tttgtgtgct	tatggatttg	1140
tgtaatcatt	gatgcttaat	gttgtggatt	cataatataa	aaagtggctc	ctgtccttta	1200

WO 99/09155

PCT/US98/17044

38

tattttattca	tgtgctagaa	atagtatgca	ttatataaag	agtatgaagt	tttcataagc	1260
ctttatatatt	caagctcttt	atttaaacad	tggttggaata	tgtggcataa	gccttggttc	1320
atttatttaa	taaactggag	taatataata	taataaaaaa	aaaaaaaaaa	aactcgaggg	1380
ggggcccggt	acccaatcgc	cctat				1405

<210> 74
 <211> 907
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (455)
 <223> n equals a,t,g, or c

<400> 74	
gggtcgaccc	acgcgtccgg
acttgccggg	tagctcccc
gggaagtgcc	atgttatctg
acccatgtgc	ccctcaacta
cattattttt	ctggctggcc
ttcatccctg	gatgctctcc
agcaacgatg	gctttctctg
gagtttcctt	tgtctttctg
tcaaggttta	cccaattggg
cagaatagca	ccccttctcc
tccacctctg	aaatgtcagc
agaggcagca	ctttctctct
tgaattcaca	ctctacagca
ttatacatatt	tttttcaagt
gtcttgtaaa	tattttgata
ggcggcc	

<210> 75
 <211> 687
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (461)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (481)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (534)
 <223> n equals a,t,g, or c

<400> 75	
ggctgtgaac	actgcatctt
agaggcagca	cttggcacc

WO 99/09155

PCT/US98/17044

39

gaaatgaatt	ggtatcatga	gaacaaagag	gcaacatgca	attgccaaat	atttggccta	180
tattttattg	tttcctttct	ttctccagta	ctggcagcag	cccatgatgc	taagaaatat	240
cccgtttggt	tatgaagtta	atgtggagat	taaaagtcac	tccctgttct	acccacaccc	300
tttttcttgt	gtatagcatg	tgactgagct	gattggaagg	catatagccc	agtggccaag	360
cacttggggc	tcagtgtgat	ggctgacaca	tgtttctgac	tctgtccatt	tctatwttgt	420
tgtggacaag	ccttggcctt	ctcagctgtc	aaatgggggt	nacaacagct	ctacatatag	480
ncctgtagca	attaaatgaa	agcatttagg	gccaggcatg	gtggccttatg	gcgntgggtcc	540
cagcacttag	ggaggccaag	gcaggacaaa	gtgggctctt	gtctttgagc	cctagagttt	600
gagaccagcc	tgggcaacat	agtgaggccc	tgtctctaaa	aaaaaaaaaa	aaaaaaaaaac	660
tcgagggggg	gcccgtaccc	aatcgcc				687

<210> 76

<211> 792

<212> DNA

<213> Homo sapiens

<400> 76

gaattcggca	cgagggtgaag	cacactcaca	tactcaaattg	cacacacact	catacacaca	60
gccccacacg	ctagcacata	cactcccttc	actccgcccc	tcttgtaagg	cgatttcttc	120
ttcccaggac	aggagctaga	ggtgcagcct	gggaccactc	agccaagaag	ccaagggcca	180
ggcatgcccc	ggcctggagc	actttattca	tcttttacgt	ctttttatta	cacattctcg	240
aatcaccagc	tcctccttgc	cttgcttctc	ctgggtttca	ttgcctcttg	cagtctcttc	300
ctctctcgag	tgtttctaac	tttttccacc	caattatgga	aaaagtaaga	accgagaaca	360
gcgaaaacaa	ccaaaacaaa	atctatatagct	atttctcatt	gaaatcctgg	aagaattttg	420
ggttttyccct	tcgatttctc	tcaccactc	acgcattcac	caattatgta	tttgtttact	480
caatgagtgc	agctcaggcc	gagggtgcca	gcctccacgg	gatgaggggc	tagacactct	540
gatttcaccc	cgacacctgc	tgggtgcaag	scgctcagtc	tgcagccagc	tctaggtccc	600
gcccccttgc	gttgggctgc	gggtggggcg	ggctgcttgg	cctgcccaga	ctcgccagga	660
aagacatgct	gctgcggacc	aatcagagtg	gcccaagctg	ggaggaggcc	ttgccccgcc	720
ctccccctgcc	ccgcccactt	ggcgctggga	ataaccacgt	ggaaacccaa	ctccgaggtc	780
tctggcgctc	ga					792

<210> 77

<211> 756

<212> DNA

<213> Homo sapiens

<400> 77

tcgagtaccc	tgaagtccctc	ctgctgttgt	ttccaaccaa	gaaagttttc	catgagtaag	60
tctgagcaat	gccgagctgc	ttgcccagct	gccctggagc	aggagctatc	actgggcagg	120
ggctgggtggg	ggtgggcaac	agaagggata	ggaagccaga	ttcaccagc	cagtccecca	180
gcatcaccaa	agcaaagccc	ctccctcctc	caaagcatgt	gggatagggtg	taatagttac	240
acacatgggt	ctttgcagtg	ggacagactg	aggcctccac	ctgttctgcc	accttctatc	300
tacacaatca	ggacatgttc	tcaaagggtta	tttgctgcag	cccagtccty	ttcctattct	360
catatgaatg	tcagagggcc	cctgatccag	ccccacaaca	cccaggggcc	ttttcttacc	420
ccaagcctct	caagcctgct	gttccaccag	agcagcccag	cytgcacact	gtcagcytgg	480
cctctgtcta	ggtacgccc	gccaggctca	gcgctgctga	ccacaccacc	aagactgcag	540
agaggctgag	caaacagccc	tgctgggggc	tctcacacct	catcaccact	taccactttg	600
agggaccaag	gcaggccagg	agacatccat	cttgagaaat	gccaggcctg	ggccaatcat	660
gtgacagcta	ctttcccagc	actctccctc	cctctctcgc	tctttcctct	ctctccagaa	720
cttcttgagg	agtacaaggc	ccctcgtgcc	gaattc			756

<210> 78

<211> 751

<212> DNA

WO 99/09155

PCT/US98/17044

40

<213> Homo sapiens

<220>

<221> SITE

<222> (750)

<223> n equals a,t,g, or c

<400> 78

gcggccatgg	tgaccatggt	gacaggggtcc	cagccagaaa	ccacaatggg	atggaaactc	60
ctggggctgc	tgtcagcagc	tgggagacac	agcgctgggg	gagaccaggc	attccccagg	120
cccaagggag	aagcagagtc	ggcctcgctt	gagccagacg	caggccttgg	gtttaccctc	180
catggaccag	acgtaaagtc	taatgggtgac	atgagatttt	taatgtcttt	acatctgcag	240
atgtacacgt	cagcaaaatt	gcatacacaca	aacctcactg	caggcccagg	ctttcctctt	300
tccaggtttc	accaacctcc	tccctccgtc	ttggctgcct	gtccctccac	caatcagctc	360
tcacctgccc	caggtgaccc	gcgttaacag	tggcacatga	atttctcaca	ttcatacaca	420
cataaatgca	cgtctcttca	ggcaaataca	catttggaag	ggattttcct	cctggcttgt	480
cctatgaacg	taagaacgtg	atctgcacgt	ttttctgaga	gttgctcttt	ctcctaaccc	540
actcctccct	gtgccccacc	catgtggcca	gccctccgtg	tccaccatcc	tctgctccct	600
sccagggctt	tgctccagga	acgaagtccc	aggcagcctc	ctaggacaca	agtttctgtt	660
ccttctgctc	ccttgggggt	tcctcgtaga	atgaagactc	ccagtggagt	tactgggtca	720
aagaagacct	gtatttttag	tttccctcgn	c			751

<210> 79

<211> 1411

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (541)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1324)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1370)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1395)

<223> n equals a,t,g, or c

<400> 79

gaagattctt	tcttctgaaa	gccaagcacc	acaaggaaaa	aaaattatta	atagctcagg	60
ttaaaaacac	ccattttaa	aaaaacaaga	gcatttgtaa	taggaagtgt	ttatacaaat	120
agcacatttg	tgatatgttg	aaaagcatct	ctcttggcaa	ccaatctatg	tttgaggaag	180
attgggtaat	gctgatgtgt	tccattcatg	aaactgtatt	tgatacataa	tcctattatt	240
aattcgtatg	cttagtcaac	ctaggaaatc	aaaataatgt	tttgaagtgc	ttatttgagc	300
aatatggcct	tgacttggag	ggtagtttta	gttggtttgt	ttttaagtga	ctgtgggtta	360
aagcacaaat	gccccagggt	ggggagactt	ctctctgtga	ttattgttgc	tattaaattc	420
tgaactgtat	ccatatttta	aggaaggagc	taaaaatgga	aattcatgaa	acataaatgg	480
tatcaagaac	tttatcagta	tgctttgttg	aaagcagaaa	ttaagataat	aattgagttc	540

WO 99/09155

PCT/US98/17044

41

naattcgcct	ctccgcattg	cctattgata	cactttacta	atcatgaaat	tctaacctaa	600
aaggaaaaca	ttttcctgct	tgtcttagaa	gaaagtggaa	taattccact	gattgtgata	660
atggtttcaa	tttctacaca	atataaatat	ccagtataaa	ggaaagcgtt	aagtcggtaa	720
gctagaggat	tgtraatatc	ttttatgtcc	tctagataaa	acacccgatt	aacagatggt	780
aaacctttta	atgttttgat	ttgctttaaa	aatggccttc	ctacacatta	gctccagcta	840
aaaagacaca	ttggagagct	tagaggataa	gtctctggag	magaatttat	cacacacaaa	900
agttacacca	acagaatacc	aagcagaatg	atgaggacct	gtaaaatacc	ttgtgcccta	960
ttaaaaaaaa	aaaaaaaaaa	aaaagccagt	arctgaatcc	attttgattt	ttggttgagt	1020
ttcctacaca	aagaagaaaa	taactgagaa	tctggaatgt	tgtagtccat	cctttaaaga	1080
gtaagaaagt	agcagttaat	gctagtaacc	gtgaattagg	caccactgaa	agcacatccc	1140
gaatttcttt	aacaacaaca	ttttatagtg	aacactacaa	gtttttatat	ttaaaawtta	1200
agactctgta	tatccttaag	gtgctctatg	ctttaccmgt	aattcacagg	gtatttcaaa	1260
tggtagaatc	atttttagctt	ctgtgcttcc	tttttctaaa	taatgcaact	tgtaagagtt	1320
gacnatgtaa	taagccttat	aatagtataa	ccgtccagga	gatatatatn	tatatatcca	1380
ccccccccca	cgggnacaca	gattttacca	a			1411

<210> 80

<211> 866

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (14)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (27)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (33)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (105)

<223> n equals a,t,g, or c

<400> 80

cctggcttgc	tggncaagcc	ttggtgncca	tgntgaacaa	gttttgtgga	agttctgggg	60
agactccaag	aactaccagg	aacagggata	cgagtgccag	gctgnatctc	ttgctcctct	120
gcagagtcag	caggcttctt	ctcagagatg	acagaagacg	agttgggtgg	gctgcagcag	180
atgttctttg	gcacatcat	ctgtgcactg	gccacgctgg	ctgctaaggg	cgacttggtg	240
ttcaccgcca	tcttcattgg	ggctgtggcg	gccatgactg	gctactgggt	gtcagagcgc	300
agtgaccgtg	tgctggaggg	cttcatcaag	ggcagataat	cgcggccacc	acctgtagga	360
cctcctccca	cccacgctgc	ccccagagct	tgggctgccc	tcctgctgga	cactcaggac	420
agcttggttt	atttttgaga	gtggggtaag	cacccctacc	tgccttacag	agcagcccag	480
gtacccaggc	ccgggcagac	aaggcccctg	gggtaaaaag	tagccctgaa	ggtggatacc	540
atgagctctt	cacctggcgg	ggactggcag	gcttcacaa	gtgtgaattt	caaaagttht	600
tccttaatgg	tggtctgctag	agctttggcc	cctgcttagg	attaggtgg	cctcacaggg	660
gtggggccat	cacagctccc	tcctgccagc	tgcattgctg	cagttcctgt	tctgtgttca	720
ccacatcccc	acaccccat	gccacttatt	tattcatctc	aggaaataaa	gaaaggtctt	780
ggaaagttaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaactc	gagggggggg	ccgtacccaa	840
tcgccctatg	atgtagtcgt	attaca				866

WO 99/09155

PCT/US98/17044

42

<210> 81
 <211> 2078
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (1177)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1187)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (2057)
 <223> n equals a,t,g, or c

<400> 81
 ggcacgagga gttgtgcaga tacctggctg agagctggct caccttccag attcacctgc 60
 aggagctgct gcagtacaag aggcagaatc cagctcagtt ctgcgttcga gtctgctctg 120
 gctgtgctgt gttggctgtg ttgggacact atgttccagg gattatgatt tcctacattg 180
 tcttggtgag tatcctgctg tggcccctgg tggtttatca tgagctgac cagaggatgt 240
 acactcgcct ggagcccctg ctcatgcagc tggactacag catgaaggca gaagccaatg 300
 cyctgcatca caaacacgac aagaggaagc gtcaggggaa gaatgcaccc ccaggagggtg 360
 atgagccact ggmagagaca gagagtga aa gcgaggcaga gctggctggc ttctccccag 420
 tgggtggatgt gaagaaaaca gcattggcct tggccattta cagactcaga gctgtcagat 480
 gaggaggctt ctatcttgga gagtgggtggc ttctccgtat cccgggccac aactccgcag 540
 ctgactgatg tctccgagga tttggaccag cagagcctgc caagtgaacc agaggagacc 600
 ctaagccggg acctagggga gggagaggag ggagagctgg cccctcccga agacctacta 660
 ggccgtcctc aagctctgtc aaggcaagcc ctggactcgg aggaagagga agaggatgtg 720
 gcagctaagg aaaccttggt gcggctctca tccccctcc actttgtgaa cacgcacttc 780
 aatggggcag ggtcccccm agatggagtg aaatgctccc ctggaggacc agtggagaca 840
 ctgagccccg agacagtgag tgggtggcctc actgctctgc ccggcaccct gtcacctcca 900
 ctttgccctg ttggaagtga cccagcccc tccccctcca ttctcccacc tgttccccag 960
 gactcaccac agcccctgcc tgcccctgag gaagaagagg cactcaccac tgaggacttt 1020
 gagttgctgg atcaggggga gctggagcag ctgaatgcag agctgggctt ggagccagag 1080
 acaccgcaa aaccccctga tgctccaccc ctggggcccc acatccattc tytggtacat 1140
 cagaccaaga agctcaggcc gtggcagagc catgagncca gccgttnagg aaggagctgc 1200
 aggcacagta gggcttcttg gctaggagtg ttgctgtttc ctcttttgcc taccactctg 1260
 ggggtggggca gtgtgtgggg aagctggctg tcggatggta gctattccac cctctgcctg 1320
 cctgcctgcc tgctgtcctg ggcattgggc agtacctgtg cctaggattg gttttaaatt 1380
 tgtaaataat tttccatttg ggttagtgga tgtgaacagg gctagggaag tccttcccac 1440
 agcctgcgct tgccctccctg cctcatctct attctcattc cactatgccc caagccctgg 1500
 tgggtctggcc ctttcttttt cctcctatcc tcagggacct gtgctgctct gccctcatgt 1560
 cccacttggg tgttttagttg aggcacttta taatttttct cttgtcttgt gttcctttct 1620
 gctttatttc cctgctgtgt cctgtcctta gcagctcaac cccatccttt gccagctcct 1680
 cctatcccgt gggcactggc caagcttttag ggaggctcct ggtctgggaa gtaaagagta 1740
 aacctggggc agtgggtcag gccagtagtt acactcttag gtcactgtag tctgtgtaac 1800
 cttcactgca tccttgcccc attcagcccc gcctttcatg atgcaggaga gcagggatcc 1860
 cgcagtacat ggccgagca ctggagtgg tgagcatgtg ctctctcttg agattaggag 1920
 cttccttact gctcctctgg gtgatccaag tgtagtggga cccctacta gggtcaggaa 1980
 gtggacacta acatctgtgc aggtgttgac ttgaaaaata aagtgttgat tggctagaaa 2040
 aaaaaaaaaa aaaattnctg cggtccgcaa gggaattc 2078

WO 99/09155

PCT/US98/17044

43

<210> 82
 <211> 1064
 <212> DNA
 <213> Homo sapiens

<400> 82
 gtgttggttct gttaaaagac tgtccactgt tttctttttc agtaattaat ggtcacacac 60
 tgtgttttacg gctgttgcta gaaattgcag acaacccgga ggcggtcgat gtgaaagatg 120
 ccaaaggaca aacaccactg atgcttgcag tagcatatgg acatattgac gctgtttcat 180
 tgttacttga aaaggaagcc aacgtrgaca ctgttgacat cctaggatgc acagctttac 240
 acagaggggt atgtacatct ttctcagctc tagtcaagca atttttttta tgagctgttt 300
 tcttttttag caaacaatta caaagggcct actttgattg gattttttagc aaaaaatggt 360
 tagcaaaaat tgtttcctaa tacaaccaat taaccttatt cagtccaaaa gaaattacaa 420
 aatccttggc aaaggcaaaa taatggaagg ttttgctctt aagatttcat gttagattgt 480
 gataatagat gcatgaacac ctactgctgg tgaaattggg tctgctttct gactacaaaa 540
 tacaagtata tcatagaaaa tttgcagaat attttttttt aaagcccaga gaagaaaatc 600
 acaatcacca gtaatcatac ctctggaga taaccactat ttgatgtata ttatctcaa 660
 tcttttttct atatatagat ttgtttttaga ttttaaaaag agaatactga agatatcatt 720
 tggattctgc ttttttctct tagtatatca aggatctttt ttcatttcat ttttttctgc 780
 atcatgattt ttaatgcctc attgtgttca agtgtcatag tttatttcaa tgattacctg 840
 gttttcagta gttatgcaat ttctaattgt ttgtccttac aaataatgcc aaaatatgta 900
 tcctgtgggc aattatttgc acacatctgt tgaagtgttt ggtttttttt tttttaatct 960
 cactcttata acccaggttg cagtgaagcc agatcacacc actgcattcc agcctgggtg 1020
 acacagcgag actccatctc aaaaaaaaaa aaaaaaaaac tcga 1064

<210> 83
 <211> 1126
 <212> DNA
 <213> Homo sapiens

<400> 83
 ggcacgagcg gcgccccggc tgcttctgct ctttctgggt ccgctgctgt gggccccggc 60
 tgcggtccgg gccggcccag atgaagacct yagccaccgg aacaaagaac cgccggcgcc 120
 ggcccagcag ctgcagccgc agcctgtggc tgtgcagggc cccgagccgg cccgggtcga 180
 ggacccctat ggtgtagccg tgggtggaac tgtggggcac tgcctgtgca cgggattggc 240
 agtaattgga ggaagaatga tagcacagaa aatctctgtc agaactgtga caatcatagg 300
 aggcacgtt tttttggcgt ttgcattttc tgcactattt ataagccctg attctgggtt 360
 ttaacaagct gtttggtcat ctatathtag tttaaaatag gtagtattat ctttctgtac 420
 atagtgtaca ttacaactaa aagtgatgga aaaatactgt attttgtagc actgattttg 480
 tgagtttgac ccattattat gtctgagata taatcattga ttctatttgt aacaaggagt 540
 tttaaaagaa acctgacttc taagtgtggg tttttcttct ctccaacata attatgttaa 600
 tatggtcctc atttttcttt tgggtgcagaa ccgttgtgca gtggggtcta ccatgcaatt 660
 ttctttcagc actgaccctt ttttaaggaa taaaattttt ctcttctatc acttaggtgt 720
 ttttaagatgt ttaccttaaa gtttttcttg gggaaagaat gaattaattt ctatttctta 780
 aaacatttcc ctgagccagt aaacagtagt ttaatcattg gtcttttcaa aactaggtgt 840
 ttaaaaaaag agacatatat gatattgctg ttatatcaat aacatggcac aacaagaact 900
 gtctgccagg tcattcttcc tctttttttt ttaattgggt aggacacca atataaaaac 960
 agtcaatatt tgacaatgtg gaattaccaa attaaaagag aatactatga atgtattcat 1020
 attttttcta tattgaataa acaatgtaac atagataaca atataaataa aagtgggtatg 1080
 accaaaaaaa aaaaaaaca aaaaaaaaaa aaaaaaaagg gcggcc 1126

<210> 84
 <211> 30
 <212> PRT

WO 99/09155

PCT/US98/17044

44

<213> Homo sapiens

<220>

<221> SITE

<222> (30)

<223> Xaa equals stop translation

<400> 84

Met	Pro	Ala	Leu	Ser	Met	Ala	Leu	Thr	Met	Leu	Gly	Cys	Tyr	Ala	Ile
1				5					10					15	

Ala	Ile	Leu	Leu	Phe	Val	Thr	Leu	Val	Arg	Lys	Pro	Ala	Xaa
		20					25						30

<210> 85

<211> 34

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (34)

<223> Xaa equals stop translation

<400> 85

Met	Phe	Cys	Ile	Ser	Leu	Ser	Phe	Phe	Asn	Leu	Pro	Glu	Tyr	Ser	Pro
1				5					10					15	

Cys	Ser	Leu	Leu	Ser	Val	Gln	Glu	Leu	Val	Pro	Gln	Phe	Phe	Tyr	Val
		20						25						30	

Val Xaa

<210> 86

<211> 65

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (55)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 86

Met	Lys	Val	Ala	Val	Arg	Gly	Lys	Gln	Arg	Glu	Cys	Arg	Asp	Arg	Ile
1				5				10						15	

Leu	Gly	Lys	Lys	Thr	Lys	Ala	Trp	Thr	Gln	Arg	Arg	Arg	Ser	Lys	Cys
		20						25						30	

Gly	Ser	Gly	Tyr	Lys	Val	Arg	Val	Ser	Val	Gln	Glu	Val	Asn	Lys	Val
		35					40					45			

Ser	Arg	Thr	Arg	Lys	Ser	Xaa	Arg	Ser	Arg	Lys	Pro	Ala	Phe	Gly	Asp
		50				55					60				

WO 99/09155

PCT/US98/17044

45

Arg
65

<210> 87
 <211> 27
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (27)
 <223> Xaa equals stop translation

<400> 87
 Met Leu Leu Phe Phe Phe Trp Thr Leu Phe Arg Glu Ser Val Asp His
 1 5 10 15

Asn Asn Ser Asp Thr Phe Phe Ser Gly Pro Xaa
 20 25

<210> 88
 <211> 49
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (49)
 <223> Xaa equals stop translation

<400> 88
 Met Leu Ser Lys Ser Ser Lys Met Val Ser Val Lys Arg Ala Asp Pro
 1 5 10 15

Gly Ser Leu Gly Phe Thr Phe Leu Leu Ser Ser Leu Pro Lys Cys Thr
 20 25 30

Val Gly Val Ser Arg Gly Arg Pro Thr Cys Thr Ser Cys Ser Asp Gly
 35 40 45

Xaa

<210> 89
 <211> 33
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (33)
 <223> Xaa equals stop translation

<400> 89

WO 99/09155

PCT/US98/17044

46

Met	Ser	Met	Asp	Leu	Ala	Asn	Leu	Tyr	Leu	Leu	Phe	Ile	Val	His	Arg
1				5					10					15	

Phe	Leu	Ile	Phe	Phe	Ile	Pro	Val	Ser	Phe	Lys	Leu	Pro	Ser	Phe	Glu
			20					25					30		

Xaa

<210> 90
 <211> 23
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (23)
 <223> Xaa equals stop translation

<400> 90

Met	Tyr	Leu	Val	Phe	Cys	Leu	Ser	Cys	Val	Ser	Asn	Gln	Gly	Pro	His
1				5					10					15	

Ser	Pro	Val	Gly	Thr	Trp	Xaa
			20			

<210> 91
 <211> 55
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (55)
 <223> Xaa equals stop translation

<400> 91

Met	Ser	Asn	Val	Val	Phe	Ser	Leu	Lys	Ala	Val	Met	Trp	Val	Leu	Phe
1				5					10					15	

Tyr	Cys	Leu	Phe	Val	Cys	Cys	Cys	Ile	Leu	Phe	Ser	Leu	Leu	Phe	Ala
			20					25					30		

Leu	Gln	Asn	Ala	Leu	Gly	Lys	Gly	Trp	Phe	Leu	Ser	Leu	Leu	Val	Cys
		35					40					45			

Val	Phe	Phe	Phe	Phe	Phe	Xaa
	50					55

<210> 92
 <211> 39
 <212> PRT
 <213> Homo sapiens

<220>

WO 99/09155

PCT/US98/17044

47

<221> SITE
 <222> (16)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (39)
 <223> Xaa equals stop translation

<400> 92
 Met Ser Thr Val Lys Gln Ile Val Met Gly Leu Tyr Phe Val Tyr Xaa
 1 5 10 15
 Tyr Val Cys Phe Phe Tyr Ser Thr Phe Cys Gly Ser Ser Val Leu Leu
 20 25 30
 Val Ala Ser Ser Leu Leu Xaa
 35

<210> 93
 <211> 53
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (53)
 <223> Xaa equals stop translation

<400> 93
 Met Cys Leu Phe Phe Glu Asn Val Thr Leu Leu Phe Val Ile Val Leu
 1 5 10 15
 His Phe Ser Ala Phe Arg Pro Leu Tyr Phe His Lys Thr Pro Lys Thr
 20 25 30
 Ala Phe Asn Tyr Ile Ile Met Ser Val Phe Leu Asp Thr Asn Phe Cys
 35 40 45
 Ser Arg Met Thr Xaa
 50

<210> 94
 <211> 337
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (337)
 <223> Xaa equals stop translation

<400> 94
 Met Ile Ser Tyr Ile Val Leu Leu Ser Ile Leu Leu Trp Pro Leu Val
 1 5 10 15

WO 99/09155

PCT/US98/17044

48

Val Tyr His Glu Leu Ile Gln Arg Met Tyr Thr Arg Leu Glu Pro Leu
 20 25 30

Leu Met Gln Leu Asp Tyr Ser Met Lys Ala Glu Ala Asn Ala Leu His
 35 40 45

His Lys His Asp Lys Arg Lys Arg Gln Gly Lys Asn Ala Pro Pro Gly
 50 55 60

Gly Asp Glu Pro Leu Ala Glu Thr Glu Ser Glu Ser Glu Ala Glu Leu
 65 70 75 80

Ala Gly Phe Ser Pro Val Val Asp Val Lys Lys Thr Ala Leu Ala Leu
 85 90 95

Ala Ile Thr Asp Ser Glu Leu Ser Asp Glu Glu Ala Ser Ile Leu Glu
 100 105 110

Ser Gly Gly Phe Ser Val Ser Arg Ala Thr Thr Pro Gln Leu Thr Asp
 115 120 125

Val Ser Glu Asp Leu Asp Gln Gln Ser Leu Pro Ser Glu Pro Glu Glu
 130 135 140

Thr Leu Ser Arg Asp Leu Gly Glu Gly Glu Gly Glu Leu Ala Pro
 145 150 155 160

Pro Glu Asp Leu Leu Gly Arg Pro Gln Ala Leu Ser Arg Gln Ala Leu
 165 170 175

Asp Ser Glu Glu Glu Glu Glu Asp Val Ala Ala Lys Glu Thr Leu Leu
 180 185 190

Arg Leu Ser Ser Pro Leu His Phe Val Asn Thr His Phe Asn Gly Ala
 195 200 205

Gly Ser Pro Gln Asp Gly Val Lys Cys Ser Pro Gly Gly Pro Val Glu
 210 215 220

Thr Leu Ser Pro Glu Thr Val Ser Gly Gly Leu Thr Ala Leu Pro Gly
 225 230 235 240

Thr Leu Ser Pro Pro Leu Cys Leu Val Gly Ser Asp Pro Ala Pro Ser
 245 250 255

Pro Ser Ile Leu Pro Pro Val Pro Gln Asp Ser Pro Gln Pro Leu Pro
 260 265 270

Ala Pro Glu Glu Glu Glu Ala Leu Thr Thr Glu Asp Phe Glu Leu Leu
 275 280 285

Asp Gln Gly Glu Leu Glu Gln Leu Asn Ala Glu Leu Gly Leu Glu Pro
 290 295 300

Glu Thr Pro Pro Lys Pro Pro Asp Ala Pro Pro Leu Gly Pro Asp Ile
 305 310 315 320

His Ser Leu Val Gln Ser Asp Gln Glu Ala Gln Ala Val Ala Glu Pro

WO 99/09155

PCT/US98/17044

325 49 330 335

Xaa

<210> 95
 <211> 49
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (49)
 <223> Xaa equals stop translation

<400> 95
 Met Leu Pro Tyr Ser Leu Pro Phe His Ile Ser Cys Thr Ser Ser Leu
 1 5 10 15
 Ser His His Leu His Pro His Leu Leu Ser Leu Leu Leu Ser Phe Ser
 20 25 30
 Pro Lys Gly Val Thr Ala Asp Val Lys Ile Ser Leu Met Met Ala Lys
 35 40 45

Xaa

<210> 96
 <211> 38
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (38)
 <223> Xaa equals stop translation

<400> 96
 Met Arg Gly Ala His Leu Thr Ala Leu Glu Met Leu Thr Ala Phe Ala
 1 5 10 15
 Ser His Ile Arg Ala Arg Asp Ala Ala Gly Ser Gly Asp Lys Pro Gly
 20 25 30

Ala Asp Thr Gly Arg Xaa
 35

<210> 97
 <211> 29
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE

WO 99/09155

PCT/US98/17044

50

<222> (29)

<223> Xaa equals stop translation

<400> 97

Met	Leu	Phe	Lys	Leu	Phe	Phe	Ser	Leu	Ile	Leu	Phe	Ser	Phe	Val	Val
1				5					10					15	

Ser	Cys	Ile	Phe	Ser	Val	Ser	Ile	Asn	Ile	Pro	Leu	Xaa
			20					25				

<210> 98

<211> 36

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (36)

<223> Xaa equals stop translation

<400> 98

Met	Pro	Phe	Met	Phe	Leu	Ser	Leu	Pro	Arg	Asp	Thr	Phe	Leu	Met	Leu
1				5					10					15	

Glu	Leu	Val	Leu	Gly	Thr	Phe	Thr	Cys	Asn	Gly	Ser	Phe	Phe	Ile	His
			20					25						30	

Lys	Ala	Ser	Xaa
			35

<210> 99

<211> 182

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (182)

<223> Xaa equals stop translation

<400> 99

Met	Ala	Ala	Leu	Cys	Arg	Thr	Arg	Ala	Val	Ala	Ala	Glu	Ser	His	Phe
1				5					10					15	

Leu	Arg	Val	Phe	Leu	Phe	Phe	Arg	Pro	Phe	Arg	Gly	Val	Gly	Thr	Glu
			20					25						30	

Ser	Gly	Ser	Glu	Ser	Gly	Ser	Ser	Asn	Ala	Lys	Glu	Pro	Lys	Thr	Arg
			35					40					45		

Ala	Gly	Gly	Phe	Ala	Ser	Ala	Leu	Glu	Arg	His	Ser	Glu	Leu	Leu	Gln
			50				55					60			

Lys	Gly	Ser	Pro	Lys	Asn	Val	Glu	Ser	Phe	Ala	Ser	Met	Leu	Arg	His
					70							75			80

WO 99/09155

PCT/US98/17044

51
 Ser Pro Leu Thr Gln Met Gly Pro Ala Lys Asp Lys Leu Val Ile Gly
 85 90 95
 Arg Ile Phe His Ile Val Glu Asn Asp Leu Tyr Ile Asp Phe Gly Gly
 100 105 110
 Lys Phe His Cys Val Cys Arg Arg Pro Glu Val Asp Gly Glu Lys Tyr
 115 120 125
 Gln Lys Gly Thr Arg Val Arg Leu Arg Leu Leu Asp Leu Glu Leu Thr
 130 135 140
 Ser Arg Phe Leu Gly Ala Thr Thr Asp Thr Thr Val Leu Glu Ala Asn
 145 150 155 160
 Ala Val Leu Leu Gly Ile Gln Glu Ser Lys Asp Ser Arg Ser Lys Glu
 165 170 175
 Glu His His Glu Lys Xaa
 180

<210> 100
 <211> 84
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (84)
 <223> Xaa equals stop translation

<400> 100
 Met Asn Val Leu Val Tyr Ser Asp Lys Glu Lys Lys Asn Gln Lys Ser
 1 5 10 15
 Gly Leu Asn Leu Ile Val Phe Ile Ile Lys Ile Leu Lys Met Thr Leu
 20 25 30
 Ile Ala Arg Lys Thr Gly Trp Gly Ile Ser Pro Leu Leu Ser Val Thr
 35 40 45
 Met Arg Ile Ile Pro Ala Leu Val Phe Asn Thr Arg Leu Pro Thr Phe
 50 55 60
 Ile Ile Ser Leu Ile Phe Leu Leu Phe Ser Cys Ile Cys Glu Leu Val
 65 70 75 80
 Gln Glu Cys Xaa

<210> 101
 <211> 25
 <212> PRT
 <213> Homo sapiens

<220>

WO 99/09155

PCT/US98/17044

52

<221> SITE

<222> (25)

<223> Xaa equals stop translation

<400> 101

Met	Gln	Val	Leu	Met	Leu	Ala	His	Phe	Leu	Ile	Leu	Leu	Glu	His	Val
1				5					10					15	

Gln	Gly	Arg	Cys	Ser	Asp	Asn	Asn	Xaa
			20					25

<210> 102

<211> 32

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (32)

<223> Xaa equals stop translation

<400> 102

Met	Asp	Cys	Met	Cys	Ile	Tyr	Met	Phe	Leu	Ile	Ile	Leu	Ile	Asn	Val
1				5					10					15	

Cys	Arg	Phe	Gln	Gly	Thr	Asn	Phe	Ser	Pro	Leu	Tyr	Val	Tyr	Ser	Xaa
			20					25					30		

<210> 103

<211> 28

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (28)

<223> Xaa equals stop translation

<400> 103

Met	Ile	Ile	Ala	Pro	Ile	Cys	Leu	Ile	Pro	Phe	Leu	Ile	Thr	Leu	Val
1				5					10					15	

Val	Trp	Arg	Ser	Lys	Asp	Ser	Glu	Ala	Gln	Ala	Xaa
				20					25		

<210> 104

<211> 87

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

WO 99/09155

PCT/US98/17044

53

<222> (55)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (87)

<223> Xaa equals stop translation

<400> 104

Met	Gly	Val	Leu	Ala	Glu	His	Gly	Gly	His	Pro	Ala	Gln	Glu	His	Phe
1				5					10					15	

Pro	Lys	Leu	Leu	Gly	Leu	Leu	Phe	Pro	Leu	Leu	Ala	Arg	Glu	Arg	His
			20					25					30		

Asp	Arg	Val	Arg	Asp	Asn	Ile	Cys	Gly	Ala	Leu	Ala	Arg	Leu	Leu	Met
		35					40					45			

Ala	Ser	Pro	Thr	Arg	Lys	Xaa	Arg	Ala	Pro	Gly	Ala	Gly	Cys	Pro	Thr
	50					55					60				

Ala	Cys	Pro	Ala	Thr	Glu	Gly	Gly	Leu	Gly	Gly	Val	Gly	Gln	Pro	Leu
65					70					75					80

Gly	Ala	Ser	Ser	Ala	Ser	Xaa
					85	

<210> 105

<211> 128

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (128)

<223> Xaa equals stop translation

<400> 105

Met	Lys	Val	Ala	Phe	Leu	Leu	Gly	Ser	Leu	Ala	Ala	Arg	Gly	Ser	Asp
1				5					10					15	

Thr	Arg	Ser	Asn	Thr	Glu	Leu	Ser	Ser	Gly	Ala	Lys	Val	Phe	Pro	Val
			20					25					30		

Ser	Ser	Ala	Arg	Glu	Pro	Ser	Pro	Pro	Ala	Ser	Phe	Arg	Ser	Gln	Cys
		35					40					45			

Ser	Ser	Asn	Thr	Val	Tyr	Thr	Leu	Phe	Cys	Phe	Gln	Ile	Tyr	Pro	Glu
	50					55					60				

Ala	Leu	Leu	Ser	Ile	Asn	Asp	Tyr	Thr	Ile	Lys	Val	Ser	Val	Ile	Leu
65					70					75					80

Glu	Leu	Ile	Ser	Val	Gly	Ile	Ser	Cys	Met	Gln	Ser	Val	Ala	Phe	Arg
				85					90					95	

Gly	Leu	Ser	Pro	Ile	Leu	Val	Ser	Cys	Arg	Ala	Asp	Cys	Ser	Leu	His
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

WO 99/09155

PCT/US98/17044

54

100 105 110

Leu Asp Leu Asn Glu Gly Leu Trp Leu Glu Cys Val Arg Ser Arg Xaa
 115 120 125

<210> 106
 <211> 31
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (31)
 <223> Xaa equals stop translation

<400> 106
 Met Arg Lys Glu Glu Gln Val Phe Phe Val Met Leu Leu Arg Lys Tyr
 1 5 10 15

Pro Glu Ser Gln His His Asp Leu Leu Val Lys Gln Asn Lys Xaa
 20 25 30

<210> 107
 <211> 32
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (32)
 <223> Xaa equals stop translation

<400> 107
 Met Arg Ile Val Val Leu Val Thr Phe Met Cys Leu Gly Arg Leu Arg
 1 5 10 15

Cys Ser Thr Ser Leu Arg His Ser Gln Asn Ala Asn Leu Leu Phe Xaa
 20 25 30

<210> 108
 <211> 96
 <212> PRT
 <213> Homo sapiens

<400> 108
 Met Phe Leu Ser Ser Ser Asn Gln Ser Ser Thr Cys Met Lys Thr Leu
 1 5 10 15

Val Ile Leu Val Ser Ser Trp Arg Ala Gln Gly His Ala Ala Gly Phe

SUBSTITUTE SHEET (RULE 26)

WO 99/09155

PCT/US98/17044

56

<221> SITE

<222> (356)

<223> Xaa equals stop translation

<400> 111

Met	Phe	Tyr	Leu	Leu	Leu	Ser	Leu	Leu	Met	Ile	Lys	Val	Lys	Ser	Ser	1	5	10	15
Ser	Asp	Pro	Arg	Ala	Ala	Val	His	Asn	Gly	Phe	Trp	Phe	Phe	Lys	Phe	20	25	30	
Ala	Ala	Ala	Ile	Ala	Ile	Ile	Ile	Gly	Ala	Phe	Phe	Ile	Pro	Glu	Gly	35	40	45	
Thr	Phe	Thr	Thr	Val	Trp	Phe	Tyr	Val	Gly	Met	Ala	Gly	Ala	Phe	Cys	50	55	60	
Phe	Ile	Leu	Ile	Gln	Leu	Val	Leu	Leu	Ile	Asp	Phe	Ala	His	Ser	Trp	65	70	75	80
Asn	Glu	Ser	Trp	Val	Glu	Lys	Met	Glu	Glu	Gly	Asn	Ser	Arg	Cys	Trp	85	90	95	
Tyr	Ala	Ala	Leu	Leu	Ser	Ala	Thr	Ala	Leu	Asn	Tyr	Leu	Leu	Ser	Leu	100	105	110	
Val	Ala	Ile	Val	Leu	Phe	Phe	Val	Tyr	Tyr	Thr	His	Pro	Ala	Ser	Cys	115	120	125	
Ser	Glu	Asn	Lys	Ala	Phe	Ile	Ser	Val	Asn	Met	Leu	Leu	Cys	Val	Gly	130	135	140	
Ala	Ser	Val	Met	Ser	Ile	Leu	Pro	Lys	Ile	Gln	Glu	Ser	Gln	Pro	Arg	145	150	155	160
Ser	Gly	Leu	Leu	Gln	Ser	Ser	Val	Ile	Thr	Val	Tyr	Thr	Met	Tyr	Leu	165	170	175	
Thr	Trp	Ser	Ala	Met	Thr	Asn	Glu	Pro	Glu	Thr	Asn	Cys	Asn	Pro	Ser	180	185	190	
Leu	Leu	Ser	Ile	Ile	Gly	Tyr	Asn	Thr	Thr	Ser	Thr	Val	Pro	Lys	Glu	195	200	205	
Gly	Gln	Ser	Val	Gln	Trp	Trp	His	Ala	Gln	Gly	Ile	Ile	Gly	Leu	Ile	210	215	220	
Leu	Phe	Leu	Leu	Cys	Val	Phe	Tyr	Ser	Ser	Ile	Arg	Thr	Ser	Asn	Asn	225	230	235	240
Ser	Gln	Val	Asn	Lys	Leu	Thr	Leu	Thr	Ser	Asp	Glu	Ser	Thr	Leu	Ile	245	250	255	
Glu	Asp	Gly	Gly	Ala	Arg	Ser	Asp	Gly	Ser	Leu	Glu	Asp	Gly	Asp	Asp	260	265	270	
Val	His	Arg	Ala	Val	Asp	Asn	Glu	Arg	Asp	Gly	Val	Thr	Tyr	Ser	Tyr	275	280	285	

SUBSTITUTE SHEET (RULE 26)

WO 99/09155

PCT/US98/17044

57

Ser Phe Phe His Phe Met Leu Phe Leu Ala Ser Leu Tyr Ile Met Met
 290 295 300

Thr Leu Thr Asn Trp Tyr Arg Tyr Glu Pro Ser Arg Glu Met Lys Ser
 305 310 315 320

Gln Trp Thr Ala Val Trp Val Lys Ile Ser Ser Ser Trp Ile Gly Ile
 325 330 335

Val Leu Tyr Val Trp Thr Leu Val Ala Pro Leu Val Leu Thr Asn Arg
 340 345 350

Asp Phe Asp Xaa
 355

<210> 112
 <211> 71
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (71)
 <223> Xaa equals stop translation

<400> 112
 Met His Trp Leu Gly Arg Gly Trp Arg Leu Leu Glu Gly Gly Glu Lys
 1 5 10 15

Glu Leu Pro Thr Trp Ser Leu Leu Leu Leu Tyr Pro Gly Cys Leu Gln
 20 25 30

Ser Cys Ser Thr Thr Pro Trp Thr Thr Pro Ser Gln Met Pro Glu Ala
 35 40 45

Thr Gly Gly Gln Gly Arg Gln Gly Gly Leu Pro Ala Leu Leu Gln Gln
 50 55 60

Arg Ala Thr Thr Leu Gly Xaa
 65 70

<210> 113
 <211> 171
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (171)
 <223> Xaa equals stop translation

<400> 113
 Met Val Pro Val Leu Leu Ser Leu Leu Leu Leu Leu Gly Pro Ala Val
 1 5 10 15

WO 99/09155

PCT/US98/17044

58

Pro Gln Glu Asn Gln Asp Gly Arg Tyr Ser Leu Thr Tyr Ile Tyr Thr
 20 25 30

Gly Leu Ser Lys His Val Glu Asp Val Pro Ala Phe Gln Ala Leu Gly
 35 40 45

Ser Leu Asn Asp Leu Gln Phe Phe Arg Tyr Asn Ser Lys Asp Arg Lys
 50 55 60

Ser Gln Pro Met Gly Leu Trp Arg Gln Val Glu Gly Met Glu Asp Trp
 65 70 75 80

Lys Gln Asp Ser Gln Leu Gln Lys Ala Arg Glu Asp Ile Phe Met Glu
 85 90 95

Thr Leu Lys Asp Ile Val Glu Tyr Tyr Asn Asp Ser Asn Gly Ser His
 100 105 110

Val Leu Gln Gly Arg Phe Gly Cys Glu Ile Glu Asn Asn Arg Ser Ser
 115 120 125

Gly Ala Phe Trp Lys Tyr Tyr Tyr Asp Gly Lys Asp Tyr Ile Glu Phe
 130 135 140

Asn Lys Glu Ile Pro Ala Trp Val Pro Phe Asp Pro Ala Ala Gln Ile
 145 150 155 160

Thr Lys Gln Lys Trp Asp Ala Cys Leu Glu Xaa
 165 170

<210> 114
 <211> 36
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (36)
 <223> Xaa equals stop translation

<400> 114
 Met Gly Leu Phe Asn Gln Cys Asp Tyr Ser Asp Pro Ser Leu Gln Leu
 1 5 10 15

Val Phe Phe Leu Met Ala Leu Phe His Ile Leu Phe Ser Leu Thr Thr
 20 25 30

Leu Ile Met Xaa
 35

<210> 115
 <211> 14
 <212> PRT
 <213> Homo sapiens

<220>

WO 99/09155

PCT/US98/17044

59

<221> SITE

<222> (14)

<223> Xaa equals stop translation

<400> 115

Met Arg Asp His Glu Ile Trp Glu Gly Pro Gly Ala Glu Xaa
 1 5 10

<210> 116

<211> 156

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (156)

<223> Xaa equals stop translation

<400> 116

Met Phe Glu His Phe Ser Leu Phe Phe Val Cys Val Phe Gln Ile Asn
 1 5 10 15

Val Phe Phe Tyr Thr Ile Pro Leu Ala Ile Lys Leu Lys Glu His Pro
 20 25 30

Ile Phe Phe Met Phe Ile Gln Ile Ala Val Ile Ala Ile Phe Lys Ser
 35 40 45

Tyr Pro Thr Val Gly Asp Val Ala Leu Tyr Met Ala Phe Phe Pro Val
 50 55 60

Trp Asn His Leu Tyr Arg Phe Leu Arg Asn Ile Phe Val Leu Thr Cys
 65 70 75 80

Ile Ile Ile Val Cys Ser Leu Leu Phe Pro Val Leu Trp His Leu Trp
 85 90 95

Ile Tyr Ala Gly Ser Ala Asn Ser Asn Phe Phe Tyr Ala Ile Thr Leu
 100 105 110

Thr Phe Asn Val Gly Gln Ile Leu Leu Ile Ser Asp Tyr Phe Tyr Ala
 115 120 125

Phe Leu Arg Arg Glu Tyr Tyr Leu Thr His Gly Leu Tyr Leu Thr Ala
 130 135 140

Lys Asp Gly Thr Glu Ala Met Leu Val Leu Lys Xaa
 145 150 155

<210> 117

<211> 39

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

WO 99/09155

PCT/US98/17044

60

<222> (39)

<223> Xaa equals stop translation

<400> 117

Met	Val	Cys	Glu	Leu	Ala	His	Leu	Asp	His	Cys	Ile	Leu	Pro	Leu	Ser
1				5				10					15		

Phe	Leu	Val	Ser	His	Cys	His	Cys	Met	Ala	Ser	Cys	His	Cys	Glu	Ser
			20					25						30	

Trp	Pro	Ser	Leu	Ser	Leu	Xaa
			35			

<210> 118

<211> 47

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (46)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (47)

<223> Xaa equals stop translation

<400> 118

Met	Glu	Val	Val	Leu	Thr	Val	Ala	His	Pro	Leu	Arg	Glu	Arg	Arg	Lys
1				5					10					15	

Arg	Ser	Ser	Val	Ile	Cys	Val	Tyr	Cys	Cys	Leu	Leu	Phe	Cys	Leu	Phe
			20					25					30		

Tyr	Tyr	Val	Val	Phe	Ile	Asp	Phe	Val	Lys	Lys	Val	Asn	Xaa	Xaa
		35					40					45		

<210> 119

<211> 147

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (70)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (147)

<223> Xaa equals stop translation

<400> 119

Met	Lys	Ala	Ser	Val	Val	Leu	Ser	Leu	Leu	Gly	Tyr	Leu	Val	Val	Pro
1				5				10					15		

WO 99/09155

PCT/US98/17044

61

Ser Gly Ala Tyr Ile Leu Gly Arg Cys Thr Val Ala Lys Lys Leu His
 20 25 30

Asp Gly Gly Leu Asp Tyr Phe Glu Gly Tyr Ser Leu Glu Asn Trp Val
 35 40 45

Cys Leu Ala Tyr Phe Glu Ser Lys Phe Asn Pro Met Ala Ile Tyr Glu
 50 55 60

Asn Thr Arg Glu Gly Xaa Thr Gly Phe Gly Leu Phe Gln Met Arg Gly
 65 70 75 80

Ser Asp Trp Cys Gly Asp His Gly Arg Asn Arg Cys His Met Ser Cys
 85 90 95

Ser Ala Leu Leu Asn Pro Asn Leu Glu Lys Thr Ile Lys Cys Ala Lys
 100 105 110

Thr Ile Val Lys Gly Lys Glu Gly Met Gly Ala Trp Pro Thr Trp Ser
 115 120 125

Arg Tyr Cys Gln Tyr Ser Asp Thr Leu Ala Arg Trp Leu Asp Gly Cys
 130 135 140

Lys Leu Xaa
 145

<210> 120

<211> 44

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (44)

<223> Xaa equals stop translation

<400> 120

Met Tyr Leu Ser His Phe His Leu Gly Ile Val Ile Met Ala Val Ala
 1 5 10 15

Ala Leu Met Glu Lys Pro Val Leu Ala Ser Phe Ser Gly Ile Arg Ile
 20 25 30

Ser Cys His Arg Thr Ile Gly Lys Val Gln Val Xaa
 35 40

<210> 121

<211> 81

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (35)

WO 99/09155

PCT/US98/17044

62

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (52)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (74)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (81)

<223> Xaa equals stop translation

<400> 121

Met	Ser	Lys	Gly	Arg	Pro	Lys	Leu	Gly	Ser	Ser	Lys	Gly	Leu	Ala	Gly
1				5					10					15	

Gln	Leu	Trp	Leu	Leu	Thr	Leu	Arg	Leu	Leu	Leu	Gly	Ala	Leu	Leu	Val
			20					25					30		

Trp	Thr	Xaa	Ala	Tyr	Val	Tyr	Val	Val	Asn	Pro	Thr	Pro	Phe	Glu	Gly
		35					40					45			

Leu	Val	Pro	Xaa	Leu	Leu	Ser	Arg	Ala	Thr	Val	Trp	Lys	Leu	Arg	Ala
	50					55					60				

Leu	Leu	Asp	Pro	Phe	Leu	Arg	Leu	Lys	Xaa	Asp	Gly	Phe	Leu	Pro	Phe
65					70					75					80

Xaa

<210> 122

<211> 98

<212> PRT

<213> Homo sapiens

<400> 122

Met	Cys	Ser	Val	Val	Leu	Leu	Lys	Asp	Cys	Pro	Leu	Phe	Ser	Phe	Ser
1				5					10					15	

Val	Ile	Asn	Gly	His	Thr	Leu	Cys	Leu	Arg	Leu	Leu	Leu	Glu	Ile	Ala
			20					25					30		

Asp	Asn	Pro	Glu	Ala	Val	Asp	Val	Lys	Asp	Ala	Lys	Gly	Gln	Thr	Pro
		35					40					45			

Leu	Met	Leu	Ala	Val	Ala	Tyr	Gly	His	Ile	Asp	Ala	Val	Ser	Leu	Leu
	50					55				60					

Leu	Glu	Lys	Glu	Ala	Asn	Val	Asp	Thr	Val	Asp	Ile	Leu	Gly	Cys	Thr
65					70					75					80

SUBSTITUTE SHEET (RULE 26)

WO 99/09155

PCT/US98/17044

64

Pro Leu Lys Phe Leu Glu Ser Gln Ala Ser Ser Arg His His Val Ser
 35 40 45

Trp Trp Gln Leu Trp Lys Leu Leu Leu Val Cys Leu Val Gln Leu Gln
 50 55 60

Pro Cys Arg Glu Pro Ala Pro Met Gln Thr Pro Cys Ala Gly Cys Pro
 65 70 75 80

Ala Ala Ala Ala Gly Val Pro His Cys Val Gln Trp Leu Asp Pro Met
 85 90 95

Leu Thr Cys Ser His Thr Pro His Cys Ser Thr Pro Gly Leu Pro Leu
 100 105 110

Ala Val Met Gly Ser Arg Leu Val Ala
 115 120

<210> 126
 <211> 26
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (26)
 <223> Xaa equals stop translation

<400> 126
 Met Leu Pro Ser Phe Pro Ser Leu Arg Val Phe Val Ile Phe Phe Cys
 1 5 10 15

Leu Leu Val Tyr Cys Leu Phe Ala Pro Xaa
 20 25

<210> 127
 <211> 24
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (15)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (24)
 <223> Xaa equals stop translation

<400> 127
 Met Pro Ser Arg Tyr Thr Val Ser Leu Gly Arg Gly His Phe Xaa Phe
 1 5 10 15

Cys Ser Phe Phe Phe Pro Ile Xaa
 20

WO 99/09155

PCT/US98/17044

65

<210> 128
 <211> 39
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (39)
 <223> Xaa equals stop translation

<400> 128
 Met Tyr Lys Ile His Ser Glu Asn Cys Leu Val Ile Leu His Leu Phe
 1 5 10 15
 Ile Gln Lys Thr Val Ile Ser Gly Glu Pro Asn Met Leu Val Asn Ile
 20 25 30
 Phe Asn Phe Phe Pro His Xaa
 35

<210> 129
 <211> 74
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (74)
 <223> Xaa equals stop translation

<400> 129
 Met Gly Ile Ala Val Ser Met Leu Thr Tyr Pro Phe Leu Leu Val Gly
 1 5 10 15
 Asp Leu Met Ala Val Asn Asn Cys Gly Leu Gln Ala Gly Leu Pro Pro
 20 25 30
 Tyr Ser Pro Val Phe Lys Ser Trp Ile His Cys Trp Lys Tyr Leu Ser
 35 40 45
 Val Gln Gly Gln Leu Phe Arg Gly Ser Ser Leu Leu Phe Arg Arg Val
 50 55 60
 Ser Ser Gly Ser Cys Phe Ala Leu Glu Xaa
 65 70

<210> 130
 <211> 55
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (55)

WO 99/09155

PCT/US98/17044

66

<223> Xaa equals stop translation

<400> 130

Met	His	Ser	Gly	Phe	Tyr	Thr	Ser	Ala	Phe	Arg	Gly	Leu	Trp	Gln	His
1				5					10					15	

Gly	Met	Gly	Gln	Glu	Val	Leu	Leu	Leu	His	Leu	Pro	Leu	Met	Ser	Val
			20					25					30		

Thr	His	Pro	Phe	Cys	Thr	Ala	Gly	Val	Val	Asn	Ala	Phe	Val	Ser	Ser
		35					40					45			

Ser	Ser	His	Ala	Asp	Cys	Xaa
	50					55

<210> 131

<211> 44

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (44)

<223> Xaa equals stop translation

<400> 131

Met	Glu	Leu	Arg	Val	Glu	Thr	Gly	His	Phe	Thr	Gly	His	Leu	Ser	Thr
1				5					10					15	

Val	Lys	Ile	Leu	Phe	Thr	Leu	Leu	Val	Pro	Val	Phe	Tyr	Ile	Glu	Asp
			20					25					30		

Leu	Ala	Met	Asn	Cys	Tyr	Leu	Asn	Leu	Arg	Ala	Xaa
		35					40				

<210> 132

<211> 37

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (37)

<223> Xaa equals stop translation

<400> 132

Met	Phe	Phe	Gly	Ala	Pro	Thr	Ala	Gly	Ala	Val	Gln	Val	Trp	Leu	Leu
1				5					10					15	

Leu	Leu	Ser	Pro	Ala	Ala	Ser	Pro	Val	Glu	Glu	Leu	Ser	Val	Leu	Val
			20					25					30		

Pro	Cys	Gly	Gln	Xaa
			35	

WO 99/09155

PCT/US98/17044

67

<210> 133

<211> 50

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (50)

<223> Xaa equals stop translation

<400> 133

Met	Ile	Leu	Leu	Pro	Gly	Leu	Ser	His	Tyr	Asn	Ala	Leu	Gly	Leu	Phe
1				5					10					15	

Phe	Ala	Ala	Val	Leu	Leu	Phe	Leu	Asn	Leu	Gly	Gln	Val	Pro	Met	Leu
			20					25					30		

Ala	Val	Arg	Arg	Asp	Ser	Val	His	Ser	Thr	Cys	Asn	Phe	Arg	Glu	Trp
		35					40					45			

Lys Xaa

50

<210> 134

<211> 84

<212> PRT

<213> Homo sapiens

<400> 134

Met	Asn	Pro	Leu	Cys	Pro	Pro	Leu	Leu	Leu	Leu	Asp	Leu	Gln	Thr	Gln
1				5					10					15	

Cys	Pro	Gln	Arg	Cys	Ser	Tyr	Ile	Leu	Tyr	Ser	Cys	Phe	Ser	Gly	Met
			20					25					30		

Val	Leu	Met	Pro	Pro	Lys	Ala	Pro	Ala	Cys	Glu	Ser	Thr	Phe	Val	Phe
		35					40					45			

Ile	Ser	Trp	Ser	Pro	Leu	Ser	Ser	Leu	Val	Pro	Pro	Arg	Pro	Ser	Phe
	50					55					60				

His	His	Leu	Pro	Arg	His	Ser	Glu	Leu	Asp	Gln	Tyr	Leu	Cys	Gly	Arg
65					70					75					80

Leu Gly Val Thr

<210> 135

<211> 23

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (23)

<223> Xaa equals stop translation

WO 99/09155

PCT/US98/17044

68

<400> 135

Met	Leu	Leu	Val	Asn	Leu	Val	Phe	Val	Cys	Phe	Phe	Leu	Phe	Glu	Arg
1				5					10					15	

Arg	Val	His	Leu	Lys	Cys	Xaa
			20			

<210> 136

<211> 45

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (45)

<223> Xaa equals stop translation

<400> 136

Met	Met	Gly	Ile	Leu	Phe	Ile	His	Leu	Phe	Ile	Tyr	Leu	Phe	Thr	Glu
1				5					10					15	

Asp	Trp	Phe	Leu	Pro	Val	Gln	Phe	Asn	Ser	Phe	Ser	Glu	Val	Ser	Ile
			20					25					30		

Met	Ile	Arg	Lys	Ile	Asp	Cys	Ser	Tyr	Tyr	Ser	Lys	Xaa
		35					40					45

<210> 137

<211> 47

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (47)

<223> Xaa equals stop translation

<400> 137

Met	Met	Leu	Leu	Leu	Ala	Ser	Ala	Phe	Leu	Ile	Gly	Thr	Val	Leu	Gly
1				5					10					15	

Ser	Asn	Arg	Ser	Cys	Met	Ser	Gln	Cys	Cys	Gly	His	His	Lys	Ser	Gln
			20					25					30		

Lys	Ala	Gln	Lys	Thr	Ser	Ser	Phe	Ile	Thr	Ala	Pro	Val	Lys	Xaa
		35					40					45		

<210> 138

<211> 288

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

WO 99/09155

PCT/US98/17044

69

<222> (23)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 138

Met	Lys	Thr	Leu	Ala	Thr	Gly	Thr	Lys	Asn	Arg	Arg	Arg	Arg	Pro	Ala
1				5				10						15	

Ala	Ala	Ala	Ala	Ala	Cys	Xaa	Val	Gln	Gly	Pro	Glu	Pro	Ala	Arg	Val
			20					25					30		

Glu	Lys	Ile	Phe	Thr	Pro	Ala	Ala	Pro	Val	His	Thr	Asn	Lys	Glu	Asp
		35					40					45			

Pro	Ala	Thr	Gln	Thr	Asn	Leu	Gly	Phe	Ile	His	Ala	Phe	Val	Ala	Ala
	50					55					60				

Ile	Ser	Val	Ile	Ile	Val	Ser	Glu	Leu	Gly	Asp	Lys	Thr	Phe	Phe	Ile
65					70					75					80

Ala	Ala	Ile	Met	Ala	Met	Arg	Tyr	Asn	Arg	Leu	Thr	Val	Leu	Ala	Gly
				85					90					95	

Ala	Met	Leu	Ala	Leu	Gly	Leu	Met	Thr	Cys	Leu	Ser	Val	Leu	Phe	Gly
			100					105					110		

Tyr	Ala	Thr	Thr	Val	Ile	Pro	Arg	Val	Tyr	Thr	Tyr	Tyr	Val	Ser	Thr
		115					120					125			

Val	Leu	Phe	Ala	Ile	Phe	Gly	Ile	Arg	Met	Leu	Arg	Glu	Gly	Leu	Lys
	130					135					140				

Met	Ser	Pro	Asp	Glu	Gly	Gln	Glu	Glu	Leu	Glu	Glu	Val	Gln	Ala	Glu
145					150					155					160

Leu	Lys	Lys	Lys	Asp	Glu	Glu	Phe	Gln	Arg	Thr	Lys	Leu	Leu	Asn	Gly
				165					170					175	

Pro	Gly	Asp	Val	Glu	Thr	Gly	Thr	Ser	Ile	Thr	Val	Pro	Gln	Lys	Lys
			180					185					190		

Trp	Leu	His	Phe	Ile	Ser	Pro	Ile	Phe	Val	Gln	Ala	Leu	Thr	Leu	Thr
		195					200					205			

Phe	Leu	Ala	Glu	Trp	Gly	Asp	Arg	Ser	Gln	Leu	Thr	Thr	Ile	Val	Leu
	210				215					220					

Ala	Ala	Arg	Glu	Asp	Pro	Tyr	Gly	Val	Ala	Val	Gly	Gly	Thr	Val	Gly
225					230					235					240

His	Cys	Leu	Cys	Thr	Gly	Leu	Ala	Val	Ile	Gly	Gly	Arg	Met	Ile	Ala
				245					250					255	

Gln	Lys	Ile	Ser	Val	Arg	Thr	Val	Thr	Ile	Ile	Gly	Gly	Ile	Val	Phe
			260					265					270		

Leu	Ala	Phe	Ala	Phe	Ser	Ala	Leu	Phe	Ile	Ser	Pro	Asp	Ser	Gly	Phe
		275					280					285			

SUBSTITUTE SHEET (RULE 26)

WO 99/09155

PCT/US98/17044

70

<210> 139
 <211> 24
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (24)
 <223> Xaa equals stop translation

<400> 139
 Met Phe Leu Phe Leu Phe Phe Leu Leu Ile Ile Ala Ser Tyr Ile Ser
 1 5 10 15
 Ser Phe Ser Phe Gly Gln Ser Xaa
 20

<210> 140
 <211> 54
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (54)
 <223> Xaa equals stop translation

<400> 140
 Met Val Leu Leu Leu Leu Leu Gln Arg Asn Pro Gly Thr Pro Leu Phe
 1 5 10 15
 Cys Leu Val Phe Trp Ala Gly Leu Arg Lys Pro Ala Gln Phe Arg Pro
 20 25 30
 Ile Leu Gly Pro Ser Cys Pro Cys Ala Ala Ser Val Lys Arg Gly Val
 35 40 45
 Asp Ile Pro Ser Ser Xaa
 50

<210> 141
 <211> 61
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (51)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE

WO 99/09155

PCT/US98/17044

71

<222> (61)

<223> Xaa equals stop translation

<400> 141

Met	Leu	Leu	Glu	Ser	Trp	Met	Gly	Ile	Trp	Gly	Glu	Arg	Gly	Arg	Thr
1				5					10					15	

Gly	Gln	Val	Ser	Pro	Ser	Pro	Phe	Cys	Ser	Cys	Leu	Leu	Val	Ser	Ala
			20					25					30		

Leu	Leu	Glu	Leu	His	Leu	Pro	Leu	Gly	Phe	Ser	Ala	Pro	Ala	His	Phe
		35					40					45			

Pro	Ser	Xaa	Phe	Thr	Cys	Phe	Val	Ser	Phe	Pro	Cys	Xaa
	50					55					60	

<210> 142

<211> 101

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (101)

<223> Xaa equals stop translation

<400> 142

Met	Gly	Asp	Asp	Gly	Ser	Ile	Asp	Tyr	Thr	Val	His	Glu	Ala	Trp	Asn
1				5					10					15	

Glu	Ala	Thr	Asn	Val	Tyr	Leu	Ile	Val	Ile	Leu	Val	Ser	Phe	Gly	Leu
			20					25					30		

Phe	Met	Tyr	Ala	Lys	Arg	Asn	Lys	Arg	Arg	Ile	Met	Arg	Ile	Phe	Ser
		35					40					45			

Val	Pro	Pro	Thr	Glu	Glu	Thr	Leu	Ser	Glu	Pro	Asn	Phe	Tyr	Asp	Thr
	50					55					60				

Ile	Ser	Lys	Ile	Arg	Leu	Arg	Gln	Gln	Leu	Glu	Met	Tyr	Ser	Ile	Ser
65					70					75				80	

Arg	Lys	Tyr	Asp	Tyr	Gln	Gln	Pro	Gln	Asn	Gln	Ala	Asp	Ser	Val	Gln
				85					90					95	

Leu	Ser	Leu	Glu	Xaa
			100	

<210> 143

<211> 42

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (42)

WO 99/09155

PCT/US98/17044

72

<223> Xaa equals stop translation

<400> 143

Met	Phe	Ala	Phe	Leu	Leu	Gly	Ile	Tyr	Leu	Gly	Val	Lys	Leu	Leu	Asp
1				5					10					15	

Asn	Met	Phe	Asn	Tyr	Leu	Arg	Thr	Asp	Arg	Leu	Leu	Cys	Lys	Val	Ala
			20					25					30		

Asn	Met	Ser	Lys	Phe	Ser	Ser	His	Leu	Xaa
		35					40		

<210> 144

<211> 63

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (63)

<223> Xaa equals stop translation

<400> 144

Met	Phe	Gly	Cys	Arg	Ala	Val	Lys	Thr	Gln	Lys	Glu	Thr	Leu	Pro	Ser
1				5					10					15	

Ala	Pro	Gly	Ser	Pro	Pro	Leu	Val	Ala	Leu	Phe	Ser	Val	Ala	Leu	Trp
			20					25					30		

Pro	Val	Ala	Leu	Ser	Asn	Glu	Ala	Thr	Pro	His	Ser	Cys	Gly	Gln	Ala
		35					40					45			

Pro	Gly	Ala	Pro	Gly	Gln	Met	Arg	Thr	Leu	Phe	Pro	Pro	Thr	Xaa
	50					55					60			

<210> 145

<211> 33

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (33)

<223> Xaa equals stop translation

<400> 145

Met	Val	Phe	His	Leu	Pro	Leu	Ser	Asp	Leu	Phe	Phe	Met	Leu	Leu	Leu
1				5					10					15	

Ala	Pro	Lys	Lys	Ser	Arg	Met	Ala	Lys	Glu	Pro	Arg	Thr	Tyr	Trp	Asn
			20					25					30		

Xaa

WO 99/09155

PCT/US98/17044

73

<210> 146
 <211> 42
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (42)
 <223> Xaa equals stop translation

<400> 146
 Met Lys Val Gln Leu Ser Leu Gly Asn Pro Arg Gly Gln Gln Arg Thr
 1 5 10 15
 Pro Glu Leu Ile Gln Ala Leu Leu Leu Val Leu Asn Tyr Thr Leu Gly
 20 25 30
 Phe Phe Leu Leu Ser Lys Thr Phe His Xaa
 35 40

<210> 147
 <211> 41
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (35)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (41)
 <223> Xaa equals stop translation

<400> 147
 Met Asn Glu Ala Thr Met Ala Phe Ser Val Leu Ile Leu Pro Val Phe
 1 5 10 15
 Tyr Ala Gln Ile Arg Asn Lys Ser Phe Leu Cys Leu Ser Asp Ile Leu
 20 25 30
 Pro Leu Xaa Leu Ile Leu Leu Phe Xaa
 35 40

<210> 148
 <211> 44
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (44)
 <223> Xaa equals stop translation

<400> 148

WO 99/09155

PCT/US98/17044

74

Met	Asn	Trp	Tyr	His	Glu	Asn	Lys	Glu	Ala	Thr	Cys	Asn	Cys	Gln	Ile
1				5					10					15	

Phe	Gly	Leu	Tyr	Phe	Ile	Val	Ser	Phe	Leu	Ser	Pro	Val	Leu	Ala	Ala
			20					25					30		

Ala	His	Asp	Ala	Lys	Lys	Tyr	Pro	Val	Trp	Leu	Xaa
		35					40				

<210> 149
 <211> 55
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (55)
 <223> Xaa equals stop translation

<400> 149

Met	Pro	Gly	Pro	Gly	Ala	Leu	Tyr	Ser	Ser	Phe	Thr	Ser	Phe	Tyr	Tyr
1				5					10					15	

Thr	Phe	Ser	Asn	His	Gln	Leu	Leu	Leu	Ala	Leu	Leu	Leu	Leu	Gly	Phe
			20					25					30		

Ile	Ala	Ser	Cys	Ser	Phe	Phe	Leu	Ser	Arg	Val	Phe	Leu	Thr	Phe	Ser
		35					40					45			

Thr	Gln	Leu	Trp	Lys	Lys	Xaa
	50				55	

<210> 150
 <211> 165
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (100)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 150

Met	Ser	Lys	Ser	Glu	Gln	Cys	Arg	Ala	Ala	Cys	Pro	Ala	Ala	Leu	Glu
1				5					10					15	

Gln	Glu	Leu	Ser	Leu	Gly	Arg	Gly	Trp	Trp	Gly	Trp	Ala	Thr	Glu	Gly
			20					25					30		

Ile	Gly	Ser	Gln	Ile	His	Pro	Val	Ser	Pro	Pro	Ala	Ser	Pro	Lys	Gln
		35					40					45			

Ser	Pro	Ser	Leu	Leu	Gln	Ser	Met	Trp	Asp	Arg	Cys	Asn	Ser	Tyr	Thr
	50					55					60				

His	Gly	Ser	Leu	Gln	Trp	Asp	Arg	Leu	Arg	Pro	Pro	Pro	Val	Leu	Pro
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

PCT/US98/17044

[illegible]

```
<210> 151
<211> 114
<212> PRT
<213> Homo sapiens
```

```
<220>  
<221> SITE  
<222> (114)  
<223> Xaa equals stop translation
```

```

<400> 151
Met Gly Trp Lys Leu Leu Gly Leu Leu Ser Ala Ala Gly Arg His Ser
  1           5           10           15

Ala Gly Gly Asp Gln Ala Phe Pro Arg Pro Lys Gly Glu Ala Glu Ser
      20           25           30

Ala Ser Pro Glu Pro Asp Ala Gly Leu Gly Phe Thr Leu His Gly Pro
      35           40           45

Asp Val Lys Ser Asn Gly Asp Met Arg Phe Leu Met Ser Leu His Leu
  50           55           60

Gln Met Tyr Thr Ser Ala Lys Leu His His Thr Asn Leu Thr Ala Gly
  65           70           75           80

Pro Gly Phe Pro Leu Ser Arg Phe His Gln Pro Pro Pro Ser Val Leu
      85           90           95

Ala Ala Cys Pro Ser Thr Asn Gln Leu Ser Pro Ala Pro Gly Asp Pro
      100           105           110

Arg Xaa

```

<210> 152

WO 99/09155

PCT/US98/17044

76

<211> 40
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (40)
 <223> Xaa equals stop translation

<400> 152
 Met Ala Leu Thr Trp Arg Val Val Leu Val Val Leu Phe Leu Ser Asp
 1 5 10 15
 Cys Gly Leu Lys His Lys Cys Pro Lys Val Gly Arg Leu Leu Ser Val
 20 25 30
 Ile Ile Val Ala Ile Lys Phe Xaa
 35 40

<210> 153
 <211> 64
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (64)
 <223> Xaa equals stop translation

<400> 153
 Met Thr Glu Asp Glu Leu Val Val Leu Gln Gln Met Phe Phe Gly Ile
 1 5 10 15
 Ile Ile Cys Ala Leu Ala Thr Leu Ala Ala Lys Gly Asp Leu Val Phe
 20 25 30
 Thr Ala Ile Phe Ile Gly Ala Val Ala Ala Met Thr Gly Tyr Trp Leu
 35 40 45
 Ser Glu Arg Ser Asp Arg Val Leu Glu Gly Phe Ile Lys Gly Arg Xaa
 50 55 60

<210> 154
 <211> 118
 <212> PRT
 <213> Homo sapiens

<400> 154
 Met Val Ala Ile Pro Pro Ser Ala Cys Leu Pro Ala Cys Cys Pro Gly
 1 5 10 15
 His Gly Ala Val Pro Val Pro Arg Ile Gly Phe Lys Phe Val Asn Asn
 20 25 30

WO 99/09155

PCT/US98/17044

77

Phe Pro Phe Gly Leu Val Asp Val Asn Arg Ala Arg Glu Val Leu Pro
 35 40 45

Thr Ala Cys Ala Cys Leu Pro Ala Ser Ser Leu Phe Ser Phe His Tyr
 50 55 60

Ala Pro Ser Pro Gly Gly Leu Ala Leu Ser Phe Ser Ser Tyr Pro Gln
 65 70 75 80

Gly Pro Val Leu Leu Cys Pro His Val Pro Leu Gly Cys Leu Val Glu
 85 90 95

Ala Leu Tyr Asn Phe Ser Leu Val Leu Cys Ser Phe Leu Leu Tyr Phe
 100 105 110

Pro Ala Val Ser Cys Pro
 115

<210> 155
 <211> 28
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (28)
 <223> Xaa equals stop translation

<400> 155
 Met His Ser Phe Thr Gln Arg Gly Met Tyr Ile Phe Leu Ser Ser Ser
 1 5 10 15

Gln Ala Ile Phe Leu Met Ser Cys Phe Leu Phe Xaa
 20 25

<210> 156
 <211> 46
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (46)
 <223> Xaa equals stop translation

<400> 156
 Met Val Leu Ile Phe Leu Leu Val Gln Asn Arg Cys Ala Val Gly Ser
 1 5 10 15

Thr Met Gln Phe Ser Phe Ser Thr Asp Pro Phe Leu Arg Asn Thr Asn
 20 25 30

Phe Leu Leu His His Leu Gly Val Leu Arg Cys Leu Pro Xaa
 35 40 45

WO 99/09155

PCT/US98/17044

78

<210> 157
 <211> 51
 <212> PRT
 <213> Homo sapiens

<400> 157
 Phe Ile Thr Pro Glu Asp Gly Ser Lys Asp Val Phe Val His Phe Ser
 1 5 10 15
 Ala Ile Ser Ser Gln Gly Phe Lys Thr Leu Ala Glu Gly Gln Arg Val
 20 25 30
 Glu Phe Glu Ile Thr Asn Gly Ala Lys Gly Pro Ser Ala Ala Asn Val
 35 40 45
 Ile Ala Ile
 50

<210> 158
 <211> 141
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (37)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (54)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 158
 Arg Ala Gly Gly Pro Arg Leu Pro Arg Thr Arg Val Gly Arg Pro Ala
 1 5 10 15
 Ala Leu Arg Leu Leu Leu Leu Leu Gly Ala Val Leu Asn Pro His Glu
 20 25 30
 Ala Leu Ala Gln Xaa Leu Pro Thr Thr Gly Thr Pro Gly Ser Glu Gly
 35 40 45
 Gly Thr Val Lys Asn Xaa Glu Thr Ala Val Gln Phe Cys Trp Asn His
 50 55 60
 Tyr Lys Asp Gln Met Asp Pro Ile Glu Lys Asp Trp Cys Asp Trp Ala
 65 70 75 80
 Met Ile Ser Arg Pro Tyr Ser Thr Leu Arg Asp Cys Leu Glu His Phe
 85 90 95
 Ala Glu Leu Phe Asp Leu Gly Phe Pro Asn Pro Leu Ala Glu Arg Ile
 100 105 110
 Ile Phe Glu Thr His Gln Ile His Phe Ala Asn Cys Ser Leu Val Gln

WO 99/09155

PCT/US98/17044

115 120 79 125

Pro Thr Phe Ser Asp Pro Pro Glu Asp Val Leu Leu Ala

130 135 140

<210> 159

<211> 60

<212> PRT

<213> Homo sapiens

<400> 159

Cys Trp Asn His Tyr Lys Asp Gln Met Asp Pro Ile Glu Lys Asp Trp

1 5 10 15

Cys Asp Trp Ala Met Ile Ser Arg Pro Tyr Ser Thr Leu Arg Asp Cys

20 25 30

Leu Glu His Phe Ala Glu Leu Phe Asp Leu Gly Phe Pro Asn Pro Leu

35 40 45

Ala Glu Arg Ile Ile Phe Glu Thr His Gln Ile His

50 55 60

<210> 160

<211> 48

<212> PRT

<213> Homo sapiens

<400> 160

Phe Ala Asn Cys Ser Leu Val Gln Pro Thr Phe Ser Asp Pro Pro Glu

1 5 10 15

Asp Val Leu Leu Ala Met Ile Ile Ala Pro Ile Cys Leu Ile Pro Phe

20 25 30

Leu Ile Thr Leu Val Val Trp Arg Ser Lys Asp Ser Glu Ala Gln Ala

35 40 45

<210> 161

<211> 10

<212> PRT

<213> Homo sapiens

<400> 161

Arg Ala Gly Gly Pro Arg Leu Pro Arg Thr

1 5 10

<210> 162

<211> 8

<212> PRT

<213> Homo sapiens

WO 99/09155

PCT/US98/17044

80

<400> 162

Asn Pro His Glu Ala Leu Ala Gln
 1 5

<210> 163

<211> 118

<212> PRT

<213> Homo sapiens

<400> 163

Ala Gln Glu Arg Ser Cys Leu His Leu Val Cys Ile Arg Cys Ser Cys
 1 5 10 15

Asp Val Val Glu Met Gly Ser Val Leu Gly Leu Cys Ser Met Ala Ser
 20 25 30

Trp Ile Pro Cys Leu Cys Gly Ser Ala Pro Cys Leu Leu Cys Arg Cys
 35 40 45

Cys Pro Ser Gly Asn Asn Ser Thr Val Thr Arg Leu Ile Tyr Ala Leu
 50 55 60

Phe Leu Leu Val Gly Val Cys Val Ala Cys Val Met Leu Ile Pro Gly
 65 70 75 80

Met Glu Glu Gln Leu Asn Lys Ile Pro Gly Phe Cys Glu Asn Glu Lys
 85 90 95

Gly Val Val Pro Cys Asn Ile Leu Val Gly Tyr Lys Ala Val Tyr Arg
 100 105 110

Leu Cys Phe Gly Leu Ala
 115

<210> 164

<211> 74

<212> PRT

<213> Homo sapiens

<400> 164

Ile Pro Cys Leu Cys Gly Ser Ala Pro Cys Leu Leu Cys Arg Cys Cys
 1 5 10 15

Pro Ser Gly Asn Asn Ser Thr Val Thr Arg Leu Ile Tyr Ala Leu Phe
 20 25 30

Leu Leu Val Gly Val Cys Val Ala Cys Val Met Leu Ile Pro Gly Met
 35 40 45

Glu Glu Gln Leu Asn Lys Ile Pro Gly Phe Cys Glu Asn Glu Lys Gly
 50 55 60

Val Val Pro Cys Asn Ile Leu Val Gly Tyr
 65 70

WO 99/09155

PCT/US98/17044

81

<210> 165
 <211> 95
 <212> PRT
 <213> Homo sapiens

<400> 165
 Ala Arg Ser Asp Gly Ser Leu Glu Asp Gly Asp Asp Val His Arg Ala
 1 5 10 15
 Val Asp Asn Glu Arg Asp Gly Val Thr Tyr Ser Tyr Ser Phe Phe His
 20 25 30
 Phe Met Leu Phe Leu Ala Ser Leu Tyr Ile Met Met Thr Leu Thr Asn
 35 40 45
 Trp Tyr Arg Tyr Glu Pro Ser Arg Glu Met Lys Ser Gln Trp Thr Ala
 50 55 60
 Val Trp Val Lys Ile Ser Ser Ser Trp Ile Gly Ile Val Leu Tyr Val
 65 70 75 80
 Trp Thr Leu Val Ala Pro Leu Val Leu Thr Asn Arg Asp Phe Asp
 85 90 95

<210> 166
 <211> 28
 <212> PRT
 <213> Homo sapiens

<400> 166
 Asn Glu Lys Gly Val Val Pro Cys Asn Ile Leu Val Gly Tyr Lys Ala
 1 5 10 15
 Val Tyr Arg Leu Cys Phe Gly Leu Ala Met Phe Tyr
 20 25

<210> 167
 <211> 19
 <212> PRT
 <213> Homo sapiens

<400> 167
 Met Ile Lys Val Lys Ser Ser Ser Asp Pro Arg Ala Ala Val His Asn
 1 5 10 15

Gly Phe Trp

<210> 168
 <211> 21
 <212> PRT
 <213> Homo sapiens

<400> 168

WO 99/09155

PCT/US98/17044

82

Gly Met Ala Gly Ala Phe Cys Phe Ile Leu Ile Gln Leu Val Leu Leu
 1 5 10 15

Ile Asp Phe Ala His
 20

<210> 169
 <211> 24
 <212> PRT
 <213> Homo sapiens

<400> 169
 Tyr Ala Ala Leu Leu Ser Ala Thr Ala Leu Asn Tyr Leu Leu Ser Leu
 1 5 10 15

Val Ala Ile Val Leu Phe Phe Val
 20

<210> 170
 <211> 21
 <212> PRT
 <213> Homo sapiens

<400> 170
 Pro Ser Leu Leu Ser Ile Ile Gly Tyr Asn Thr Thr Ser Thr Val Pro
 1 5 10 15

Lys Glu Gly Gln Ser
 20

<210> 171
 <211> 22
 <212> PRT
 <213> Homo sapiens

<400> 171
 Tyr Ser Ser Ile Arg Thr Ser Asn Asn Ser Gln Val Asn Lys Leu Thr
 1 5 10 15

Leu Thr Ser Asp Glu Ser
 20

<210> 172
 <211> 20
 <212> PRT
 <213> Homo sapiens

<400> 172
 Asp Asn Glu Arg Asp Gly Val Thr Tyr Ser Tyr Ser Phe Phe His Phe
 1 5 10 15

Met Leu Phe Leu
 20

WO 99/09155

PCT/US98/17044

83

<210> 173
 <211> 18
 <212> PRT
 <213> Homo sapiens

<400> 173
 Ile Val Leu Tyr Val Trp Thr Leu Val Ala Pro Leu Val Leu Thr Asn
 1 5 10 15

Arg Asp

<210> 174
 <211> 11
 <212> PRT
 <213> Homo sapiens

<400> 174
 Asp Pro Arg Val Arg Ala Asp Thr Met Val Arg
 1 5 10

<210> 175
 <211> 45
 <212> PRT
 <213> Homo sapiens

<400> 175
 Gly Pro Ala Val Pro Gln Glu Asn Gln Asp Gly Arg Tyr Ser Leu Thr
 1 5 10 15

Tyr Ile Tyr Thr Gly Leu Ser Lys His Val Glu Asp Val Pro Ala Phe
 20 25 30

Gln Ala Leu Gly Ser Leu Asn Asp Leu Gln Phe Phe Arg
 35 40 45

<210> 176
 <211> 21
 <212> PRT
 <213> Homo sapiens

<400> 176
 Tyr Asn Ser Lys Asp Arg Lys Ser Gln Pro Met Gly Leu Trp Arg Gln
 1 5 10 15

Val Glu Gly Met Glu
 20

<210> 177
 <211> 22
 <212> PRT
 <213> Homo sapiens

WO 99/09155

PCT/US98/17044

84

<400> 177

Phe	Met	Glu	Thr	Leu	Lys	Asp	Ile	Val	Glu	Tyr	Tyr	Asn	Asp	Ser	Asn
1				5					10					15	

Gly	Ser	His	Val	Leu	Gln
				20	

<210> 178

<211> 20

<212> PRT

<213> Homo sapiens

<400> 178

Asn	Arg	Ser	Ser	Gly	Ala	Phe	Trp	Lys	Tyr	Tyr	Tyr	Asp	Gly	Lys	Asp
1				5					10					15	

Tyr	Ile	Glu	Phe
			20

<210> 179

<211> 71

<212> PRT

<213> Homo sapiens

<400> 179

Ile	Arg	His	Glu	Thr	Glu	Cys	Gly	Ile	Asp	His	Ile	Cys	Ile	His	Arg
1				5					10					15	

His	Cys	Val	His	Ile	Thr	Ile	Leu	Asn	Ser	Asn	Cys	Ser	Pro	Ala	Phe
			20					25					30		

Cys	Asn	Lys	Arg	Gly	Ile	Cys	Asn	Asn	Lys	His	His	Cys	His	Cys	Asn
		35					40					45			

Tyr	Leu	Trp	Asp	Pro	Pro	Asn	Cys	Leu	Ile	Lys	Gly	Tyr	Gly	Gly	Ser
	50					55					60				

Val	Asp	Ser	Gly	Pro	Pro	Pro
65					70	

<210> 180

<211> 11

<212> PRT

<213> Homo sapiens

<400> 180

Gly	Ile	Cys	Asn	Asn	Lys	His	His	Cys	His	Cys
1				5					10	

<210> 181

<211> 145

<212> PRT

<213> Homo sapiens

WO 99/09155

PCT/US98/17044

85

<220>

<221> SITE

<222> (29)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (34)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 181

Phe	Cys	Tyr	Leu	Cys	Ile	Leu	Leu	Leu	Ile	Val	Leu	Phe	Ile	Leu	Leu
1				5					10					15	

Cys	Cys	Leu	Tyr	Arg	Leu	Cys	Lys	Lys	Ser	Lys	Pro	Xaa	Lys	Lys	Gln
			20					25					30		

Gln	Xaa	Val	Gln	Thr	Pro	Ser	Ala	Lys	Glu	Glu	Glu	Lys	Ile	Gln	Arg
		35					40					45			

Arg	Pro	His	Glu	Leu	Pro	Pro	Gln	Ser	Gln	Pro	Trp	Val	Met	Pro	Ser
	50					55					60				

Gln	Ser	Gln	Pro	Pro	Val	Thr	Pro	Ser	Gln	Ser	His	Pro	Gln	Val	Met
65					70					75					80

Pro	Ser	Gln	Ser	Gln	Pro	Pro	Val	Thr	Pro	Ser	Gln	Ser	Gln	Pro	Arg
				85					90					95	

Val	Met	Pro	Ser	Gln	Ser	Gln	Pro	Pro	Val	Met	Pro	Ser	Gln	Ser	His
			100					105					110		

Pro	Gln	Leu	Thr	Pro	Ser	Gln	Ser	Gln	Pro	Pro	Val	Thr	Pro	Ser	Gln
		115					120					125			

Arg	Gln	Pro	Gln	Leu	Met	Pro	Ser	Gln	Ser	Gln	Pro	Pro	Val	Thr	Pro
	130					135					140				

Ser
145

<210> 182

<211> 234

<212> PRT

<213> Homo sapiens

<400> 182

Gly	Ser	Phe	Arg	Gly	Thr	Gly	Arg	Gly	Arg	Asp	Gly	Ala	Gln	His	Pro
1				5					10					15	

Leu	Leu	Tyr	Val	Lys	Leu	Leu	Ile	Gln	Val	Gly	His	Glu	Pro	Met	Pro
			20					25					30		

Pro	Thr	Leu	Gly	Thr	Asn	Val	Leu	Gly	Arg	Lys	Val	Leu	Tyr	Leu	Pro
		35					40					45			

Ser	Phe	Phe	Thr	Tyr	Ala	Lys	Tyr	Ile	Val	Gln	Val	Asp	Gly	Lys	Ile
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

WO 99/09155

PCT/US98/17044

50 55 86 60
 Gly Leu Phe Arg Gly Leu Ser Pro Arg Leu Met Ser Asn Ala Leu Ser
 65 70 75 80
 Thr Val Thr Arg Gly Ser Met Lys Lys Val Phe Pro Pro Asp Glu Ile
 85 90 95
 Glu Gln Val Ser Asn Lys Asp Asp Met Lys Thr Ser Leu Lys Lys Val
 100 105 110
 Val Lys Glu Thr Ser Tyr Glu Met Met Met Gln Cys Val Ser Arg Met
 115 120 125
 Leu Ala His Pro Leu His Val Ile Ser Met Arg Cys Met Val Gln Phe
 130 135 140
 Val Gly Arg Glu Ala Lys Tyr Ser Gly Val Leu Ser Ser Ile Gly Lys
 145 150 155 160
 Ile Phe Lys Glu Glu Gly Leu Leu Gly Phe Phe Val Gly Leu Ile Pro
 165 170 175
 His Leu Leu Gly Asp Val Val Phe Leu Trp Gly Cys Asn Leu Leu Ala
 180 185 190
 His Phe Ile Asn Ala Tyr Leu Val Asp Asp Ser Val Ser Asp Thr Pro
 195 200 205
 Gly Gly Leu Gly Asn Asp Gln Asn Pro Gly Ser Gln Phe Ser Gln Ala
 210 215 220
 Leu Ala Ile Arg Ser Tyr Thr Lys Phe Val
 225 230

<210> 183

<211> 120

<212> PRT

<213> Homo sapiens

<400> 183

Ala Arg Ala Ala Pro Arg Leu Leu Leu Leu Phe Leu Val Pro Leu Leu
 1 5 10 15
 Trp Ala Pro Ala Ala Val Arg Ala Gly Pro Asp Glu Asp Leu Ser His
 20 25 30
 Arg Asn Lys Glu Pro Pro Ala Pro Ala Gln Gln Leu Gln Pro Gln Pro
 35 40 45
 Val Ala Val Gln Gly Pro Glu Pro Ala Arg Val Glu Asp Pro Tyr Gly
 50 55 60
 Val Ala Val Gly Gly Thr Val Gly His Cys Leu Cys Thr Gly Leu Ala
 65 70 75 80
 Val Ile Gly Gly Arg Met Ile Ala Gln Lys Ile Ser Val Arg Thr Val

<400> 186
Gln Val Ser Ala Leu Pro Pro Pro Pro Met Gln Tyr Ile Lys Glu Tyr
1 5 10 15

WO 99/09155

PCT/US98/17044

88

Thr Asp Glu Asn Ile Gln Glu Gly Leu Ala
 20 25

<210> 187
 <211> 24
 <212> PRT
 <213> Homo sapiens

<400> 187
 Ser Gln Gly Ile Glu Arg Leu His Pro Met Gln Phe Asp His Lys Lys
 1 5 10 15

Glu Leu Arg Lys Leu Asn Met Ser
 20

<210> 188
 <211> 31
 <212> PRT
 <213> Homo sapiens

<400> 188
 Leu Glu Thr Ala Glu Arg Phe Gln Lys His Leu Glu Arg Val Ile Glu
 1 5 10 15

Met Ile Gln Asn Cys Leu Ala Ser Leu Pro Asp Asp Leu Pro His
 20 25 30

<210> 189
 <211> 154
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (136)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 189
 Met Thr Met Ile Thr Pro Ser Ser Lys Leu Thr Leu Thr Lys Gly Asn
 1 5 10 15

Lys Ser Trp Ser Ser Thr Ala Val Ala Ala Ala Leu Glu Leu Val Asp
 20 25 30

Pro Pro Gly Cys Arg Asn Ser Pro Pro Pro Pro His Thr Pro Phe Ser
 35 40 45

Tyr Ala Phe Gly Val Leu Asp Gly Asn Leu Gly Gly Glu Arg Lys Asp
 50 55 60

Arg Ser Gly Leu Pro Gln Pro Leu Leu Leu Leu Ser Pro Arg Val Arg
 65 70 75 80

Ile Ala Gly Ala Pro Pro Pro Ser Trp Phe Leu Arg Thr Arg Pro Phe

WO 99/09155

PCT/US98/17044

[illegible]

```
<210> 190
<211> 28
<212> PRT
<213> Homo sapiens
```

```
<400> 190
Leu Thr Leu Thr Lys Gly Asn Lys Ser Trp Ser Ser Thr Ala Val Ala
  1                      5                      10                      15

Ala Ala Leu Glu Leu Val Asp Pro Pro Gly Cys Arg
      20                      25
```

What Is Claimed Is:

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
 - (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity;
 - (f) a polynucleotide which is a variant of SEQ ID NO:X;
 - (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
 - (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
 - (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.
2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.
3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence

identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

9. A recombinant host cell produced by the method of claim 8.

10. The recombinant host cell of claim 9 comprising vector sequences.

11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;

(c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(g) a variant of SEQ ID NO:Y;

(h) an allelic variant of SEQ ID NO:Y; or

(i) a species homologue of the SEQ ID NO:Y.

12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:

(a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

(a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

22. A method of identifying an activity in a biological assay, wherein the method comprises:

(a) expressing SEQ ID NO:X in a cell;

(b) isolating the supernatant;

(c) detecting an activity in a biological assay; and

(d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 22.